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Abbreviations 
 
β-1,4 GalT-V: β-1,4 Galactosyltransferase-V    NSTEMI: non-ST elevation myocardial infarction 
ACS: acute coronary syndromes     OxLDL: oxidized low-density lipoprotein  
AMI: acute myocardial infarction     PA: phosphatidic acid 
BMI: body mass index      PC: phosphatidylcholine 
CAD: Coronary artery disease     PC1, PC2: principal component 1,2 
CE: Cholesteryl esters      PC-O/-P: Plasmanyl/Plasmenyl PC 
CER: ceramides       PCA: Principal Component Analysis 
Cho: cholesterol      PE: phosphatidylethanolamine 
CV: coefficient of variation      PECAM-1: platelet-endothelial cell adhesion molecule-1  
CVD: cardiovascular disease     PG: phosphatidylglycerol  
DG: diglycerides       PI: phosphatidylinositol 
D-PDMP: D-1-phenyl-2-2-decanoylamino-3-morpholino-1-propanol PKC: protein kinase C 
ESI: electrospray ionization      PL: phospholipids 
FA: fatty acids       PLA2: phospholipase A2  
FBS: fetal bovine serum      PS: phosphatidylserine 
FC: fold change      PUFA: polyunsaturated fatty acid 
FDR: false discovery rate     QC: quality control 
GL: Glycerolipids       QTOF: quadrupole time of flight 
GlcCer: glucosylceramide      ROS: reactive oxygen species 
GM-CSF: granulocyte macrophage-colony stimulating factor RT: retention time 
GP: glycerophospholipids      S1P: sphingosine-1-phosphate 
GSL: glycosphingolipids      SA: stable angina 
HDL: high-density lipoprotein     SD: standard deviation 
HexCer: hexosylceramide      SM: sphingomyelin 
ICAM-1: intercellular adhesion molecule-1    SMCs: smooth muscle cells 
IL: interleukin       SP: Sphingolipids 
LacCer: lactosylceramide      Sph: sphingosine  
LDL: low-density lipoprotein     STEMI: ST elevation myocardial infarction  
LDLR: low-density lipoprotein receptor    TAG/TG: triglycerides  
LPL: lysophospholipids      TGF- β transforming growth factor-β 
m/z: mass to charge     TIC: total ion current 
Mac-1: macrophage-1 antigen     TNF-α: tumor necrosis factor-α 
MCP-1: monocyte chemoattractant protein-1    UA: unstable angina  
M-CSF: macrophage-colony stimulating factor    UPLC: ultra-high pressure liquid chromatography 
MG: monoglycerides      VCAM-1: vascular cell adhesion molecule-1 
MI: myocardial infarction      VLA-4: very late antigen-4 
MS: mass spectrometry      VLDL: very low-density lipoproteins 
MS/MS: tandem mass spectrometry     VEGF: vascular endothelial growth factor 
MUFA: monounsaturated fatty acid      
NADPH: nicotinamide adenine dinucleotide phosphate    
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Monocytes play a major role in atherosclerosis, a chronic inflammatory disease of the arterial wall 
and specifically, the recruitment of circulating monocytes to the site of injury and their diapedesis 
through the endothelium (extravasation) are crucial events in atherosclerotic plaque progression. 
Monocytes are classified into three subsets according to the differential expression of the 
lipopolysaccharide receptor (CD14) and the FcγIII receptor (CD16): CD14++CD16- classical 
monocytes, intermediate CD14++CD16+ monocytes and non-classical CD14+CD16++.  
During circulation, monocytes are exposed to several environmental stimuli that may alter their 
metabolic state thus inducing a cellular reprogramming with important effects on their functional 
profile. Recent data indicated that subjects with altered blood lipid levels display circulating 
monocytes with an inflammatory profile. 
Most of researches investigated the mechanisms by which lipids and lipoproteins affects the 
monocyte functions leading to plaque formation, but no information about the relationship between 
cellular lipid composition and monocyte function are available. 
Aim of the study was to investigate a lipid profile of monocytes in healthy subjects (HS) and 
coronary artery disease (CAD) patients, and its influence on monocyte migration.  
Monocyte lipidomic profile was evaluated through an untargeted liquid chromatography-time of 
flight mass spectrometry platform operating in positive and negative ionization mode. Monocyte 
migration assay was performed using fetal bovine serum (FBS), or autologous serum as chemotactic 
stimuli. 
By means of an untargeted lipidomics approach, we evidence a different profile in CAD monocytes 
compared to HS, with a marked increase in lactosylceramide (d34:1) (d18:1/16:0) in patient’s 
monocytes. Moreover, we demonstrate that monocytes obtained from CAD patients show a 
significant increase in FBS- and autologous serum-mediated migration compared to HS. The 
lactosylceramide levels positive correlate with monocyte migration and the treatment with the 
inhibitor of lactosylceramide synthase significantly reduces the monocyte migration. The results of 
this study suggest that lipidomics profile may dysregulate cell function, such as migration in CAD 
patients’ monocytes.  
 
 
 
 
 - 7 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Introduction 
  
2. Introduction 
- 8 - 
 
2.1 Atherosclerosis 
 
2.1.1 Definition and overview 
Atherosclerosis is a chronic and degenerative inflammatory disease characterized by alterations of 
the vascular wall of medium and large arteries resulting in the atherosclerotic plaque formation and 
its progression1. Atherosclerotic plaques show heterogeneity in terms of both morphology and 
composition leading to different clinical outcomes. Most plaques remain asymptomatic, some 
become obstructive characterizing the stable angina (SA) condition, while others elicit thrombus 
formation and may result in acute coronary syndromes (ACS)2. 
The underlying causes of the disease have been studied since 1900 when atherosclerosis was 
supposed to be mainly related to the aging process3. In 1913, Anitschkov’s work demonstrated, for 
the first time, that high cholesterol (Cho) level can increase the incidence of the pathology4 which 
was also later confirmed in the 1950s by Keys5. The role of Cho has become increasingly important 
when the presence of low-density lipoprotein (LDL) cellular receptors (LDLR), capable of 
removing Cho from blood, has been discovered6. On this basis, it was observed that subjects 
showing an insufficient number of LDLR or carrying genetic mutation of the receptor structure are 
more prone to develop hypercholesterolemia and Cho-related diseases7. In the 1990s, Ross 
formulated the “response to injury” hypothesis according to which endothelial damage represents 
the first step in the development of an atherosclerotic lesion, followed by migration to the vessel 
wall of circulating monocytes and T lymphocytes8. Since these cells have a crucial role in local and 
systemic infection, others theories have been formulated indicating infectious diseases as possible 
causes of atherosclerosis9. In support of this, the presence of lesions of the vessel walls similar to 
that observed in human with atherosclerotic disease was reported in animal infected with avian 
herpes virus10. In addition, observational studies in humans proposed an association of infectious 
agents such as certain viruses and bacteria with atherosclerosis, coronary events, or restenosis after 
arterial intervention11. However, currently the involvement of bacterial or viral infections in the 
development of atheromasic pathology has been completely ruled out. In the last two decades, the 
results of numerous studies have led to the definition of atherosclerosis as a disease on an 
inflammatory basis, rather than a disease due only to an alteration in the accumulation and 
distribution of Cho1, 12. 
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Atherosclerosis is a complicated and multifactorial disease, indeed, several epidemiological studies 
have identified several risk factors that can contribute to the onset of the disease and that can be 
classified, according to European Society of Cardiology (ESC), as modifiable or not modifiable. 
Not modifiable risk factors include age and gender. The incidence of atherosclerosis increases with 
advancing age and specifically the risk increases after the age of 45 for men while in women after 
5513. This effect in women coincides with the onset of menopause when estrogens levels decrease. 
Consequently, the estrogenic protective role, consisting in the improvement of the lipoprotein 
profile, is reduced14, 15. Genetic predispositions also promote the development of atherosclerosis. 
Indeed, people with a family history of cardiovascular disease (CVD) or hereditary alterations in 
the genes involved in lipid, glucose and amino acid metabolism, show an increased CVD risk14, 16. 
On the other hand, modifiable risk factors can be monitored and controlled thus allowing a 
prevention or a delay in the onset of the disease. These include diet, lifestyle (smoking and/or lack 
of physical exercise) and metabolic syndromes, which are a cluster of conditions such as 
hypertension, hyperglycemia, obesity and dyslipidaemia17. Concerning the food intake, several 
epidemiological studies have shown that plasma Cho levels and death from CVD are lower in Japan 
and southern Europe compared to the northern countries. This difference is associated with 
saturated fatty acids (FA), animal proteins, sodium and sugar increased consumption combined also 
with a sedentary lifestyle18. Moreover, an unhealthy diet can lead to other conditions such as 
overweight or obesity, which increase mortality risk for men and women of all racial and ethnic 
groups.  About half of the obese population also exhibits insulin resistance defined as a defective 
uptake or utilization of glucose in response to insulin. Clinically, this pathology can be diagnosed 
by a fasting plasma glucose test (glucose level of 100 to 125 mg/dL) or by an oral glucose tolerance 
test defined as 2 hours plasma glucose value of 140 to 199 mg/dL19. These glucose levels are also 
associated with type-2 diabetes mellitus. High blood glucose concentration can injure the vascular 
wall by inducing reactive oxygen species (ROS) production, stimulating the endothelial cells 
apoptosis and inactivating proteins through their glycation20-22. Moreover, elevated insulin levels 
promote the development of atheromasic plaque by stimulating smooth muscle cells (SMCs) 
proliferation and activating hepatic Cho biosynthesis23. Diabetes is characterized by the 
development of microvascular and macrovascular complications that can be exacerbated by the 
presence of concomitant diagnosis of hypertension. Guidelines from the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 
recommend a systolic blood pressure below of 140 mmHg and a diastolic blood pressure above 90 
mmHg. These goals have been lowered to 130 mmHg and 80 mmHg respectively, for patients with 
diabetes or chronic kidney disease specifically24. The rising incidence of hypertension is of interest 
since even moderate increase in blood pressure can increase the CVD risk. Indeed, hypertensive 
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patients are characterized by high angiotensin II level, a vasoconstrictor mediator that stimulate 
SMCs proliferation but also induce inflammation and LDL oxidation (oxLDL)25. Furthermore, a 
high blood pressure leads to an increased permeability of the vessel wall to lipoproteins thus 
promoting the onset of atherosclerosis26. Hypertension but also smoking habits can cause narrowing 
and hardening of arteries that decrease the blood flow and thus the supply of oxygen to the tissues. 
This lumen reduction also led to deposit of Cho that characterizes the first phase of atherosclerotic 
plaque formation. Moreover cigarette smoking is also associated with endothelial dysfunction, 
increased oxidation of atherogenic lipids and reduced high-density lipoprotein (HDL) levels27. 
Another major risk factor for CVD is hypercholesterolemia characterized by high blood total Cho 
levels28. Cho is transported by several classes of lipoproteins such as very low-density lipoproteins 
(VLDL), LDL and HDL. Specifically, the risk of CVD increases linearly with LDL levels, indeed 
LDL levels represents the most used diagnostic test to evaluate the risk of atherosclerosis. The goal 
is an LDL level below 70 mg/dL for high-risk patients and statins are the most effective and most 
frequently prescribed medications to decrease LDL cholesterol levels. It was demonstrated that 
every 1 mmol/l reduction in LDL cholesterol is associated with 10–20% reduction in the risk of 
cardiovascular events29. However, statin therapy only modestly improved the HDL cholesterol 
whose low level (below 40 mg/dL) is an independent and predictive risk factor for CVD30.  
The identification of the different risk factors and their mechanisms of action has already led to the 
development of some successful therapeutic strategies. For example, intensive lifestyle 
modifications clearly have the potential to reduce CVD risk however many patients are reluctant to 
follow a healthy regimen for long periods of time31. In addition, several medications such as lipid-
lowering or antihypertensive drugs have been prescribed to inhibit the progression of atherosclerotic 
disease and reduce its complications. Most of the currently available drugs, however, are specific 
for a single risk factor with a little effect on the others. Thus, the goal of the new-developed 
treatments is to address several CVD risk factors with a single agent that in conjunction with an 
improvement in lifestyle habits may reduce CVD risk.  
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2.1.2 Atherosclerotic plaque formation  
Atherosclerosis is characterized by the formation, in the vascular lumen, of an atherosclerotic 
plaque consisting of lipids, activated SMCs, immune cells, foam cells, a necrotic core and calcified 
areas9. Atherosclerotic plaques mainly develop in specific region of the arterial tree that are most 
susceptible to low or oscillatory endothelial shear stress. These sites are located near branching 
points or along internal curvatures, indeed, abdominal aorta, coronary and carotid arteries appear to 
be the most affected32. Before development of atheromasic plaques, these sites are characterized by 
an adaptive intimal thickening consisting in an early accumulation of SMCs (Figure 1A). 
 
  
Figure 1 Atherosclerotic plaque development and progression 
A: Adaptive intimal thickening characterized by smooth muscle cell accumulation. 
B: Fatty streak formation following accumulation of foam cells. 
C: Pathological intimal thickening and lipid pools accumulation in the absence of necrosis. 
D: Fibroatheroma and necrotic core formation. 
E: Calcification and fibrocalcific plaque formation. 
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Plaque formation begins with an accumulation of LDL in the arterial intima, where they may be 
subjected to modifications as oxidation (oxLDL) or aggregation33. OxLDL stimulate the response 
of the innate and adaptive immune system, inducing the expression by endothelial cells and SMCs, 
of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1), chemoattractant factors such as monocyte chemoattractant 
protein-1 (MCP-1), and growth factors as granulocyte macrophage-colony stimulating factor (GM-
CSF) and macrophage-colony stimulating factor (M-CSF), that interact with monocyte receptors to 
promote their migration and the subsequent differentiation to macrophages34. Macrophages are 
heterogeneous cells, which show different phenotypes, thus exerting multiple functions during the 
development of atheromasic lesions. Indeed, macrophages characterized by a pro-inflammatory 
phenotype (M1), produce pro-inflammatory cytokines as interleukin-1β (IL-1β) and tumor necrosis 
factor-α (TNF-α) and ROS that may stimulate LDL retention and their oxidation, and other 
mediators that may participate in the process of atherosclerosis such as plasminogen activators, 
cathepsins and matrix metallo-proteinases35. On the contrary, macrophages showing an anti-
inflammatory phenotype (M2) secrete factors such as transforming growth factor-β (TGF-β) that 
favor the resolution of inflammation36. Macrophages participate in the clearance of oxLDL, 
accumulate lipids thus transforming into foam cells through a mechanism that involves scavenger 
receptors. These receptors mediate mainly the uptake of oxLDL, that can be hydrolyzed in 
intracellular lithic compartments, but also the uptake of native LDL37. Foam cells accumulation is 
a hallmark of an inflammatory state of the vascular wall. These cells accrue within the proteoglycan 
layer of the intima forming several overlapping layers, which appear as yellow-colored fatty streaks 
(Figure 1B). These are completely reversible in the absence of the stimuli that caused their 
formation. They may already be present in fetal or neonatal aortas during the first six months of 
life, probably as a consequence of the mother risk factors; however, their number declines in the 
following years. During adolescence, fatty streaks can reappear especially in atherosclerotic-prone 
regions of the coronary arteries and the aorta38.  
  
2. Introduction 
- 13 - 
 
2.1.2.1 Necrotic core formation 
While many fatty streaks do not progress further, others, especially those that develop in 
predilection sites, evolve into atherosclerotic lesions. The distinctive feature is an accumulation of 
lipid material in the intima39-41. At first, small pools of lipids are visible under the layer of foam 
cells, without alterations of the normal structure of the vessel wall. This type of lesion is called 
pathological intimal thickening (Figure 1C) and is commonly observed from 20 to 30 years of age 
in the coronary arteries39. A necrotic core (or lipid-rich core) characterize the more advance lesions. 
The necrotic core formation, following invasion by macrophages, is a process that irreversibly 
destroys the normal structure of the intima28. In the presence of a necrotic core, the lesion is called 
fibroatheroma (Figure 1D). Apoptosis and necrosis play an important role during the development 
of the necrotic core42. Whilst a high number of apoptotic macrophages and SMCs is detectable in 
the atherosclerotic lesion, specifically at the margins of the necrotic core43, the presence of free 
apoptotic debris in lesions which are not associated with phagocytic cells, suggests that an altered 
process of apoptotic cell removal (i.e. efferocytosis) occurs thus promoting the growth of the 
necrotic core36, 44. In addition, the chemical composition of the necrotic core suggests that the 
accumulation of lipids from different sources, such as Cho esters from LDL and free Cho from 
erythrocyte membranes, released during intraplaque hemorrhagic events, may also contribute to the 
development of atheroma45. 
 
2.1.2.2 Plaque angiogenesis and intraplaque hemorrhage 
During the progression of atheromasic plaque, new blood vessels are formed which originate from 
the adventitial vasa vasorum and provide an alternative route of entry to monocytes and immune 
cells46. These vessels are fragile and leaky, leading to the extravasation of plasma proteins and 
erythrocytes, which in turn promote the necrotic core expansion and inflammation45, 47. It has been 
observed that intraplaque bleeding is associated with the presence of macrophages expressing 
CD163, a scavenger receptor that binds the haptoglobin-hemoglobin complex thus preventing 
cytotoxic effects caused by free hemoglobin. These macrophages lack the typical markers of M1 
phenotype (TNF-α and inducible nitric oxide synthase), but express the mannose receptor, 
characterizing M2 macrophages, and are resistant to foam cell formation48. 
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2.1.2.3 Fibrous cap formation 
The connective tissue, present in the initial stages of the lesion, is gradually replaced by fibrous 
tissue rich in collagen fibers that becomes the dominant component as the atheromasic plaque 
progresses49. Collagen, elastin and proteoglycans of the fibrous matrix are mainly produced by 
damaged SMCs. SMCs are present in small quantities in normal intima, however, their number rises 
significantly during the development of the lesion. This increase is due to both local proliferation 
of synthetic SMCs, or migration from media to intima of contractile SMCs with a subsequent shift 
towards the synthetic phenotype. These cells, showing a synthetic phenotype, are characterized by 
an abundant rough endoplasmic reticulum and Golgi apparatus and scattered myofilaments50.  
 
2.1.2.4 Calcification 
The presence of calcifications is a common aspect in the progression of atherosclerotic plaque and 
the incidence of fibrocalcific plaques (Figure 1E) increases with age. These plaques are 
characterized by microscopic calcium granules that can then expand to form larger calcium deposits 
utilizing apoptotic cells, the extracellular matrix and the necrotic core content as focal points for the 
development51, 52. The necrotic nucleus may then completely calcify, and the calcifications may 
occupy most of the surface of the plaque. Sometimes calcified lesions can evolve into osseous 
metaplasia; however, this is a rare event that only occurs in arteries with a high calcification status51. 
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2.1.3 Histological classification of atherosclerotic plaque  
The histological classification of atherosclerotic plaques has been studied since the beginning of 
the 20th century when two types of lesions were recognized. The former, "fatty streak", was 
associated with an intimal thin lipid deposit in children. The latter, "fibrous plaque", represented a 
thick fibrolipidic layer presents in adults. The pathologist Aschoff was a strong promoter of the 
theory supporting the intimal lipid and fibrolipidic deposits as an early and late stage of one disease. 
He defined the first stage as "atherosis" or "atheromatosis" mainly characterized by lipid deposition, 
while, the fibrolipidic stage was defined “atherosclerosis”50. Thereafter, the pathogenesis of 
atherosclerotic lesions was studied on the basis of microscopic analysis of arteries obtained from 
different subjects affected by atherosclerotic disease and divided into groups according to age. 
Following the research of Stary et al. (1994)39, the histological classification, proposed by the 
American Heart Association, distinguished six different stages of atherosclerotic lesion53.   
The type I lesion is defined as intimal thickening or “initial lesion” and it appears to be most 
common in children. It is characterized by small deposits of lipids and limited endothelial changes. 
The human intima changes are minimal, indeed small isolated groups of foam cells are observed 
and SMCs show low proliferative activity54. 
Type II lesions refer to the presence of fatty streaks, yellow-colored streaks on the intimal surface 
of arteries. Macrophages are the most numerous cells present at the level of the lesion, however, 
an increase in the number of T lymphocytes and mast cells compared to the type I lesion and normal 
intima is also observed. Moreover, abundant macrophage foam cells form layers rather than single 
isolated spots and they are interspersed with SMCs containing lipid droplets39. Lipids that 
characterize the type II lesion are mainly phospholipids (PL), free Cho and Cho esters and among 
these cholesteryl oleate and cholesteryl linoleate55. Type II lesions can be divided into two 
subgroups: type IIa and type IIb also defined as advance lesion-prone and advance lesion-resistant, 
respectively. While the former represents a small class of lesions localized at the level of specific 
adaptive intimal thickenings in predictable areas, the latter subgroup is larger, and it includes lesions 
that are found at the level of a thin intima. Morphologically, these two categories differ in terms 
of presence of SMCs, abundance of intercellular matrix, accumulation of lipoproteins and 
macrophages and localization of foam cells and extracellular lipid droplets. Furthermore, type IIa 
lesions are the first to evolve into type III lesions, while type IIb lesions may progress slowly or not 
at all39. The designation ‘type III lesions’ refers to lesions that show intermediate morphological 
characteristics between type II lesions and advanced lesions. The intimal pathological thickening 
(type III) is characterized by a layer of SMCs in a proteoglycan-collagen matrix above the 
underlying lipid pools rich in hyaluronan and versican. The structural modifications of the 
glycosaminoglycan chains in proteoglycans represent one of the initial triggers for the development 
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of the lesion favoring the binding of atherogenic plasma lipoproteins to the extracellular matrix in 
the lipid pools56. Another characteristic of type III injury is a higher content of free Cho, FA, 
sphingomyelin (SM), lysolecithin and triglycerides (TG) compared to type II lesions. Moreover, 
Cho esters contain a high percentage of linoleic acid and low levels of oleic acid while the opposite 
occurs in type II lesions57.  
Type III lesions represent a transitional state between type I and II, which are defined as “early” 
lesions, and the other “later” advanced lesions. Atherosclerotic lesions are considered advanced 
when an accumulation of lipids is observed in association with disorganization and thickening of 
the intima of the vessel and deformation of the vessel wall. In addition, complications such as 
fissures, hematomas and thrombosis often occur in these conditions39.  
Advanced lesions are in turn subdivided into types IV, V and VI.  
The type IV lesion, also known as atheroma, is characterized by a dense accumulation of 
extracellular lipids (lipid cores) formed as a result of the confluence of the small isolated lipid pools 
typical of type III lesions. In the region between the lipid core and the endothelial surface there are 
SMCs, macrophages and macrophage foam cells but also lymphocytes and mast cells. In addition, 
there is a severe disorganization of the intima and consequent formation of fibrous tissue above the 
lipid core. When an increase in fibrous connective tissue, mainly collagen, is observed, the lesion 
is defined as type V and it is characterized by a large lipid-rich necrotic core covered by a thick 
fibrous cap50. The necrotic core evolves thus an “early” and “later” ones can be distinguished. An 
early necrotic core is described by the presence of foamy macrophages that infiltrate the luminal 
surface of the lipid pools. Moreover, the presence of proteoglycans, versican and hyaluronan, 
typically absent in the late necrotic core, was observed. Late necrotic cores are distinguished by the 
increased presence of cell debris resulting from a defective phagocytic clearance of apoptotic cells. 
Another discriminating feature is the presence of free Cho partly attributed to the apoptotic death 
of macrophages58. According to the morphology, type V lesions can be classified into three 
subtypes. Type Va lesion is multi-layered: different lipid cores surrounded by thick fibrous 
connective tissue are superimposed and for this reason, it is called “multilayered fibroatheroma”. 
Lesions, with a high calcium content, are called type Vb or calcific lesions; on the contrary, lesions 
with minimal presence of lipids but high fibrous connective tissue are type Vc or fibrotic lesions59. 
The last stage of atherosclerotic plaque is the type VI or complicated lesions. Specifically, these are 
type IV or V lesions in which disruptions of the lesion surface (type VIa), hematoma or hemorrhage 
(type VIb) and thrombosis (type VIc) occur. These events may occur individually or simultaneously 
as in the VIabc type.   
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2.1.4 Clinical manifestation of atherosclerosis 
Since the beginning of the 21st century, a dramatic increase in the incidence of cardiovascular 
disease was observed. Although statistics indicate that the death rates are now decreasing, CVD 
remain the leading cause of mortality and morbidity in Europe. Therefore, 3.9 million deaths from 
cardiovascular disease (45% of all deaths), are recorded each year in Europe60. 
Coronary artery disease (CAD) is the most common of the cardiovascular diseases and it includes 
SA, unstable angina (UA), myocardial infarction (MI) and sudden cardiac death. Moreover, 
myocardial infarctions are clinically classified into ST elevation MI (STEMI) and non-ST elevation 
MI (NSTEMI) based on changes on electrocardiogram. Atherosclerosis, especially plaque rupture 
and thrombosis, is the main leading cause of these clinical manifestations. Patients diagnosed with 
SA show a stenotic lesion that tends to be stable, fibrotic and less prone to rupture. A severe stenosis 
may progress to total thrombotic occlusion but less frequently will result in a heart attack50. On the 
contrary, ACS (UA and AMI) are often caused by luminal thrombus formation or by sudden plaque 
hemorrhage61. Specifically, thrombus appear to be mostly occlusive in STEMI while UA and 
NSTEMI are characterized by either the formation of a non-occlusive thrombus or complete 
thrombosis. Luminal thrombosis occurs mainly as a result of plaque rupture (55-65% of cases), 
plaque erosion (30-35%) and less frequently as a result of calcific nodules formation (2-7%)40. 
Plaque rupture is typically observed in a lesion characterized by a large necrotic core (usually >30% 
of plaque area), a damaged fibrous cap (thickness < 65 µm) and high macrophage infiltration. 
Thrombus is formed as a consequence of the contact between blood flow and the thrombogenic 
necrotic core62 (Figure 2B). 
 
  
Figure 2 Plaque rupture and healing 
A. Fibroatheroma with a thin fibrous cap.  
B. Plaque ruptured and thrombus formation.  
C. Healed plaque with fibrous tissue formation and constrictive remodeling. 
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Thinning of the fibrous cap can be due to the gradual loss of SMCs and collagen which constitute 
the cap itself63. In addition, infiltrated macrophages can degrade the collagen-rich cap matrix by 
secreting proteolytic enzymes, such as plasminogen activators, cathepsins and metalloproteinases64. 
The rupture of a thin fibrous cap and subsequent thrombus formation may occur spontaneously, but 
in some cases, it may be triggered also by emotional or physical stress as a consequence of 
sympathetic nervous system activation that in turn increase heart rate and blood pressure65. 
Thrombus formation can also occur after plaque erosion, without plaque rupture. Eroded plaques 
are typically poorly calcified, usually associated with negative remodeling and less inflamed than 
ruptured plaques. At the point of erosion there is a loss of the integrity of the endothelial surface, 
resulting in exposure of the SMCs of the intima and proteoglycans leading to thrombus formation, 
however the mechanism by which this occurs is not yet fully known. Vasospasm was proposed as 
trigger of endothelial damage and following thrombosis66. Calcified nodules are the least frequent 
cause of thrombosis. These, which occur in highly calcified arteries, penetrated the lumen of the 
vessels destroying the collagen layer and the endothelium. The nodules are surrounded by fibrin 
and often associated with small platelet-rich thrombi that are non-occlusive. Calcified nodules are 
more likely found in elderly patients and specifically observed in the tortuous regions of coronary 
arteries58. In addition, thrombi from ruptured, eroded or calcified plaques can be silent and 
eventually repaired to form healed lesions (Figure 2C). These lesions are characterized by a fibrous 
cap rich in type I collagen which is overlaid with a new layer rich in proteoglycans and type III 
collagen with interspersed SMCs. Luminous thrombus may be non-occlusive or occlusive leading 
to the development of a chronic total occlusion. Histological studies have shown that the frequency 
of healed plaques correlates with the degree of vessel wall narrowing. Indeed, it has been observed 
that the incidence of healed lesions rises from 20% of lesions with a stenosis <50%, to 70% with a 
stenosis degree >50%67. 
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2.1.5 Perspective for prevention 
In research and clinical practice, it is necessary to characterize the atherosclerotic disease and 
atheromasic plaques, defining some important and measurable parameters that highlight the stage 
of the disease and the risk of progression. Some of the parameters used are plaque burden, activity 
and vulnerability. Plaque burden is a measure of the extent of atherosclerosis, regardless of cellular 
composition and plaque activity. It can be calculated as the volume of plaque, (arterial surface 
covered by the lesion), or through the measurement of the calcium amount by computed 
tomography, or as the intima-media thickness defined by ultrasound68. Plaque activity, on the other 
hand, is a tool for identifying causal factors that can contribute to the progression of the disease. 
This parameter, which can be evaluated through imaging techniques, or through the measurement 
of circulating plasma biomarkers, can be used to verify the effectiveness of pharmacological 
therapies. Usually, the term plaque activity refers to the inflammatory state, measured for example 
in terms of macrophage density in plaques. However, there is a profound difference between the 
inflammation that characterizes the initial stages of the lesion and the specific inflammation of 
fibrous cap that causes rupture and thrombosis69. Several other processes can be classified as factors 
that modulate plaque activity, including the extent of intimal necrosis, which is perhaps the most 
damaging consequence of the disease. Angiogenesis, endothelial damage and intraplaque 
hemorrhage that often accompany inflammation are other potential biomarkers69. Many efforts have 
been made to identify the peculiar characteristics of vulnerable plaques in order to predict which 
plaques are at risk of developing a thrombotic condition and to understand the mechanism leading 
to their formation70. The term "vulnerable plaque" is used to indicate plaques with a high risk of 
rupture or erosion or to describe a set of histological features that increase the risk of thrombus 
formation. On this basis, patients with a high short-term risk of developing an acute clinical event 
are classified as "vulnerable". This propensity is indeed influenced by the parameters described 
above such as the extent and activity of plaque, but also by the systemic thrombotic predisposition 
and the susceptibility of the myocardium to ischemia and arrhythmia71.  
In summary, the mechanisms that lead to the narrowing of the fibrous cap and the consequent plaque 
rupture, are still unclear and the trigger for thrombotic event in eroded plaques are even less known. 
Extensive research in this field could lead to the definition of new therapeutic treatments for the 
prevention and limitation of the progression of atherosclerotic disease. For example, periodic 
evaluations of plaque burden in middle-aged people can  improve the risk stratification of patients, 
thus enabling preventive therapies in a larger number of patients at risk72. However, to achieve an 
improvement of prevention strategies, the importance of lifestyle aspects such as quality of diet, 
physical activity and weight control should also be taken into account.   
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2.2 Monocytes 
 
The definition of atherosclerosis as an inflammatory disease has delineate a pathophysiological role 
of cells such as monocytes and macrophages. Monocytes are fundamental during the development 
of atherosclerosis from the early lesion to the final plaque rupture. After the initial injury, the 
attachment and subsequent migration of monocytes to the subendothelial space is stimulated by 
activated endothelial cells expressing adhesion molecules. Monocytes can then differentiate into 
macrophages that incorporate oxLDL and produce cytokines by promoting inflammation. The 
perpetuation of this cycle promotes the progression of early lesions in advanced atherosclerotic 
plaques.  
The study of the development and functional characterization of monocytes and their 
pathophysiological role in atherosclerosis is therefore fundamental. 
 
2.2.1 Definition and overview 
The first observations on monocytes can be traced back to the second half of the 19th century and 
are specifically linked to the introduction of microscopy. In 1880, Ehrlich developed a technique of 
cytological staining and through the use of aniline and neutral dyes, he described white blood cells 
(WBC) according to nuclear morphology. By this way, he classified mononuclear leukocytes, 
characterized by a large kidney-shaped nucleus that he called "Übergangszelle" or "transitional 
cells" now known as monocytes, and polymorphonuclear cells with neutrophilic (neutrophils), 
acidophilic (eosinophils) or basophilic (basophils) granules73. The introduction of the denomination 
"monocytes" seems to be attributable to the scientist Artur Pappenheim in 191074. Subsequently, 
the first in vitro studies were conducted describing the migratory capacity of these cells and their 
differentiation into tissue macrophages following acute insults as inflammatory stimuli75. 
Actually, monocytes represent a highly plastic and heterogeneous cell population that refers to the 
mononuclear phagocytic system. These cells are characterized by a kidney/bean-shaped nucleus. 
As blood circulating cells, these amount to about 10% of total peripheral leukocytes in humans and 
4% in mice.  
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2.2.2 Monocyte heterogeneity and subsets 
Monocytes are a heterogeneous cell population showing differences in terms of morphology, 
phenotype and functions.  
Monocytes show distinct phenotypes due to the different expression, on the cell surface, of two 
markers: the lipopolysaccharide (LPS) receptor antigen, CD14, and the immunoglobulin G Fcγ 
receptor, CD16. According to the nomenclature approved by the Nomenclature Committee for the 
International Union of Immunological Societies, human monocytes are then classified into three 
subpopulations: classical CD14++CD16-, intermediate CD14++CD16+ and non-classical 
CD14+CD16++ monocytes76. Each of these subsets show peculiar characteristics in terms of 
expression of cell adhesion molecules and chemokine receptors resulting in different phenotypes 
with different functions (Figure 3). 
 
Classical monocytes represent the largest subgroup: 80-90% of the total monocyte count. These 
cells display a high expression of the chemokine receptor (CCR) type 2, that is the receptor of MCP-
1, of chemokine receptor (CXCR) 1,2 and 4 and high levels of the cell adhesion molecule L-Selectin 
(CD62L) while CX3CR1 (the fractalkine receptor) and CCR5 show lower levels. Following 
stimulation with LPS, this subset produces several chemokines and cytokines such as interleukin 
(IL)-10, IL-6, IL-8, IL-1β, TNF-α and CCL2 (chemokine ligand also known as MCP-1). The main 
function is linked to the immune response, specifically, due to the high expression of 
Figure 3 Human monocyte subsets 
Human monocytes are classified into three subsets based on the different expression on the cell surface of specific receptor: 
classical CD14++CD16- monocytes, intermediate CD14++CD16+ monocytes and non-classical CD14+CD16++ monocytes. 
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myeloperoxidase, several receptors such as, CD32, CD64, signal-regulatory protein α (SIRPα), and 
CD36 that highlights their role in the phagocytic process. These cells are considered as 
inflammatory mediators as they are rapidly recruited to inflamed tissue due to the recognition, by 
their receptor CCR2, of MCP-1 produced by tissue resident-macrophages. Furthermore, classical 
monocytes are rich in genes related to angiogenesis and coagulation thus underlining their 
involvement in tissue repair and wound healing77.  
Non-classical monocytes (2-8% of total circulating monocytes) show phagocytic competences too; 
these are also ROS producers; however, their production of cytokines is greatly reduced. 
Concerning molecule expression on cell surface, non-classical monocytes display ICAM-1, opsonin 
receptors FcγRI and FcγRII, major histocompatibility complex (MHC) class II and CX3CR1 but 
low levels of CD11b and CD33 while they do not express CCR2 and CD62L at all. The main 
function is the patrolling of the blood circulation for the control and removal of damaged cells. This 
activity is due to the interaction between fractalkine (CX3CL1) expressed on endothelial cells, and 
its receptor CX3CR1 allowing the attraction and arresting of monocytes to the endothelium. 
Moreover, non-classical monocytes show a high expression of genes involved in the rearrangement 
of the cytoskeleton77. 
Intermediate monocytes (2-10% of total circulating monocytes) appear as an intermediate state 
between classical and non-classical monocytes, as these cells show the expression of a mixture of 
markers that characterize both classical and non-classical subsets. The expression of CCR1, CCR2 
and CXCR2 characterizes the intermediate monocytes. Furthermore, CX3CR1 and CCR5 are 
present on the cell surface, as well as MHC class II that is more expressed in this group than the 
others are. Intermediate monocytes produce large quantities of ROS and pro-inflammatory 
cytokines such as TNF-α and IL-1β following stimulation with LPS; however, they are also the 
main producers of the anti-inflammatory IL-1078. 
To conclude, monocyte population is composed by three subsets showing different phenotypes, 
however, whether these phenotypes are distinct or constitute a wide continuum is still unclear. To 
date it is assumed that dynamic changes rather than marked differences appear between the subset 
of monocytes in terms of phenotype and functionality. In in vivo studies performed with deuterium 
labelling, show that during steady state but also during endotoxemia, monocytogenesis proceeds 
from the onset of classical monocytes, which subsequently become intermediate and finally non-
classical. The evidence that circulating monocytes change their phenotype from one subset to 
another followed by an increasing of the degree of CD16 expression, support this hypothesis. The 
dynamic changes of monocyte subsets also occur during pathologies such as major systemic 
inflammation79.   
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2.2.3 Monocyte development 
 
Monocytes originate in the bone marrow (Figure 4) from hematopoietic stem cells (HSC) which in 
turn generate a heterogeneous population of multipotent progenitors (MPP) that differentiate into 
two separate precursors: common lymphoid progenitors (CLP) or common myeloid progenitors 
(CMP). While the former originates lymphoid cells such as B, T, and natural killer cells, the latter 
gives rise to megakaryocyte and erythrocyte progenitors (MEP) or granulocyte and macrophage 
progenitors (GMP). Basophils, neutrophils and eosinophils originate directly from GMP as does the 
monocyte-macrophage/dendritic cells progenitors (MDP). At this point, two distinct lineages are 
distinguished: dendritic cells differentiate from the common dendritic cell precursors (CDP) while 
the common monocyte progenitors (cMoP) give rise to monocytes80. The differentiation of 
monocytes from cMoP involves an intermediate stage of pre-monocytes characterized by a high 
expression of CXCR4. These cells differentiate in 24h to monocytes poor in CXCR4 but rich in 
CCR281. It has been observed that in CCR2-deficient mice, monocytes remain trapped in the bone 
marrow with a consequent reduction in the number of circulating monocytes82. Consequently, it is 
likely that CCR2 and its ligands CCL2 and CCL7, rather than CXCR4 regulate the exit of 
monocytes from the bone marrow into the blood flow. 
Although the generation of monocytes is considerable in the bone marrow, a small amount of MDP 
and cMoP was also observed in the spleen83. In fact, the spleen represents a small reservoir of 
Figure 4 Hematopoietic development in the bone marrow 
Representation of the tree-like hierarchy model of hematopoietic cell development in the bone marrow.  
CDP: Common Dendritic cells Precursors; CLP: Common Lymphocyte Precursors; cMoP: common Monocyte 
Precursors; CMP: Common Myeloid Precursors; GMP: Granulocyte Macrophage Precursors; HSC: Hematopoietic Stem 
Cells; MDP: Monocyte-Macrophage/Dendritic cell Precursors; MEP: Megakaryocyte/Erythrocyte Precursors; 
MPP: Multipotent Precursors; 
.  
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monocytes and, in particular, during the inflammatory state, there is an increase in emergency 
extramedullary monopoiesis mediated by IL-1β84. Thus, splenic monocytes are then mobilized and 
recruited towards the injured tissue as observed in atherosclerosis85. 
Under homeostatic conditions, classical monocytes remain in the circulation for about a day before 
they migrate to the tissues to differentiate into local tissue-resident macrophages. Monocyte-derived 
macrophages show significant differences compared to their circulating precursors, indeed, they 
adapt to the local environment and acquire functions similar to those of the macrophages they are 
replacing86. On the other hand, monocytes may also migrate towards tissue and retain their 
characteristics and identity thus constituting a local reservoir of monocytes87. An alternative 
pathway is the transition of classical monocytes to the non-classical subset through intermediate 
monocytes, which remain in the circulation for about 4 days79. Non-classical monocytes show a 
longer life span of about 2 days in mice and up to 7 days in humans. This increased life span ensures 
a constant number of non-classical monocytes even during pathological conditions and especially 
following inflammatory stimuli that promote the differentiation of classical monocyte to 
macrophage thus blocking the transition to non-classical ones. The number of non-classical 
monocytes is therefore deeply affected by the physiological state of the organism in fact even 
exercise and age can influence the balance of monocyte subsets79.  
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2.2.4 Monocyte in atherosclerosis 
Monocytes have been observed to play a key role in atherosclerosis both during the process of 
initiation and formation of atherosclerotic plaque, which is accelerated by different risk factors, but 
also during the acute inflammatory phase leading to destabilization and plaque rupture. In addition, 
monocytes are also involved during healing by promoting the accumulation of myofibroblasts, 
angiogenesis process and myocardial healing and remodeling88 (Figure 5). 
 
2.2.4.1 Monocyte recruitment and transmigration  
A key factor in the pathogenesis of atherosclerotic disease is the recruitment of circulating 
monocytes to the vascular endothelium. This process consists of three fundamental steps: the 
adherence of monocytes, their rolling along the vascular wall and finally the transmigration into the 
subendothelial space. The capture and rolling of monocytes are mediated by the interaction between 
the CCL5 and CXCL1 chemokines present on the endothelial surface and the corresponding 
monocyte receptors89. Several adhesion molecules are also involved in the process and these belong 
to four families: selectins, immunoglobulins, integrins and mucin-like glycoproteins. The family of 
selectins, transmembrane monomeric glycoproteins, comprises several classes, each characterized 
Figure 5 Role of monocytes in atherosclerosis 
The key roles of the three monocyte subsets in atherosclerosis are depicted. At first (stage I), classical monocytes promote 
inflammation and phagocyte necrotic debris. During stage II, non-classical and intermediate monocytes attenuate 
inflammation and promote healing, angiogenesis, tissue repair and remodelling. 
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by a different site of expression. L-selectin, is expressed by monocytes and most types of leukocyte, 
interacts with the ligands expressed by the endothelium and allows a transient adhesion; E-selectin 
or CD62E is expressed on activated endothelial cells and binds the sialylated oligosaccharides 
groups present on protein surface of leukocytes; P-selectin or CD62P, can be expressed by both 
endothelial cells and platelets. P-selectin, under physiological conditions, is located in intracellular 
granules, while during inflammation, the release of chemical mediators stimulates its translocation 
on the cell surface making it available for interaction with leukocyte ligands90. This last selectin 
appears to be the most responsible for monocyte rolling in atherosclerosis. Immunoglobulins such 
as VCAM-1 and ICAM-1 are present on the endothelial surface and represent the ligands for the 
integrins expressed by leukocytes91. Integrins, integral membrane glycoproteins, are heterodimers 
formed by α and β subunits: monocytes express integrin-β1 that recognize VCAM-1, and integrin-
β2 that bind ICAM-1. The α4β1 integrin known as very late antigen-4 (VLA-4) also plays an 
important role in the adhesion of monocytes to the endothelial surface; it binds to some isoforms of 
fibronectin and to VCAM-190-92. The macrophages present in the atherosclerotic lesion are involved 
in the migration of monocytes; in fact, they produce cytokines such as TNF-α and IL-1 β that induce 
the expression of ligands for integrins, especially VCAM-1 and ICAM-1. In response to lipid 
oxidation, macrophages also produce chemokines such as MCP-1, abundantly expressed in 
atheromasic lesions and involved in the amplification of the recruitment process of monocytes93. 
Another factor that can increase the migration of monocytes is represented by oxLDL. These 
lipoproteins can stimulate the expression of adhesion molecule on endothelial cells and induce the 
synthesis of chemotactic or growth factors. OxLDL can also act directly on monocytes or through 
the promotion of the formation of platelet-monocyte aggregates thus promoting the adhesion of 
monocytes to the endothelium94. Platelets are also considered mediators of monocyte recruitment 
in atherosclerosis. Through the formation of platelet-monocyte aggregates, an inflammatory 
reaction is triggered that promotes the release of chemokines CCL2 and CCL5, and cytokine IL-1β, 
inducing monocyte activation. In addition, the release from platelet α-granules of CXCL4, CCL5, 
and other chemokines involves endothelial activation thus promoting the adhesion of monocytes95. 
After diapedesis, monocytes are temporarily retained in the subendothelial space and then the cells 
are able to cross the basal membrane. CD44 and integrins-β1 are the mediators involved in the 
monocytes delay in the extracellular matrix96 but CCL5 (also known as RANTES), CXCL1 and IL-
8 are also implicated in the process93. Finally, monocyte transendothelial transmigration is regulated 
by adhesion molecules present on endothelial cell surface or in endothelial cells junctions including 
platelet-endothelial cell adhesion molecule or CD31 (PECAM-1) a member of the immunoglobulin 
superfamily97.  
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2.2.4.2 Monocyte differentiation into macrophages 
Macrophage accumulation in atherosclerotic plaque occurs both as a result of the differentiation of 
monocytes recalled from the blood circulation, and of the activation or proliferation, even if in a 
modest extent, of local macrophages that are immobilized at the site of inflammation98. Similar to 
monocytes, macrophages represent a heterogeneous population that reflects the complexity and 
diversity of the microenvironment to which monocytes are exposed99. The exposition to different 
cytokines and growth factors during the process of monocyte differentiation induces a polarization 
towards different macrophage phenotypes with extremely different and even opposing properties. 
Among several cytokines and growth factors, M-CSF and GM-CSF play a fundamental role in the 
differentiation process100. M-CSF, in the bloodstream, favours the survival of circulating monocytes 
and induces their differentiation into macrophages by modulating the levels of CD14 and CD68101, 
102. In In vitro model, the differentiation of monocytes in the presence of M-CSF, gives rise to 
macrophages with anti-inflammatory properties (M2 macrophages) characterized by a marked 
phagocytic activity and able to produce high amounts of IL-1099. On the contrary, macrophages 
obtained in the presence of GM-CSF display pro-inflammatory characteristics (M1 macrophages) 
and produce high levels of TNF-α, IL-12, IL-1, IL-6, IL-8 and IL-23 after activation with LPS103. 
These cytokines can exacerbate the endothelial dysfunction and promote oxidative stress104. M2 
phenotype, characterized by the presence of the scavenger receptors (SR-A) and CD36, and the 
mannose receptor, display an atheroprotective role as they secrete TGF-β and anti-inflammatory 
cytokines such as IL-10, and reduce the recruitment of pro-inflammatory cells105. While M1 
macrophages sustain the expansion of the necrotic core and plaque rupture106. Thus, based on their 
anti-inflammatory characteristics, M2 macrophages appear to mainly derive from the differentiation 
of non-classical monocytes while extravasated classical monocytes start a differentiation process, 
which involves the upregulation of markers characteristics of M1 macrophages. In human 
atherosclerotic plaques, phenotypes M1 and M2 are simultaneously present throughout the 
evolution of plaque, as evidenced by a recent study conducted in plaques at different lesional 
stages107. Specifically, a preponderance of M2 macrophages has been described at the level of the 
vascular adventitious layer. On the contrary, M1 macrophages appear to be mainly distributed at 
the plaque rupture site while in the fibrous cap there is no significant difference in the prevalence 
of the two subgroups107. 
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2.2.4.3 Monocytes subsets and cardiovascular outcomes  
An increasing number of evidences highlights an association between the development of 
atherosclerosis and CD16+ monocytes (both intermediate and non-classical)108-115. CD16+ 
monocytes are correlated with traditional cardiovascular risk factors such as Body Mass Index 
(BMI), diabetes, obesity and insulin resistance111-113, but also with high serum levels of TNF-α114. 
A significant relationship is demonstrated between increased levels of CD16+ monocytes and 
thickening of the intima or the occurrence of vulnerable atherosclerotic plaque in patients with both 
SA and UA111, 112, 115. Further studies are carried out with specific reference to the two distinct 
subsets intermediate and non-classical monocytes. The number of non-classical monocytes are 
positively correlated with high levels of total plasma Cho, LDL and TG while a negative correlation 
is observed with HDL levels108, 109. Moreover, Rogacev et al investigated the heterogeneity of 
monocytes more thoroughly through the HOM SWEET HOMe study (Heterogeneity of Monocytes 
in Subjects Who Undergo Elective Coronary Angiography-The Homburg Evaluation). The results 
show an association between cardiovascular events and a high count of total monocytes, classical 
and intermediate monocytes, but not with non-classical monocytes116. Moreover, an association 
between low levels of HDL and intermediate monocytes count is reported, pointing out that a high 
count of this subset may represent an independent determinant of cardiovascular events110. More 
specifically, there is a strong association between the monocyte count and ACS, due to the fact that 
the evolution from stable CAD to ACS is partly linked to the upsurge of the inflammatory state 
linked to the monocyte activity. A rise in monocyte count following AMI, which is maintained for 
7 months, is observed. Following AMI, monocytes invade the infarct area promoting healing and 
remodelling of myocardial tissue117. Interestingly, classic monocytes reach their highest levels 3 
days after the onset of AMI while CD16+ monocytes increase at day 5118. A similar study conducted 
in STEMI patients, shows an association between levels of classical monocytes and a larger extent 
of transmural infarction with a larger infarct size while a high count of non-classical monocytes is 
found in patients with increased tissue recovery. Therefore, these results confirm the role of 
classical monocytes in amplifying the inflammatory response and of non-classical monocytes in the 
healing process119. Moreover, at the level of the infarct area, within the first 5 days after AMI, the 
classical monocytes are predominant and are placed in the infarct border zone. However, during the 
following days, CD16+ monocytes invade the infarct core zone120. Intermediate monocytes are also 
linked to myocardial infarction: their count rises after 3 days from the event (in both STEMI and 
NSTEMI patients) and then returns to values comparable to stable patients in 30 days121.  
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2.3 Lipids 
Lipids play a central role in CVD since atherosclerotic plaque formation is initiated as lipid particles 
accumulate and become trapped in vessel walls. The interplay between lipids and immune cells is 
believed to be a driving force in the chronic inflammation of the arterial wall during atherosclerosis. 
Therefore, the study of the lipid composition of immune cells, such as monocyte, could evidence a 
possible association between lipid species and cardiovascular events. 
2.3.1 Lipid classification, nomenclature and structures 
Lipids have always been recognized as a group of hydrophobic molecules and therefore highly 
soluble in organic solvents122. However, this definition is not exhaustive because complex lipids 
such as glycosphingolipids (GSL), precursors of lipid biosynthesis or their degradation products, 
are also soluble in water123. An alternative was proposed by Christie who defined lipids as ' FA, 
their derivatives and substances biosynthetically or functionally related'124. The Lipid Library125 and 
Cyberlipids126 divide lipids into "simple" and "complex", the former include molecules that after 
hydrolysis generate two distinct products (e.g. acylglycerols → fatty acids + glycerol) while 
complex lipids lead to the production of three or more distinct entities (glycerophospholipids → 
fatty acids + glycerol + head group). Currently, the Lipid Metabolites and Pathways Strategy (LIPID 
MAPS) consortium, a multi-institutional group created in 2003, has defined a classification of lipids 
based on their structural and biosynthetic characteristics. Therefore, lipids are defined as 
hydrophobic or amphiphilic molecules that are formed, at least in part, by condensation of ketoacyl 
or isoprene groups127, 128. Based on this assumption, lipids are classified into 8 groups: FA, 
glycerolipids (GL), glycerophospholipids (GP), sphingolipids (SP), saccharolipids, polyketides 
(resulting from condensation of ketoacyl subunits), sterol lipids and prenol lipids127, 128. 
The nomenclature of lipids includes systematic names and common names. Systematic names have 
been assigned following the guidelines formulated by the International Union of Pure and Applied 
Chemists and the International Union of Biochemistry and Molecular Biology (IUPAC-IUBMB) 
Commission on Biochemical Nomenclature in 1975129. Common names, on the other hand, are 
abbreviations that allow to easily identify acyl/alkyl chains in GL, SP and GP. By this way, lipids 
are represented by the marks that identify the lipid class (e.g. TG for triglycerides) or the lipid head 
group (e.g. PC for phosphocholines) followed by the side-chains indicated in brackets. Side-chains 
are represented by the number of carbons that make up the chain and the number of chain 
unsaturation (e.g. TG (16:0/18:1/16:0)). If the composition of the side-chains is not known, 
abbreviations such as TG (52:1) are used where the numbers in brackets refer to the total number 
of carbons and the total number of double bonds of the all side-chains127, 128. 
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2.3.1.1 Fatty acids 
FA are fundamental molecules as they represent the basic structure for the construction of complex 
lipids. FA are chains that are built up by successive repetitions of a methylene group that impart the 
characteristic hydrophobicity and contained a terminal carboxylic acid127, 128. Hydrocarbon chains 
diversify in terms of length, structure (linear or branched) and degree of unsaturation (presence of 
double bonds). According to these characteristics, FA can be further divided into short-chain FA 
(less than 6 carbons), medium-chain FA (from 6 to 12 carbons) and long-chain FA (more than 12 
carbons). Moreover, FA can be saturated (no double bonds) or the degree of unsaturation can vary 
from 1 double bond (monounsaturated FA or MUFA) to two or more (polyunsaturated FA or 
PUFA). These double bonds may differ in the position along the chain and in orientation (cis or 
trans). The number, position and orientation of the double bonds are fundamental characteristics of 
FA in that they alter the arrangement in the lipid membrane thus modifying its biophysical 
characteristics such as curvature, fluidity and structure130. FA biosynthesis takes place in the 
cytoplasm and is catalysed by the multienzyme complex fatty acid synthase. The first reaction 
consists in the formation of malonyl-CoA from acetyl-CoA and CO2. Then a cyclic repetition of 
reactions occurs that lead to the elongation of the FA chain through the repetitive addition of two 
carbon atoms donated by malonyl-CoA. After the addition of each 2-carbons-unit, double bond 
reduction reactions occur for the formation of saturated FA. The final product is palmitic acid, a 
saturated FA constituted by 16 carbon atoms (16:0). However, longer FA chains can be obtained 
through elongation reactions catalysed by elongases; alternatively, FA with a higher unsaturation 
degree can be obtained through the activity of desaturases enzymes. Elongation and desaturation 
pathways occur mainly in the liver130. 
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2.3.1.2 Glycerolipids and glycerophospholipids 
GL and GP share the presence of a molecule of glycerol in their structure. GL include acylglycerols 
mono-, di-, tri- fatty acid esters of glycerol: monoglycerides or monoacylglycerols (MG or MAG), 
diglycerides or diacylglycerols (DG or DAG) and triglycerides or triacylglycerols (TG or TAG) 
(Figure 6). FA linked at the sn-1 and sn-3 carbons of glycerol are usually saturated while the fatty 
acid esterified at the sn-2 carbon is more flexible and usually unsaturated. TG synthesis occurs in 
adipose tissue from dihydroxyacetone phosphate (DHAP), produced during glycolysis. The enzyme 
glycerol-3-phosphate dehydrogenase reduces DHAP to glycerol 3-phosphate with subsequent direct 
esterification of FA to carbon 1 and 2 and while carbon 3 esterification occurs after 
dephosphorylation130. 
 
  
Figure 6 Triacylglycerol structure 
General structure of a saturated triacylglycerol. Triacylglycerol is an ester derived from glycerol (blue) linked to three fatty 
acids (green). 
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GP or more simply PL are characterized by the presence of a phosphate group esterified to a 
hydroxyl group (sn-3 position) of the glycerol backbone. Typically, the remaining two hydroxyl 
groups of glycerol exhibit acylated long-chain FA, however, alkyl-linked and alkenyl-linked 
(plasmalogen) GP may also be found. Thus, PL with a saturated 1-O-alkyl ether group are called 
plasmanyl-PL (“O”-prefix for the nomenclature) while the presence of a monounsaturated 1-O-
alkenyl ether groups appoints the denomination plasmenyl-PL (“P”-prefix for the nomenclature). 
Moreover, lysophospholipids (LPL) are PL whose FA chain has been removed from either the sn-
1 or sn-2 position. PL can be divided into additional categories based on the nature of the polar head 
group linked to phosphate. The common head groups are choline, ethanolamine, serine, glycerol 
and inositol; thus, the following classes of PL are categorized: phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG) and 
phosphatidylinositol (PI) respectively (Figure 7). The simplest PL is phosphatidic acid (PA). 
Further diversity of these molecular species is due to the different combination of the FA 
composition at the sn-1 and sn-2 position127, 128. PC are the most abundant PL in cell membrane (40-
50% of total PL) followed by PE which are enriched in mitochondrial inner membranes (40% of 
total PL). The Kennedy pathway is the main mechanism of de novo biosynthesis of PC and PE, the 
most abundant PL. The first reaction occurs in the cytosol and involves the phosphorylation of 
choline (or ethanolamine) by kinase forming phosphocholine (or phosphoethanolamine). In the rate-
limiting step, starting from cytidine triphosphate (CTP), the formation of the intermediate CDP-
choline (or CDP-ethanolamine) occurs with pyrophosphate release. The final reaction occurs in 
Golgi or in the endoplasmic reticulum and leads to the formation of PC (or PE) using DAG as lipid 
anchor and release cytidine monophosphate131. The FA configuration characterizing the newly 
synthetized PC and PE can experience further variation by acyl-remodelling reactions in the Lands 
pathway132.  
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Figure 7 Phospholipid structures 
The structure of phospholipids consist of a glycerol backbone (blue) with two fatty acid tails (green) and a polar head 
group (red) linked to phosphate (yellow). According to the nature of the head group, the following classes of phospholipids 
are categorized: phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, 
phosphatidylserine and phosphatidylinositol. 
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2.3.1.3 Sphingolipids 
SP are a complex family of molecules that share a common structure, a long-chain nitrogenous 
base, sphingosine (Sph), a sphingoid base that display amphiphilic properties due to the presence 
of two hydroxyl groups and an amino group in its polar portion.  
SPH is synthesized de novo from serine and a long-chain fatty acyl-CoA, palmitoyl-CoA by serine 
palmitoyl-transferase. SP can be divided into different classes: sphingosine derivatives such as 
sphingosine-1-phosphate (S1P), ceramides (CER), phosphosphingolipids and GSL (Figure 8).  
CER derived from Sph to which a FA is bound with amide bond. These FA are usually saturated or 
monounsaturated and have a chain length from 14 to 26 carbon atoms. Depending on the FA chain 
length, CER can be classified as medium chain (12-14 carbons), long chain (16-18 carbons), very-
long chain (20-24 carbons) and ultra-long chain (>26 carbons)133. Carbon 2 can be characterized by 
the presence of a hydroxyl group; in this case, the designation "t" is assigned to identify these 
ceramides while in the absence of the hydroxyl group, "d" is assigned. CER can be generated by de 
novo synthesis, by ceramide synthase enzymes that produce dihydroceramide from 
dihydrosphingosine and FA, or they can be derived from the salvage pathway that produces CER 
from SPH and FA133. CER are precursors of more complex SP.  
Phosphosphingolipids present a polar head and a phosphate group linked to the free hydroxyl group 
of CER. Among the phosphosphingolipids, the most abundant are the SM, which are characterized 
by the presence of phosphocholines.  
GSL are divided on the basis of the carbohydrate linked: neutral GSL contain one or more 
uncharged sugars such as glucose (glucosylceramide (GlcCer)) or galactose (galactosylceramide 
(GalCer)) and lactose (lactosylceramide (LacCer)) Acid GSL contain ionized functional groups 
(phosphate or sulphate) bound to sugar such as sialic acid (gangliosides), and finally there are basic 
and amphoteric GSL127, 128. 
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Figure 8 Sphingolipid structures 
Sphingolipids share sphingosine (blue) as common backbone structure to which a fatty acid (green) is bound with amide 
bond. Sphingolipid with a hydrogen atom as R group is a ceramide. Other common R groups include phosphocholine 
(yielding a sphingomyelin), glucose (glucosylceramide) or lactose (lactosylceramide). 
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2.3.1.4 Sterol lipids and prenol lipids 
Sterol and prenol lipids share a common biosynthetic pathway as they result from condensation of 
isoprene subunits, however display differences in the structure and functions. Among sterols, Cho 
and its derivatives constitute an important component of membrane lipids. Cho is characterized by 
a planar structure constituted by four fused rings and a hydrocarbon side chain130. The first reaction 
in Cho biosynthesis is the acetoacetyl-CoA formation, which is transformed to 
hydroxymethylglutaryl-CoA (HMG-CoA) by HMG-CoA reductase. HMG-CoA is finally 
converted to Cho through several condensation and isomerisation reactions134. Cholesteryl esters 
(CE) are Cho derivate in which a FA is esterified with the hydroxyl group present on Cho carbon 
C3. This reaction is catalysed by lecithin: cholesterol acyl transferase130. 
2.3.1.5 Saccharolipids and polyketides 
Saccharolipids (SL) are molecules in which fatty acyl groups are directly linked to a sugar 
backbone. These differ from glycolipids in which the fatty acyl portion of the molecule is linked to 
a glycerol backbone. SL include glycans and phosphorylated derivatives. The most common SL are 
the acylated glucosamine precursors of the lipid A component of the lipopolysaccharides in Gram-
negative bacteria127, 128. 
Polyketides (PK) include several characteristic molecules of animals, plants and microbes127, 128. 
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2.3.2 Lipid biological functions 
Lipids are a heterogeneous group of molecules abundant in the diet, and present in blood, tissues 
and cells in which these molecules are not casually dispersed but extremely ordered according to 
their function135. Both free FA and the FA components of complex lipids show different biological 
functions influenced by their structural characteristics. Complex lipids show a role in lipid transport, 
cell membrane structure and cell signalling.  
2.3.2.1 Membrane components 
The fundamental role that lipids play at the level of biological membranes consists in modulating 
the physical assets of the membrane and consequently lipid dynamics, hydrophobic thickness, 
intrinsic contraction tendency, and electrostatic surface136. Plasma membrane is asymmetric: the 
inner leaflet is typically composed of charged PS, large amounts of PE and a smaller content of PC. 
On the contrary, the outer surface is mostly composed of SP, GL and a larger number of PC. This 
configuration is fundamental, and its alteration leads to cell death.  
Specifically, PE and PS play a key role in membrane architecture. PE are characterised by a conical 
structure with a small polar head group that allows the formation of reversible non-lamellar 
structures required, for example, for the formation of intermediate assemblies during membrane 
fusion processes. Furthermore, PE generate pressure stress involved in the membrane curvature, 
modulating the structure, folding and activity of the membrane proteins137.  
Moreover, PS, maintain membrane asymmetry and curvature. PS modulate the assembly and 
activation of different enzyme complexes present on the cell surface. These lipids are also essential 
for the recognition by phagocytes of apoptotic or senescent cells138.  
The inner surface of the plasma membrane is also rich in plasmalogens. Due to their vinyl ether 
bond, these lipids play an important role as endogenous antioxidants and regulate the fluidity, fusion 
tendency and thickness of the membrane139. The increase membrane rigidity due to an increased 
plasmalogens concentration, leads to an improved interaction of receptors with signalling proteins 
involved in the phagocytosis process140. 
Overall, the plasma membrane is formed by a mixture of Cho and saturated (mainly SP) and 
unsaturated lipids mostly represented by PC. Specifically, it is composed of saturated and 
unsaturated FA in an approximate 1:1 ratio. Under homeostatic conditions, , the membrane bilayer 
is fluid allowing lipids of the membrane to migrate within it130. Consequently, alterations of this 
proportion can induce changes in the fluidity of the membrane and thus in its functions. The 
saturated FA that predominantly composed plasma membrane are palmitic acid and stearic acid, 
while the unsaturated FA present in greater quantities are oleic acid and palmitoleic acid141. Both 
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the FA composition of the lipid bilayer and the FA structure (number, position and orientation of 
the double bonds) influence the membrane fluidity, which in turn modulates the activity and 
functions of the integral membrane proteins. 
2.3.2.2 Energy source, cell signaling and gene expression 
FA modulate different cellular functions, as they are not only structural constituents of membrane 
but also energy sources. In fact, FA released following TG hydrolysis are used as fuels through β-
oxidation in mitochondria and peroxisomes. The β-oxidation rate is controlled by the concentration 
of intracellular free FA in turn influenced by the plasmatic concentration of free FA130.  
Moreover, membrane lipids and PL are substrates for the formation of second lipid messengers 
involved in signal transduction. Eicosanoids for example are signalling molecules made by the 
enzymatic or non-enzymatic oxidation of arachidonic acid or other 20-carbon PUFA. These PUFA 
are released from membrane PC by the phospholipase A2 (PLA2) enzyme. Alternatively, the release 
from phosphatidylinositol-4,5-biphosphate is catalysed by phospholipase C or a DAG lipase. 
Furthermore, the hydrolysis of PL by phospholipase C and D leads to the production of second 
messengers such as DAG and PA that activate enzymes such as protein kinase C (PKC). PA are 
also regulators of membrane trafficking as well as key step in PL biosynthesis142. 
In addition to their effect on the cellular signalling process, FA can influence gene expression by 
acting on PPARs transcriptional factors. FA in fact bind directly to PPAR which in turn interacts 
with PPAR response elements in gene promoters specifically those of enzymes involved in the FA 
β-oxidation143.  
Moreover, lipids regulate protein anchor to membrane by protein-lipid interactions. Specifically, 
membrane proteins are linked to glycosyl phosphatidylinositol or sterol, palmitoyl, prenyl moieties 
modulating protein bound to membranes144. 
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2.3.3 Lipids and atherosclerosis 
Lipids are implicated in the pathogenesis of several diseases and alterations of lipid metabolism 
play a key role in various pathologies related to atherosclerosis. For example, a correlation between 
obesity and SM, PC, PE, CE, PI and TAG levels detected in obese patients has been observed145. 
Moreover, patients with familiar hypercholesterolemia are characterized by different ratios of 
SM/PC and PC/LPC compared to normolipidemic subjects as well as by a positive correlation 
between SM and LPC versus LDL and VLDL respectively146. Recent advances in the field of 
lipidomics have made possible to determine the lipidome of atherosclerotic plaques by highlighting 
the presence of CE, SM, PC and LPC128, 147. In particular, unstable plaques are characterized by a 
high lipid content, especially free Cho and CE148, while PL and TAG are present in greater quantities 
in stable plaques. Considering the plasma lipid profile of SA and UA patients, a positive association 
between SA and CER, PI or PE and a negative correlation with LPC and plasmalogens have been 
observed149. Lipids have a specific role in plasmatic lipoprotein structure and a specific lipid 
composition has been observed for each class of plasmatic lipoproteins: LDL are rich in CE and 
SM while HDL have a high content of PC, PE and plasmalogen150. PL are necessary for the 
formation and stability of lipoproteins, which therefore consist of a monolayer of Cho and PL 
(especially PC) surrounding a neutral lipid core composed of TAG and CE. DAG and SP with lower 
concentration are also present in lipoproteins151. In addition, the role of PC biosynthesis in the 
secretion of VLDL152 has been demonstrated since low levels of PC in the endoplasmic reticulum 
lead to an impairment of VLDL formation153. 
As circulating cells, monocytes in blood are exposed to lipoproteins before their migration to the 
injured endothelium. It has been observed that dyslipidaemia can influence the recall of monocytes, 
migration and their phenotype154. In hypertriglyceridemic conditions, the accumulation of non-
classical monocytes and the CCL4-mediated extravasion are increased155.  
TAG are present in plasma often associated with proteins forming triglyceride-rich lipoproteins (i.e. 
VLDL). Recent research shows that VLDL deposit at the level of the endothelium damaging it and 
promoting the recruitment and adhesion of circulating monocytes through the upregulation of 
ICAM-1 and VCAM-1. In addition, VLDL participate in the development of atherosclerotic plaque 
by stimulating the inflammatory process and the production of cytokines156. Hypercholesterolemia 
also stimulates the production of classical monocytes as well as their CCR5-mediated recruitment. 
In patients with familiar hypercholesterolemia, increased levels of CCR2 are observed on 
circulating monocytes that positively correlate with LDL levels and with the accumulation of lipids 
in monocytes157. This shift in the phenotype of monocytes is associated with an increase in the 
number of monocytes and their migratory capacity due to the increased expression of adhesion 
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molecules, chemokine receptors and CD11b, CD11c and CD18 integrins158. Thus, monocytes in the 
extravascular tissue compartment can incorporate circulating lipids transforming into 'foamy 
monocytes', which transport lipids from the blood to peripheral tissues contributing to the formation 
of foam cells. Lipid uptake occurs via LDLR or the scavenger receptors CD36 and SRA1. A high 
lipid loading in monocytes affects the cytoskeleton by blocking the signalling of RhoA family 
molecules leading to an impairment of monocyte migration159.  
2.3.3.1 Role of sphingolipids and lactosylceramide on cellular functions 
SP and their derivatives such as SM, CER, SPH and S1P and GSL are important mediators of cell 
proliferation, differentiation and apoptosis160. SM are related to atherosclerosis due to the 
observation that high levels of these lipids have been observed in atherosclerotic lesions compared 
to normal artery tissues161. In addition, in human carotid plaques, increased levels of SP associated 
with symptoms and production of inflammatory cytokines and histological markers of plaque 
instability, are observed160. Plasma levels of SM and CER are also increased in CAD patients (both 
SA and AMI) compared to healthy subjects162. Moreover, the atherogenic lipoproteins VLDL and 
LDL are rich in SM163. High levels of platelet SM and TAG are observed in STEMI patients 
compared to control subjects164. In addition, plasma concentrations of SM are independent risk 
factors for coronary heart disease and these levels are prognostic in ACS patients165.  
Regarding to S1P, it shows a positive correlation with HDL, its major plasma carrier, and S1P-HDL 
reduce atherosclerosis through inhibition of adhesion molecule expression in endothelial cells and 
production of MCP-1 in SMCs166. However free-S1P shows an opposite effect as it is an 
extracellular ligand for its G protein-coupled receptor and can contribute to inflammatory reactions 
and several cellular responses such as differentiation, survival, apoptosis, proliferation and 
angiogenesis167 through the activation of downstream effectors like adenylate cyclase, 
phospholipase C, phosphatidylinositol-3 kinase, Ras and RhoA168. 
CER mediate several cellular processes such as apoptosis, autophagy, inflammation, FA β-
oxidation and endoplasmic reticulum stress169. Their activity is due to the effect exerted on the 
membranes and by the direct interaction with target proteins. It has been observed that CER form 
large ceramide-rich platforms (CRPs) that play a role in different cellular processes such as cell 
death and immune response through membrane protein recruitment and the formation of receptor 
clustering170. The characteristics of FA that constituted CER, length and saturation of the acyl chain 
specifically, but also the proportion of long-chain and very long-chain species, influence membrane 
fluidity and consequently cell migration171, 172. In addition, CER regulate membrane permeability 
through the formation of channels on lysosomal and mitochondrial membranes173. It has been 
observed that high levels of 16-carbons CER, through the modulation of membrane fluidity, inhibit 
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FA β-oxidation and destroy receptors for insulin signalling174, 175. Indeed, CER appear to be strongly 
related to obesity and insulin resistance176. A role of CER in the formation of atherosclerotic plaque 
has also been highlighted. Specifically, the reduction of plasma levels of very-long chain CER 
correlates with a reduced infiltration of monocytes/macrophages and prevents the formation of 
plaques in atherosclerosis-prone mice177. These results are in agreement with a recent clinical study 
that indicates a high very long chain/long chain CER ratio in plasma as a possible biomarker for 
several heart diseases178. 
GSL play an important role in several cellular functions such as cell-cell recognition, cell adhesion, 
protein trafficking, and signal transducuction179-182. Typically, they are present at low 
concentrations on the outer membrane, however high levels can be observed on the surface of 
specialized cells such as neurons and endothelial cells183. GSL are synthesized by glucose transfer 
from the nucleotide-sugar UDP-glucose, to CER to form GlcCer. Similarly, the addition of 
galactose from UDP-galactose to GlcCer by galactosyltransferase leads to the production of 
lactosylceramide (LacCer)184 (Figure 9).  
 
Galactosyltransferase, also called lactosylceramide synthase, belongs to the family of β-1,4GalT-
transferases and mainly localized in the Golgi apparatus. To date two isoforms, with 68% 
homology185, are known to be present in mammalian tissues: β-1,4GalT-V constitutively expressed 
in most adult tissues and β-1,4GalT-VI whose expression is tissue-specific, and it is predominant 
in adult brain cells and present at low levels in other adult tissues186. The gene encoding for the 
isoform V is for example highly expressed in human endothelial cells185 and is activated by 
inflammatory cytokines such as TNF-α187, 188. In addition, growth factors such as platelet-derived 
growth factor and epidermal growth factor or oxLDL increase enzyme activity in cultured human 
kidney cells, SMCs and human aortic endothelial cells189. The increase in enzyme activity leads to 
a consequent increased production of LacCer. Furthermore, the enzyme activity is inhibited dose-
dependently by D-1-phenyl-2-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a GlcCer 
analogue190 and inhibitor of both GlcCer and LacCer synthase191. In contrast, the L-isoform of 
PDMP induce enzyme activation191. Interest in LacCer synthase and its product LacCer has 
Figure 9 Lactosylceramide 
The structure of lactosylceramide d34:1 (d18:1/16:0) is represented. It is composed by two sugar molecule (glucose and 
galactose), sphingoid base (d18:1) and a 16 carbon chain fatty acid. 
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increased due to the involvement in cell proliferation190, cell adhesion, transendothelial migration 
and angiogenesis187, 192, 193. In vitro studies have demonstrated the ability of exogenously added 
LacCer to bind to glycosaminoglycan present on the outer surface of eukaryotic cells194. In addition, 
human macrophages treated with LDL show an augmented expression of LacCer on cell surface 
revealed by confocal microscopy195. However, influence of LDL on LacCer synthase seems to be 
cell-specific since in normal human kidney cells196 and aortic SMCs197, LDLs decrease enzyme 
activity resulting in inhibition of cell proliferation while a stimulatory effect is observed in human 
renal cancer proximal tubular cells196. Furthermore, LDL are likely to be the transporters of LacCer, 
and subjects with family hypercholesterolemia characterized by non-functional LDLR do not 
efficiently metabolize LacCer198.  
In human aortic SMCs, LacCer have been observed to increase cell proliferation199, an effect also 
shared by oxLDL in a dose-dependent manner190. This action is counteracted by the antibody 
against LacCer and by D-PDMP. These observations suggest that oxLDL-mediated proliferation 
involves the activation of LacCer synthase resulting in the production of LacCer200 which in turn 
promote proliferation through the activation of a signalling cascade involving ROS, p21 Ras GTP, 
MEK and Raf kinases, p44mitogen activated protein kinase and c-fos expression201. In addition, the 
nature of the FA that compose these lipids directly influences the proliferation and production of 
ROS. In fact, in human atherosclerotic plaques, C16:0, C22:0 and C24:0 participate to a greater 
extent in cell proliferation than stearoyl (C18:0)-LacCer202. To carry out this effect, LacCer 
specifically stimulates the activity of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, enzymes that produce ROS. This has been demonstrated in studies conducted on human 
neutrophils in which the addition of exogenous LacCer leads to a production of ROS and increased 
expression of cell surface glycoprotein macrophage-1 antigen (Mac-1) promoting the adhesion of 
neutrophils to endothelial cells203. In a further study on human monocytes U937, LacCer was 
observed to activate PKC and PLA2 thus stimulating the expression of PECAM-1 and adhesion to 
endothelial cells193. Moreover, LacCer and LacCer synthase play a role in mediating the pro-
inflammatory effect of TNF-α released in inflammatory conditions such as atherosclerosis. In 
endothelial cells, TNF-α or oxLDL stimulates LacCer synthase leading to an overproduction of 
LacCer which in turn modulates the NADPH oxidase activity and production of ROS. Through this 
pathway (Figure 10), an increased expression of ICAM-1 by modulation of nuclear factor NF-κB 
and increased adhesion to endothelial cells of monocytes and neutrophils that express Mac-1 occur. 
However, pre-incubation of endothelial cells with D-PDMP, reverse the LacCer-mediated effect. 
This inhibition is avoided by treatment with exogenous LacCer but no other GSL such as GluCer187.  
LacCer is also involved in the angiogenesis that occurs during atherosclerosis. Its involvement is 
demonstrated in both in vitro studies conducted with human aortic endothelial cells and human 
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umbilical vein endothelial cell and in vivo studies in a mouse model of angiogenesis192. These 
studies show how vascular endothelial growth factor (VEGF), mediator of all processes involved 
in angiogenesis such as cell migration, proliferation and differentiation to capillary loops204, dose-
dependently increases the activity of LacCer synthase and LacCer levels as much as TNF-α. 
Similarly, the signalling pathway involves the activation NF-κB that modulates β-1,4GalT-V 
expression and consequently, the formation of ROS, the production of PECAM-1 and the 
recruitment of PLA2 for the induction of angiogenesis. This effect is reverted through the use of D-
PDMP, antibody against LacCer, PECAM-1 and β-1,4GalT-V peptide. In addition, pre-treatment 
of human umbilical vein endothelial cell with antioxidants as N-acetyl-L-cysteine or NF-κB 
inhibitor pyrolidine dithiocarbamate, significantly diminished VEGF- and LacCer- mediated 
PECAM-1 expression192. 
 
 
  
Figure 10 Lactosylceramide signalling pathway 
Tumor necrosis factor-α (TNF- α) and oxidized-low-density lipoproteins (OxLDL) stimulate lactosylceramide synthase 
(LacCer synthase) and lactosylceramide (LacCer) synthesis, which in turn activates nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase leading to reactive oxygen species (ROS) production. ROS modulate nuclear transcription 
factor NF-κB that ultimately involves the overexpression of intercellular adhesion molecule-1 (ICAM-1) on cell surface 
and allows monocyte or neutrophil adhesion through the interaction with macrophage antigen-1 (MAC-1). D-1-phenyl-2-
2-decanoylamino-3-morpholino-1-propanol (D-PDMP) is an inhibitor of this signalling pathway. 
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2.3.4 Lipidomics 
The term 'lipidome' describes the complete lipid composition of a cell, tissue or organism205. The 
application of mass spectrometry (MS) to lipidome analysis has extended the knowledge of the 
wide variety of lipid molecular species. In 2003, Han and Gross coined the term 'lipidomics' to 
indicate a wide-ranging analysis of cellular lipidome through a comprehensive MS approach206. 
Lipidomics aims to identify lipid alterations in a system such as health and disease states, and to 
characterize molecular species involved in lipid metabolism and lipid-mediated signalling207. Due 
to the complexity and heterogeneity of lipid structures, the use of a single experimental approach 
makes the analysis challenging. Thus, lipidomics practices two approaches, the target study of 
individual lipid classes or the untargeted profiling of the entire lipid extracts. The typical workflow 
of an untargeted lipidomics experiment begins with the experimental design followed by sample 
collection and preparation, analytical instrument analysis (data acquisition), data processing, 
statistical analysis and, finally, results interpretation (Figure 11). 
 
  
Figure 11 Lipidomics workflow 
A schematic representation of the untargeted lipidomics workflow is depicted: study design, sample preparation, data 
acquisition (liquid chromatography-quadrupole time of flight-mass spectrometry analysis), data processing, lipid 
identification, statistical analysis and biological data interpretation  
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2.3.4.1 Study design, sample collection and preparation 
The first step, experimental design, is of fundamental importance: in fact, it is necessary to pay 
great attention to sampling the population so that the selected individuals best represent the study 
groups. Furthermore, it is necessary to reduce the variability among the collected samples, since 
different variables can affect the experimental outcome208. In order to determine and examine the 
most influential factors that are relevant for the hypothesis under investigation, external factors that 
can affect the variables have to be eliminated or identified so that they can be accounted for during 
data analysis. In the study design, factors like sample size, randomisation and storage must be all 
be taken into account to guarantee reproducible and successful experiments that minimise incorrect 
variability and yet highlight the metabolites of interest and their potential interactions. 
Sample preparation optimisation is essential to maximise the throughput and reproducibility of the 
analysis. Firstly, the lipid extraction from samples must be highly efficient, reproducible and ensure 
the complete removal of non-lipid contents. The suitable extraction solvents for lipids, consisting 
of both hydrophobic and hydrophilic groups, are methanol and chloroform. The most common 
technique of lipid extraction is the Folch method which uses a mixture of chloroform and methanol 
in a 2:1 ratio followed by a washing step with water for the removal of non-lipid components209. 
The Bligh and Dyer method is a modification of the previous one as it uses chloroform: methanol, 
1:2, thus making it easier to apply to biological fluids210. In this procedure, the adjustment of the 
pH of the aqueous phase and in particular the acidification allows to increase the hydrophobicity of 
lipids, by disturbing their ion interactions, thus increasing the extraction efficiency. In this way, the 
recovery of charged polar molecules such as GP is increased. In addition, acidification improves 
the efficiency of lipid ionization in mass spectrometry analyses. However, the pH must be 
monitored as the ester bonds are susceptible to acid and may encounter hydrolysis. Another factor 
influencing the sample preparation that must be monitored, is temperature as it has been observed 
that cold reduces degradation and increases the stability of lipids211.  
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2.3.4.2 Data acquisition 
The most common analytical platform applied for lipidomics is MS. A first method applied to 
lipidomic studies is the 'shotgun' approach207 which does not require any chromatographic 
separation of lipids before the infusion in the mass spectrometer. This approach is simple, high-
throughput and fast as it requires short data acquisition times. However, many compounds, such as 
PL, after concurrent infusion can compete for ionization in the electrospray ionization (ESI) source 
resulting in ion suppression. This effect can affect the detection of some molecular species. In 
addition, the separation of isobaric molecules is not possible. Other analytical methods provide a 
separation phase. In particular, gas chromatography can be applied for PL analysis. In this method, 
the compounds must be derivatized and high column temperatures are also applied which can lead 
to the degradation of some of them212. Ultra-high pressure liquid chromatography (UPLC), 
compared to other chromatographic methods, displays wide application possibilities in lipidomic 
studies. Typically, for lipid analysis is used the reversed-phase liquid chromatography that is based 
on a stationary non-polar phase (C18 or C8 columns) and mobile phases such as methanol, 
isopropanol or acetonitrile213. In this way, based on lipophilicity, lipids are separated according to 
class and within the same lipid class are separated according to the carbon chain length and the 
amount of double bonds214. 
During the MS analysis, lipids undergo ionization and vaporization in the source and are sorted by 
mass to charge ratio (m/z) in the mass analyser215. The most appropriate method for lipid ionization 
is ESI, a soft ionization technique effective for example for polar lipids that can ionize both 
positively (protonation [M+H]+) and negatively (deprotonation [M-H]-)216. In the so-called 'top-
down lipidomics', lipids can be directly identified on the basis of their m/z value. However this 
approach requires the use of high-resolution mass spectrometers that allow fast scanning and high 
mass accuracy (<5 ppm)217. The Quadrupole Time Of Flight (QTOF) mass spectrometer meets such 
requirements as it combines the stability of a quadrupole with the high efficiency, sensitivity and 
accuracy of a TOF. In the top-down lipidomic, the aim is to identify differences in the lipid pattern 
expressed rather than quantify specific molecules. The latter objective is in fact often pursued by 
the 'bottom-up' lipidomics approach with tandem mass spectrometry (MS/MS) analysis in which 
specific fragments ions allow to identify the related molecules so as to facilitate the analyte 
identification144.  
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2.3.4.3 Data processing 
Data extraction is the first significant step after data acquisition. MS data are characterized by 
information about retention time (RT), m/z values and signal intensity. There are several software 
from instrument companies (e.g. Mass Profile by Agilent Technologies) that propose algorithms to 
process the instrument-generated raw data transforming them into a two-dimensional data matrix 
that reports the measurement of abundance of different metabolites detected in the samples. Data 
processing stages are pre-processing, annotation, post-processing and finally statistical analysis 
performed in order to find metabolites differently expressed in the sample groups analyzed208. 
Data pre-processing includes chromatographic peak integration and alignment, filtering of the data 
by presence in blank samples or by eliminating peaks that do not appear in sample majority. This 
step of data cleaning is of extreme importance because lipidomics experiments often present a large 
amount of noise that can negatively affect the outcome of the analysis. This stage increases the 
quality of the data obtained and the statistical power reducing false positives218.  
Depending on the data processing, peak list can include adducts, isomers or fragments leading to 
several features detected per metabolite. Adduct-finding algorithms and de-isotope procedure are 
usually performed to avoid multiple features for one metabolite. In addition missing values can be 
imputed and data can be normalized and transformed208. This step reduces the variability between 
data by facilitating comparison between different samples.  
Missing values imputation could be performed by different approaches as introducing zero, the 
mean or the median of other samples, k-nearest neighbors (kNN) and random forest (RF) 219. 
Normalization includes statistical methods such as log transformation or auto-scaling or 
biologically-derived methods such as those that take into account the dilution effect of samples208. 
Quality control (QC) strategy is a technique applied to monitor unwanted signal instrumental 
variations that can occur in large number samples analysis and that can be minimized by 
normalization methods. QC is a sample, prepared mixing small and equal amount of all samples 
that should be analyzed repeatedly throughout an individual batch and across different batches. The 
signal variation of each molecular feature in QCs during the run allow correcting the signal of the 
same feature in each sample in relationship to the order of injection220.  
  
2. Introduction 
- 48 - 
 
2.3.4.4 Data analysis 
After data processing, the statistical analysis that can be performed are both univariate (Student’s t-
test, Wilcoxon t-test, ANOVA or Kruskal-Wallis test) and multivariate such as Principal 
Component Analysis (PCA), Partial Least Square (PLS) or Partial Least Squares-Discriminant 
Analysis (PLS-DA)208. Multivariate analyses can be supervised or unsupervised. Unsupervised 
methods investigate possible patterns or trends in data that can be either technical artifacts or 
biological effects. Among these, the PCA is the most widely used technique to obtain an overview 
of the data. PCA is a method of dimensionality reduction that consists in representing, in a 2D or 
3D scatter plot, the maximum variation of the data through the first principal components (PC1 and 
PC2) that are linear combinations of the original variables. The PCA allows therefore to observe 
possible groupings of the analyzed samples and to identify the variables that determine their 
clustering. Supervised methods such as PLS-DA evaluate data variations according to the class 
labels, which can be groups or categories that are assigned to the samples. PLS-DA through the 
score plots represent the separation of the analyzed samples according to the class label. This 
separation, as supervised, is stronger than that given by the PCA; however, it can be misleading as 
it is susceptible to data overfitting. Therefore the results of the PLS-DA must be validated208.  
The molecular features need to be identified as specific metabolites and this identification is based 
on the accurate mass, RT (indicating hydro-lipophilic properties), MS/MS spectra and isotope 
distribution. The acquired MS/MS spectra can be compared with the ones available on in-house 
metabolite spectral libraries or online databases including Human Metabolome Database 
(HMDB)221, Lipid Maps database222 and METLIN Metabolite Database223. All of these, report 
metabolite information about the molecular name, molecular weight, chemical formula, structure 
and physical properties. MS/MS spectra specific for each metabolite can be also found on the online 
databases. In addition, new tools for in silico mass spectra generation using quantum chemistry 
coupled to machine learning methods are emerging224. The Metabolomics Standard Initiative 
defined four levels of identification225: identified metabolites (level 1), putatively annotated 
compounds (level 2), putatively characterized compound classes (level 3), and unknown 
compounds (level 4). Level 1 requires the comparison of experimental metabolite to an authentic 
chemical standard analyzed with the same analytical methods. By contrast, level 2 and 3 annotation 
does not require matching to data for authentic chemical standards but is enough the comparison to 
spectra databases. Level 2 is assigned when a compound matches the online database spectrum 
while level 3 is assigned when only the class to which the compound belongs to, is defined. Finally, 
level 4 represents a discernible spectral signal that can be reproducibly detected and quantified. 
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The development of new therapeutic approaches directed towards monocytes/macrophages, pivotal 
cells in the atherosclerotic plaque formation, is becoming a focal point of interest for many research 
groups. In particular, the definition of a molecular and functional profile of circulating monocytes 
can represent a useful tool for the characterization of inflammatory condition in cardiovascular 
disease.  
In the circulation, monocytes are exposed to various soluble mediators that can lead to cell 
activation and/or metabolic profile alterations. 
Recently it has been observed that an intracellular lipid accumulation alters some cellular functions 
and changes in the composition and organization of cellular lipids can profoundly influence the 
plasticity of membranes and the signal transduction following receptor activation. However, to date, 
information on the relationship between cellular lipid composition and inflammatory response of 
monocytes is still scantly. 
The aim of the study was to determine the lipid profile, through an untargeted lipidomic analysis, 
of monocytes isolated from coronary artery disease patients and healthy subjects, in relation to the 
migratory capacity of these cells.  The characterization of a lipidic and functional profile could 
allow to identify markers that could predict the progression of the atherosclerotic disease.  
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4.1 Study population 
Sixty-two consecutive CAD patients undergoing coronary angiography due to SA or ACS as their 
first manifestation of ischaemic heart disease were enrolled in the study performed at Centro 
Cardiologico Monzino IRCCS (Milan, Italy). SA was defined as angina with stable symptoms for 
at least six months before admission (n=20). ACS diagnosis included NSTEMI (n=21) and STEMI 
(n=21) patients. NSTEMI was defined as chest pain at rest in the last 48 hours prior to admission, 
associated with evidence of transient depression of the ST segment in the 12-lead electrocardiogram 
tracing and elevated serum troponin I levels. STEMI condition was defined by the presence of 
prolonged chest pain (up to 30 min) with a pain onset of less than 12 h, and ST-elevation at the J 
point in ≥2 contiguous leads (≥0.2 mV in V1 through V3 and ≥0.1 mV in other leads). NSTEMI 
patients underwent coronary angiography within 24 h from admission while STEMI patients within 
12 h of symptom onset. All patients underwent a venous blood sample for evaluation of biological 
parameters at the time of the admission. The exclusion criteria from the study were: previous history 
of CAD (i.e. any previous diagnosis of stable or unstable coronary artery disease), severe chronic 
heart failure (NYHA class III-IV), severe heart valve disease, acute and chronic infections, liver 
diseases, neoplasia, evidence of immunologic disorders, use of anti-inflammatory or 
immunosuppressive drugs and recent (<3 months) surgical procedure or trauma. For each patients 
the following cardiovascular risk factors were annotated: family history of early CAD (first degree 
relative with a history of myocardial infarction <60 years), diabetes (fasting blood glucose >126 
mg/dl or treated diabetes), hypercholesterolemia (total Cho >200 mg/dl or treated 
hypercholesterolemia), smoking and hypertension (systolic blood pressure >140 mmHg and/or 
diastolic blood pressure >90 mmHg, or treated hypertension). BMI and laboratory data including 
complete blood count, serum glucose, serum creatinine, and lipid profile were recorded. Drug 
assumption at the time of admission were recorded too. 
Twenty-seven healthy subjects (HS), defined as healthy on the basis of clinical and haematological 
investigations, with no history of CAD, cardiovascular risk factors, inflammatory diseases, and no 
drug therapy for cardiovascular disease, were recruited as control group. 
The study was approved by the institutional ethics committee and was conducted in accordance 
with the Helsinki Declaration. All study participants signed the informed consent at the time of 
enrolment. 
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4.2 Monocyte isolation 
Venous blood samples from healthy volunteers and CAD patients were collected in tubes containing 
ethylenediaminetetaacetic acid as anti-coagulant (EDTA) (9.3 mM; Vacutainer Systems, Becton 
Dickinson, Franklin Lakes, NJ, USA). The laboratory data were recorded for all enrolled subjects. 
Samples were then centrifuged (Megafuge 1.0R centrifuge, Hareaus) at room temperature (700xg, 
4 min) and platelet-rich-plasma was removed. Mononuclear cells were isolated by Ficoll-Paque Plus 
(GE Healthcare, Milan, Italy) density centrifugation (450xg, 20 min, room temperature). To remove 
platelet contamination, the lymphocytes/monocyte-rich layer was washed with PBS (Lonza Italia 
SRL, Bergamo, Italy) containing 1 mM EDTA (Sigma-Aldrich, Milan, Italy).  
To isolate monocytes two different techniques are applied.  
4.2.1 Monocytes isolation by adhesion  
Lymphocytes/monocytes pellet was suspended in RPMI 1640 (Lonza) supplemented with 2mM L-
glutamine (Lonza), 100µg/ml penicillin and 100µg/ml streptomycin (Lonza) and 10% autologous 
serum, freshly obtained from blood clotted for 2h at 37°C. Mononuclear cells were then plated 
(2x106 cells/ml) in 35 mm well plates (PrimariaTM, Falcon, Sacco S.r.l, Como, Italy) and kept at 
37°C (5% CO2). After 2h, non-adherent cells were removed. Adherent monocytes were detached 
with trypsin-EDTA (0,1% trypsin + 0,04% EDTA) and later analyzed by flow cytometry. 
4.2.2 Monocytes isolation by negative selection 
Monocytes isolation was performed using the EasySep Negative Selection Human Monocytes 
Enrichment Kit (Stem Cell Technologies, Voden medical instruments, Monza Brianza, Italy). 
Lymphocytes/monocytes pellet was suspended in PBS at a concentration of 5x107 cells/ml. A 
cocktail of monoclonal antibodies (mAb) was added (1 µl/106 cells); then cells were incubated for 
10 minutes at 4°C. The cocktail is composed by antibodies against specific surface receptors of 
lymphocytes, dendritic cells and erythrocyte i.e. CD2, CD3, CD19, CD20, CD56, CD66b, CD123 
and glycophorin A. Subsequently magnetic particles were added (1 µl/106 cells) and samples 
incubated for 5 minutes at 4°C to let the antibodies bind to the magnetic particles. Cell suspension 
was brought up to a total volume of 2.5 ml with PBS. Samples were then put into the magnet and 
the desired fraction (monocytes) was poured off. The magnetically labelled unwanted cells remain 
held by the magnetic field. Monocytes so obtained were analyzed by flow cytometry to verify the 
samples purity degree.  
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4.3 Flow cytometry 
4.3.1 CD14 monocyte retrieval 
Monocytes obtained through the two different technique, were stained for 15 min at room 
temperature with mAb against CD14 conjugated with fluorophore allophycocyanin (APC, 10 µl). 
Isotype-matched irrelevant antibodies were used as reference. Samples were analyzed by 
FACSCalibur (BD Biosciences) and 1x104 events/sample were recorded. All data were analyzed 
using CellQuest Pro software (BD Biosciences). 
4.3.2 CD14 CD16 monocyte subset analysis in whole blood 
Whole blood (100µl) was stained for 15 min at RT with mAbs against CD14 APC-conjugated (10µl) 
and CD16 conjugated with fluorophore FITC (5µl). FACS lysing solution (700 µl) was added in 
order to remove interference of red blood cells. Isotype-matched irrelevant antibodies were used as 
reference. Samples were analyzed by Gallios (Beckman coulter) and 1x104 events/sample were 
recorded. All data were analyzed using Kaluza analysis software (Beckman coulter). 
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4.4 Monocyte migration 
Monocytes obtained by a negative selection isolation, were suspended, after washing, in RPMI 1640 
(Lonza) supplemented with L-glutamine (2 mM) (Lonza), penicillin and streptomycin (100 µg/ml) 
(Lonza) and seeded into a transwells (2x105 cells/well). Transwells for migration assay are cell 
culture inserts with a permeable membrane (5 µm pore diameter) (Corning ®Costar® 24 well). 
Cells are placed in the upper layer while cell culture medium is placed in the lower chamber. Cell 
culture medium was supplemented with 10% fetal bovine serum (FBS) or autologous serum. In 
addition, to test the migration towards human non-autologous serum, CAD monocytes were 
exposed to a medium supplemented with a pool of sera obtained from healthy subjects (HS serum 
pool); conversely HS monocytes were exposed to a medium supplemented with a CAD serum pool. 
Sera were freshly obtained from blood clotted for 2h at 37°C. Following an incubation period (3h, 
37°C), non-migrated cells were removed from the upper chamber with a cotton swab and cells that 
have migrated through the membrane were fixed in 4% paraformaldehyde and stained with Hoechst 
dyes (Sigma-Aldrich). Migrated cells were counted in a total of 10 randomly selected fields in 
duplicate wells through the Axiovert fluorescence microscope (Axiovert 200M, Zeiss). Migration 
Index is expressed as the ratio between the number of cells migrated into a medium supplemented 
with serum and the number of cells spontaneously migrated in the absence of stimulus. 
To evaluate the contribution of the de novo synthesis of LacCer on monocyte migration, cells were 
pre-incubated for 1 hour prior to the migration assay with the lactosylceramide synthase enzyme 
inhibitor D-PDMP (20 µM). Experiments using TNF-α (10 ng/ml) as a chemotactic agent were used 
as a positive control. The monocyte migration was also evaluated after the treatment of monocytes 
with standard Lactosylceramide (d18:1/16:0) (Avanti Polar Lipids) 2 µM for 30 min. 
  
4. Materials and Methods 
56 
 
4.5 Untargeted lipidomic analysis 
4.5.1 Sample preparation 
Monocytes were thawed in ice, re-suspended in 1 ml of CH3OH and transferred into 7 ml 
borosilicate tubes. Lipids were extracted by adding 2 ml of CH3Cl containing 20 mg/l butylated 
hydroxytoluene (BHT); samples were vortexed for 10 seconds at RT and sonicated in ice in an 
ultrasonic bath for 15 min (Falc, LabService, Milan). One ml of deionized H2O was added, samples 
were vortexed 10 sec and centrifuged (10000xg, 4°C, 10 min). The organic phase was collected, 
and a second extraction of the aqueous phase was performed by adding 50 µl of HCl 37% and 2 ml 
of CH3Cl containing BHT (20 mg/l). The organic phases were pooled, dried in a Speedvac and re-
suspended in 150 µl of CH3OH: CH3Cl 9:1 (v:v). A pool of these lipid extracts for quality control 
(QC) was created by combining 20 µl of each sample. Lipid extracts were aliquoted in two vials for 
the LC-QTOF-MS full scan analysis and the LC-QTOF-MS/MS analysis. Samples were 
randomized prior to injection 
4.5.2 LC-QTOF-MS sample analysis 
LC-QTOF-MS analysis was performed by an ultra-high performance liquid chromatography 
(UHPLC) system (1290 Infinity series, Agilent Technologies) coupled to a QTOF mass 
spectrometry detector (Agilent 6550 iFunnel QTOF) outfitted with Dual-Jet ESI source (Agilent 
Technologies). Samples were analyzed both in positive and in negative detection mode. Two µl was 
injected onto the Zorbax Eclipse Plus C18 Rapid Resolution HD reverse phase column (2.1 x 150 
mm, 1.8 µm, Agilent Technologies), maintained at 35°C, using a constant flow rate of 0.3 ml/min. 
For both positive and negative ionization mode, the mobile phases and their gradients (Table 1) are 
reported.  
A)  CH3CN 50% + NH4COOH 10 mM + 0.1% HCOOH   
B)  IPA 88% + H2O 2% + CH3CN 10% + NH4COOH 10 mM + 0.1% HCOOH 
Time (min) A (%) B (%) 
0 65 35 
20 5 95 
25 0 100 
27.5 0 100 
27.6 65 35 
36 65 35 
Table 1 Gradient elution of the mobile phases 
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The detector operated in full scan mode, acquiring mass spectra over the m/z range 100-1200 Da in 
positive ion mode and 50-1200 Da in negative mode with a scan rate of 1.5 scan per second. Source 
parameters for both ion modes were: drying gas temperature 230°C, drying gas flow 12 l/min, 
nebulizer pressure 35 psig, sheath gas temperature 350 °C, sheath gas flow 12 l/min, nozzle voltage 
1000 V and fragmentor 150 V, skimmer 1,65 V, octopole RF peak 750 V. Capillary voltage was set 
at 3500 V in positive ionization mode and 4000 V in negative one. The references masses, 121.0509 
m/z, 922.0098 m/z (ESI+) and 112.9856 m/z, 1033.9881 m/z (ESI-), were continuously infused to 
correct instrument variability, at a flow rate 0.05 ml/min. Data were acquired by MassHunter 
Workstation Data Acquisition software (Agilent Technologies). 
4.5.3 Performance evaluation 
Performance evaluation was assessed using QC samples approach226. QC samples were obtained by 
pooling together equal volumes of all samples of monocyte lipid extracts (CAD + HS). 
Subsequently, QCs were injected at the beginning of the analytical sequence (n=7), every nine 
injections and at the end of the analysis. 
4.5.4 Data processing 
Raw acquired data were imported in MassHunter Qualitative software (Agilent Technologies), 
converted in mzData and then analyzed by the software MZmine 2.3227 which use peak detection 
algorithm that provides a list of features, which represent possible metabolites, combining different 
information from co-eluting ions such as charge-state, isotopic distribution, presence of adducts 
and/or dimers. The most relevant parameters selected for the feature’s extraction were as follow: 
signal-to-noise ratio of 5, intensity threshold of 1x103 (to clean background noise), mass range of 
250-1000, RT ranging from 2 to 27 min, minimal peak duration of 0.2 min, and maximal peak 
duration of 1.2 min. Chromatogram deconvolution was conducted and then the peak alignment 
algorithm was performed to adjust for any slight variation in RT (RT tolerance: 0% or 0.15 min) 
and m/z (m/z tolerance: 0.005 or 5 ppm). To improve data quality, a manual feature evaluation 
procedure was performed: features present in the blank or subjected to carry over, were excluded.  
Furthermore a filtering quality procedure was applied to deem as reliable features those present in 
at least 90% of the QCs with a CV < 20%220. Features with more than 20% missing values within 
the same group (STEMI, NSTEMI, SA or HS) were removed. Missing values imputation was 
performed using Random Forest algorithm219. The datasets were corrected by sample cell number 
and normalized by sum. The robust lists finally obtained, for positive and negative mode, were 
defined as compound lists. 
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4.5.5 Compound identification 
Lipids identification was performed for each reliable feature included in the two compounds lists 
(positive and negative ionization mode). LipidMaps software was used for detected and accurate 
m/z values matching (10 ppm mass error window) The elution rules for different lipids classes were 
also considered for the identification. To further confirm the lipid putative identification, MS/MS 
analysis were also performed. Specifically, standards for the main lipid classes were purchased and 
their MS/MS spectrum was collected for lipid identification validation. The typical fragments for 
each lipid classes were then matched with the experimental MS/MS fragmentation pattern obtained 
for the putative identified features. In addition, molecular adducts as [M+Na]+ and [M+NH4]
+ in 
positive ionization mode and [M+Cl]-, [M+HCOO]- and [M+HCOONH4]
- in negative ionization 
mode were manually annotated based on RT correspondence, m/z and MS/MS fragmentation 
patterns. 
4.5.5.1 LC-QTOF-MS/MS sample analysis 
The LC-QTOF-MS/MS experiments were performed for every reliable feature included in the two 
compounds list, using the same chromatographic separation and the positive or negative ionization 
conditions previous described. Compounds were targeted using m/z value (isolation width 4 Da) 
and RT (ΔRT 0.6 min), and data were collected applying 30 eV fixed collision energy. Moreover, 
samples with the highest intensity of each compound were analyzed to optimize MS/MS spectra 
quality. Different runs were performed so as to avoid fragmentation of significant compounds co-
eluting in the same analysis. Subsequently, spectra were processed through MassHunter Qualitative 
software (Agilent Technologies). 
4.6 Lactosylceramide synthase levels  
The levels of β-1,4-galactosyltransferase 5, lactosylceramide synthase, was evaluated by ELISA kit 
(MyBioSource, Labospace, Milan). Monocytes obtained from HS and CAD patients were lysed 
with 120 µl of β-octyl glucopiranoside lysis buffer and subjected to 3 freeze and thaw cycles. The 
enzyme expression was evaluated spectrophotometrically at a wavelength of 450 nm and the 
concentration in the samples is then determined by comparing the absorbance of the samples to the 
standard curve.   
4. Materials and Methods 
59 
 
4.7 Statistical analysis 
4.7.1 Monocyte characterization 
Continuous variables are presented as mean ± standard deviation (SD), variables not normally 
distributed are presented as median and interquartile ranges (IQR), and categorical variables as 
absolute numbers and percentages.  
Comparisons between the groups were performed using ANOVA test for normally distributed 
variables, the Kruskal Wallis test for not normally distributed variables. Categorical variables were 
compared using the chi-square test or Fisher's exact test, as appropriate. Post-hoc testing of main 
effects was performed using t-tests with Bonferroni adjustments for multiple comparisons 
(α/[number of comparisons]). Trends of variation from “HS” to “STEMI” were assessed by general 
linear models. Paired t-test was used for paired-group comparisons. 
Further, all analyses were also adjusted for gender and age. 
Correlations between variables were determined using the Spearman’s rank test. 
All tests were two-sided, and a p value < 0.05 was required for statistical significance.  
All calculations were computed with the aid of the SAS software package (Version 9.4 SAS Institute 
Inc., Cary, NC). 
4.7.2 Untargeted lipidomic analysis 
The compound lists obtained from positive and negative modes were treated independently for 
statistical analysis. Mass Profiler Professional software (Agilent Technologies) was employed for 
multivariate analysis as unsupervised PCA and univariate analysis as one-way analysis of variance 
(ANOVA) test or Moderate t-test. For ANOVA test, performed for the fourth study groups (HV, 
SA, NSTEMI, STEMI), post hoc Tukey Honest significant difference (HSD) was performed while 
Benjamini-Hochberg multiple testing correction for controlling the false discovery rate (FDR) was 
applied for both ANOVA and Moderate t-test. Further volcano plot analysis with fold change (FC) 
> or < 1.5 and FDR < 0.05 by the Moderate t-test was used to identify significantly differential 
metabolites between CAD and HV groups.  
Heatmaps were obtained using MetaboAnalyst online software (http://www.metaboanalyst.ca). 
Venn diagrams were drawn by Bioinformatics & Evolutionary Genomics online software 
(http://bioinformatics.psb.ugent.be/webtools/Venn). 
Correlations between variables were performed using the Spearman’s rank test. A p value <0.05 
was considered to indicate statistical significance. 
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5.1 Study population 
The principal demographic, clinical and laboratory characteristics of CAD patient (SA, NSTEMI, 
STEMI) and of healthy subjects, enrolled in this study, are shown in Table 2. 
 
HS 
(n=27) 
SA 
(n=20) 
NSTEMI 
(n=21) 
STEMI 
(n=21) 
p value 
all 
subjects 
p value 
CAD 
groups 
Demographic characteristics 
Age, years 58 ± 11 66 ± 11 62 ± 13 64 ± 10 0.153 0.551 
Male gender, n (%) 15 (55) 20 (100) 15 (71) 15 (71) 0.003 0.015 
Clinical characteristics 
BMI, Kg/m2 25.7 ± 3.6 27.6 ± 2.4 27.4 ± 2.9 28.9 ± 2.1° 0.003 0.145 
Smoke, n (%) 5 (18) 14 (70) 10 (48) 14 (67) 0.001 0.279 
Diabetes, n (%) 1 (4) 6 (30) 5 (24) 8 (38) 0.019 0.602 
Dyslipidemia, n (%) 10 (37) 8 (40) 15 (71) 10 (48) 0.092 0.107 
Hypertension, n (%) 7 (26) 15 (75) 5 (24) 17 (81) 0.0001 0.0003 
Family history of CAD, n (%) - 10 (50) 11 (52) 12 (57) 0.0001 0.896 
Haematological parameters 
WBC, x109/l 5.8 (5.1;7.1) 7.4 (4.2;9.1) 8.8 (7.5;9.2) a 7.5 (7.2;11.2)a 0.0001 0.213 
RBC, x1012/l 4.9 ± 0.4 4.3 ± 0.5a 4.6 ± 0.6 4.6 ± 0.7 0.003 0.183 
Neutrophils, x109/l 3.3 (2.6;4) 4.6 (1.6;5.8) 5.1 (4;6.1) a 4.9 (4;7.8)a,b 0.0002 0.350 
Lymphocytes, x109/l 2 (1.7;2.4) 1.6 (1.1;2.4) 2 ( 1.7;2.1) 2.1 (1.4;2.7) 0.336 0.299 
Eosinophils, x109/l 0.2 (0.1;0.3) 0.1 (0.1;0.2) 0.3 (0.1;0.7)a,b 0.1 (0.1;0.2) 0.013 0.007 
Monocytes, x109/l 0.4 ± 0.1 0.56 ± 0.1a 0.58 ± 0.1 a 0.62 ± 0.3a 0.0001 0.308 
Platelets, x109/l 233.3 ± 46.6 211.6 ± 46.2 227.6 ± 63.2 209.5 ± 27.6 0.248 0.417 
Glycaemia, mg/dl 89 (87;95) 125 (91;126)a 118(104;139)a 118(114;154)a 0.0001 0.514 
Haemoglobin, g/dl 14.8 ± 1 12.5 ± 1.6 a 13.2 ± 1.2 a 13.8 ± 1.6b 0.0001 0.030 
Total cholesterol, mg/dl 211.7 ± 31.1 184.4 ± 31.3 a 215.4 ± 50b 207.7 ± 42.4b 0.054 0.090 
LDL, mg/dl 131.3 ± 27.8 98.4 ± 28.7 a 146.1 ± 41.2 133.1 ± 35.8 0.0002 0.006 
HDL, mg/dl 56 (48;67) 67 (58;78) 43 (40,46)a,b 41 (35;45)a,b 0.0001 0.0001 
Triglycerides, mg/dl 100 (86;125) 70 (59,152) 213(125;224)ab 194(108;211)a,b 0.0001 0.0001 
Pharmacological treatments 
Aspirin, n (%) - 7 (35) 7 (33) 11 (52) 0.0001 0.380 
β-blockers, n(%) 4 (15) 10 (50) 5 (24) 3 (14) 0.033 0.042 
ACE-inhibitors, n (%) 3 (11) 13 (65) 2 (9) 7 (33) 0.0001 0.001 
Statins, n (%) - 8 (40) 5 (24) 6 (29) 0.001 0.514 
Table 2 Study population characteristics 
Baseline demographic, clinical and laboratory characteristics of healthy subjects (HS, n=27) and coronary artery disease 
(CAD, n= 62) patients including patients with stable angina (SA, n=20), non-ST elevation myocardial infarction (NSTEMI, 
n=21) and ST elevation myocardial infarction (STEMI, n=21) patients. Data are expressed as mean±SD or median and 
interquartile range. Categorical variables are expressed as number (percentage). p-values for ANOVA t test or Kruskal-
Wallis test are shown for comparison of the 4 study groups or only of CAD patients (SA, NSTEMI, STEMI).  
a p<0.05 vs HS, b p<0.05 vs SA.  
ACE-inhibitors: angiotensin-converting enzyme inhibitors; BMI: body-mass index; HDL: high-density lipoprotein; LDL: 
low-density lipoprotein; RBC: red blood cells; WBC: white blood cells. 
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In the CAD group there is a prevalence of males (about 80%) compared to the HS group in which 
males are 55%. CAD patients show an older age even if not significant different from HS. Thus, all 
data are adjusted for sex and age. As expected, classical risk factors such as a high BMI, smoking, 
diabetes and hypertension are significant higher in CAD group than in the HS group. Patients show 
higher levels of WBC, sign of their inflammatory condition. Moreover, NSTEMI and STEMI 
patients are characterized by higher LDL and triglycerides and lower HDL compared to HS. 
SA patients show an opposite behaviour probably due to a clinical condition monitored by 
pharmacological treatments such as statins (40%). CAD patients, specifically SA, significantly 
differ from healthy volunteers for the pharmacological treatments since the former received 
cardiovascular therapy. 
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5.2 Monocyte characterization 
5.2.1 Monocyte isolation, retrieval and purity 
To isolate the monocyte population, peripheral blood mononuclear cells (PBMCs), obtained by 
Ficoll-Paque density centrifugation were processed through two different protocols which are 
summarized in Figure 12. 
 
  
Figure 12 Monocyte isolation, retrieval and purity 
Schematic representation of the two techniques applied for monocyte isolation. Peripheral blood mononuclear cells 
(PBMCs) are obtained by Ficoll-Paque density centrifugation and monocytes are isolated by adhesion (on the left) and by 
negative selection (on the right) obtaining an average purity of the cell population of 63.41% ± 5.5 and 81.41% ± 5.42 
respectively, evaluated with flow cytometry.  
63.41% ± 5.5 81.41% ± 5.42 
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In the first strategy, the separation of monocytes form lymphocytes could be performed through the 
adhesion to the plastic, indeed monocytes adhere on plate surface in the presence of a medium 
supplemented with serum. Then after several wash, non-adherent cells could be removed. Adherent 
cells were monocytes with a cell population purity of 63.41% ± 5.5 (n=4) defined on the basis of 
the CD14 expression evaluated by flow cytometry.  
Using the second isolation approach, EasySep Negative Selection Human Monocytes Enrichment 
Kit, the monocyte population purity is higher: 81.41% ± 5.42 (n=4). Indeed, when samples are put 
into the magnet, the magnetically labelled unwanted cells remain held by the magnetic field on the 
contrary, the desired fraction (monocytes) could be poured off. A great advantage of this technique 
is that, through a negative selection, the interaction between monocytes and antibodies or magnetic 
beams is prevented. The cocktail provided by the isolation kit, also contains an FcR blocker to 
prevent non-specific binding to monocytes; thus, by this way monocyte activation is avoided. 
This second technique allows to obtain monocytes with a higher degree of purity and prevent them 
from activation. Consequently, in this study we chose to perform the isolation of monocytes by a 
negative selection. 
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5.2.2 Monocyte counts 
It was first reported in the 1970s that monocytes increase their proliferative activity in bone marrow 
in response to inflammatory stimuli, leading to monocytosis, a clinical condition reflecting an 
increase number of circulating monocytes228. Given the role of inflammation as a precipitating 
factor for atherosclerosis development, a relationship between monocyte counts and cardiovascular 
diseases, is expected.  
5.2.2.1 Total monocyte count 
As shown in Figure 13, CAD patients are characterized by a higher number of monocyte count 
compared to healthy subjects (0.56±0.1 x109/l, 0.58±0.1 x109/l and 0.62±0.3 x109/l for SA, 
NSTEMI and STEMI respectively and 0.4±0.1 x109/l for HS) (p<0.05, p<0.01 and p<0.001 
respectively). Moreover, a progressive increase in the monocyte count going from HS, SA, 
NSTEMI, STEMI, was observed (p for trend< 0.001).  
 
  
Figure 13 Total monocytes count 
Total monocyte count in healthy subjects (HS, n=27), and in patients with stable angina (SA, n=20), non-ST elevation 
myocardial infarction (NSTEMI, n=21) and ST elevation myocardial infarction (STEMI, n=21). Data are represented as 
mean ± standard deviation. *p<0.05 vs HS, **p<0.01 vs HS, ***p<0.001 vs HS; p anova<0.01; p for trend< 0.001. 
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5.2.2.2 Monocyte subset count 
The three monocyte subsets were identified on the basis of the CD14 and CD16 expressions. 
In Figure 14, a representative flow cytometry analysis of monocyte subsets is shown. Overall, 
despite the inter-individual variability, classical monocytes represent the largest subgroup: 80-90% 
of the total monocyte count while non-classical and intermediate monocytes represent 2-8% and 2-
10% of the total circulating monocytes 
 
  
Figure 14 Flow cytometry analysis of monocyte subsets  
Representative flow cytometry plots of the monocyte subsets. CD14++CD16-: classical monocytes, CD14++CD16+: 
intermediate monocytes, CD14+CD16++: non-classical monocytes 
CD14+CD16++ 
Non-classical monocytes 
CD14++ CD16+ 
Intermediate monocytes 
CD14++CD16
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Specifically, classical monocytes do not show significant differences between the study groups 
(Figure 15, panel A). Interestingly, the number of intermediate monocytes appear to be higher in 
CAD patients (specifically in NSTEMI patients) compared to HS and this increase goes in parallel 
with the increase severity of the disease (p for trend< 0.05) (Figure 15, panel B). Moreover, a 
significant positive association between intermediate monocyte count and diagnosis of CAD is 
observed (R= 0.38, p<0.001).  
By contrast, non-classical monocyte count results reduced in CAD patients compared to HS group 
(Figure 15, panel C) and this reduction is marked in SA patients. Moreover, a negative association 
between non-classical monocyte count and diagnosis of CAD is observed (R= -0.30, p<0.01). 
 
  
Figure 15 Monocyte subsets count 
A) Classical monocyte count, B) intermediate monocyte count and C) non-classical monocyte counts in healthy subjects 
(HS, n=27), and patients with stable angina (SA, n=20), non-ST elevation myocardial infarction (NSTEMI, n=21) and ST 
elevation myocardial infarction (STEMI, n=21). Data are represented as mean ± standard deviation.  
B) *p<0.05 vs HS, p anova< 0.001, p for trend< 0.05; C) *p<0.05 vs HS, p anova< 0.01. 
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5.2.3 Monocyte migration 
Monocyte trafficking and migration studies could help to better understand the role of monocytes 
in atherosclerotic disease.  
In this study, the CAD patients and HS monocyte migration in the presence of different type of 
serum which represent a trafficking trigger, was evaluated 
5.2.3.1 Monocyte migration towards FBS or autologous serum 
Monocytes obtained from all the subjects participating to the study (HS, SA, NSTEMI and STEMI), 
were seeded in plates with medium supplemented with 10% of FBS or autologous serum. As shown 
in Figure 16, panel A, a progressive increase in monocyte migration is observed as the severity of 
the disease rises (p for trend<0.001). Moreover, monocytes obtained from STEMI patients have a 
significantly higher migration ability than HS (Migration Index (%): 6.7 ± 5.1 and 3 ± 1.2 
respectively, p<0.01). This result suggests that monocytes obtained from CAD patients (in 
particular from STEMI patients) are more prone to migrate towards FBS serum.  
The same result is also obtained using autologous serum as chemotactic stimulus (Figure 16, panel 
B) and a progressive significantly increase in monocyte migration is observed (p for trend<0.001). 
Specifically, the migration of STEMI and NSTEMI monocytes is higher compared to the HS group 
(Migration Index (%): 3.6 ± 2.8, 3.3 ± 3.1 and 1.5 ± 0.9 for STEMI, NSTEMI and HS respectively, 
p<0.05 vs HS). In addition, a significant positive correlation between the migration performed in 
the presence of FBS (R= 0.24, p<0.05) or autologous serum (R= 0.34, p< 0.01) and CAD diagnosis 
is observed.  
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Figure 16 Monocyte migration towards FBS or autologous serum 
Migration of monocytes obtained from healthy subjects (HS), and patients with stable angina (SA), non-ST elevation 
myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI). Migration is performed in the presence 
of A) fetal bovine serum (FBS) (HS, n= 21; SA, n=17; NSTEMI, n=17; STEMI, n=20) or B) autologous serum as 
chemotactic stimuli (HS, n= 20; SA, n=13; NSTEMI, n=16; STEMI, n=13). Data are represented as mean ± standard 
deviation. A) **p<0.01 vs HS, p anova<0.01, p for trend<0.001; B) *p<0.05 vs HS, p anova<0.05, p for trend<0.001. 
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5.2.3.2 Monocyte migration towards human non-autologous sera 
To evaluate the influence of different sera on monocyte migration, the migration assay was 
performed inducing the migration of monocytes isolated from HS towards a medium supplemented 
with a pool of sera obtained from CAD patients. As shown in Figure 17, panel A, when HS 
monocytes are exposed to a “non-autologous” serum such as FBS or CAD pool sera, their migration 
significantly increase compare to the migration obtained in presence of the autologous serum 
(Migration Index (%): 3.2 ± 1.3, 3.8 ± 3.6 and 1.3 ± 0.8 for FBS, CAD pool and AUTO 
respectively). 
In addition, when CAD patients’ monocytes are exposed to a pool of sera obtained from HS, their 
migration significantly decrease compared to that obtained in presence of the autologous serum 
(Migration Index (%): 1.7 ± 0.9 and 2.9 ±2.3 for HS pool and AUTO respectively, p<0.01).  
Similar to that observed for HS monocytes, CAD patients’ monocytes show increase migration 
towards FBS (Migration Index (%): 4.5 ± 2.4) compared to autologous serum (p<0.001). 
  
Figure 17 Monocyte migration towards serum pool obtained from HS or CAD 
Migration of monocytes obtained from A) healthy subjects (HS, n=11), and B) coronary artery disease (CAD, n= 7) patients 
is performed in the presence of fetal bovine serum (FBS), autologous serum (AUTO) and A) pool of serum obtained from 
CAD patients (CAD pool) or B) pool of serum obtained from HS (HS pool). Data are represented as mean ± standard 
deviation. A) ***p<0.001 vs AUTO, **p<0.01 vs AUTO; B) ***p<0.001 vs AUTO, **p<0.01 vs AUTO 
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5.2.4 Correlation between monocyte migration and monocyte subsets counts 
A positive correlation between the CD14++CD16+ monocyte (intermediate monocytes) count and 
the monocyte migration towards autologous serum is demonstrated. Not significant correlations are 
observed considering monocyte migration with FBS or human non-autologous sera and classical or 
non-classical monocyte counts. 
 
  
Figure 18 Monocyte migration and subset count correlation 
Correlation between monocyte migration towards autologous serum and CD14++CD16+ intermediate monocyte count. 
Monocytes are obtained from healthy subjects (HS, n=27), and coronary artery disease (CAD, n= 62) patients. 
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5.3 Untargeted lipidomics analysis 
5.3.1 Method development and validation 
The lipidomic profile of monocytes obtained from CAD patients and healthy subject, was defined 
by an untargeted mass spectrometry method that simultaneously detect a broad range of lipids. 
Given the complexity and structural variability of lipid molecules, the method development assumes 
a fundamental role in order to define the widest spectrum of molecules that can be detected 
simultaneously.  
For the development of this method, a standard solution containing standards (2 ng/ml, each) 
belonging to different lipid classes was prepared (Table 3). Thus, different methodological aspects 
(instrumental parameters, sample preparation, chromatographic separation and instrumental 
reproducibility) have been evaluated.  
Class Name m/z + m/z - 
Phosphatidylcholine PC (16:0/18:1) 760.5851 758.5706 
Phosphatidylethanolamine PE (16:0/18:1) 718.5381 716.5236 
Phosphatidylserine PS (16:0/18:1) 762.528 760.5134 
Phosphatidylglycerol PG (16:0/18:1) 749.5327 747.5182 
Phosphatidylinositol PI (16:0/18:1) 837.5488 835.5342 
Phosphatidic acid PA (16:0/18:1) 675.4959 673.4814 
Plasmenyl Phosphatidylcholine PC (P-36:1) (P-18:0/18:1) 772.6215 770.6070 
Plasmenyl Phosphatidylethanolamine PE (P-36:1) (P-18:0/18:1) 730.5745 728.5600 
Sphingomyelin SM (d34:1) (d18:1/16:0) 703.5748 701.5603 
Ceramide Cer (d34:1) (d18:1/16:0) 538.5194 536.5049 
Hexosylceramide HexCer (d34:1) (d18:1/16:0) 700.5722 698.5577 
Lactosylceramide LacCer (d42:1) (d18:1/24:0) 974.7502 972.7357 
Monoacylglycerol MG (16:0) 331.2843 329.2697 
Diacylglycerol DG (34:1) (18:1/16:0) 595.5296 593.5151 
Triacylglycerol TG (52:1) (18:0/18:1/16:0) 861.7906 859.776 
Cholesteryl ester CE (18:0) 653.6231 651.6086 
Table 3 Lipid standards 
List of lipid standard employed for the development of the untargeted lipidomic method. For each standard, the lipid class, 
the full name with the fatty acid composition and the m/z values for both positive and negative ionization mode are 
reported. 
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5.3.1.1 Instrument parameters 
There are two kind of instrument parameters: “compound dependent” and “flow dependent”. 
The first ones include voltage of nozzle, capillary, fragmentor and octopole RF peak and are defined 
on the basis of the type of molecules analyzed. The flow dependent parameters as drying gas 
temperature and flow, sheath gas temperature and flow, nebulizer pressure, are influenced by the 
flow rate of the mobile phases. For the evaluation of the instrument parameters, the standard 
solution was directly infused into the source, without chromatographic separation, and the 
parameters were evaluated for both negative and positive ionization mode. 
Table 4 shows the optimal values defined for this method as those providing the greater intensity 
of the standards examined.  
Instrument parameter Value for negative ion mode Value for positive ion mode 
Drying gas temperature (°C) 230 230 
Drying gas flow (L/min) 12 12 
Nebulizer (psig) 35 35 
Sheath gas temperature (°C) 350 350 
Sheath gas flow (L/min) 12 12 
VCap (V) 4000 3500 
Nozzle Voltage (V) 1000 1000 
Fragmentor (V) 150 150 
Skimmer1 (V) 65 65 
Octopole RF peak (V) 750 750 
Table 4 Instrument parameters 
Optimized instrument parameter defined for the untargeted lipidomic method. 
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5.3.1.2 Chromatographic separation 
The choice of both stationary and mobile phases can influence the lipid chromatographic separation. 
The reversed-phase chromatography (C18 column) was chosen since it is the optimal method for 
lipid separation, and it is mainly based on interaction between hydrophobic stationary phase and 
acyl carbon chains of the lipids. Thus, lipid can be eluted according to their class and chain length 
and degree of unsaturation of constituent FA. 
Moreover, mobile phase composition could influence ionization efficiency and specifically the 
mobile phase modifiers can facilitate molecule ionization.  
To keep the concentration constant though the entire mobile phase gradient, in our method, the used 
concentrations of ammonium formate and formic acid, are the same for the mobile phase A and B. 
These modifiers allow the formation of three adducts of molecules ([M+H]+, [M+NH4]
+, [M+Na]+) 
in positive ionization mode; while the formate adduct ([M+HCOO]-) is formed in negative ion 
mode.  
Moreover, two different flow rates were evaluated: 300 µl/min and 400 µl/min. Moreover, to obtain 
the best gradient for lipid separation, the time necessary to reach 100% of mobile phase B was tested 
as both 20 and 35 minutes. In Figure 19 an example of two different gradients and their respective 
chromatograms are reported. For both methods, the time of the isocratic conditions was 5 minutes. 
 
Figure 19 Chromatographic separation optimization 
Representative chromatograms obtained by standard solution, applying different chromatographic gradient reported in 
Table 5 and Table 6. In black is represented the chromatogram obtained using a time of 20 min to reach 100% B. In red is 
represented the chromatogram obtained using a time of 35 min to reach 100% B. 
Time (min) A (%) B (%)
0 65 35
20 0 100
25 0 100
25.5 65 35
35 65 35
Table 5 Gradient elution of the mobile phases
Time (min) A (%) B (%)
0 65 35
35 0 100
40 0 100
40.1 65 35
50 65 35
Table 6 Gradient elution of the mobile phases
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A higher resolution and separation of the chromatographic peaks is observed using a longer time. 
However, a total running time of 50 min is extremely high and would make the sample analysis 
excessively long. So, to explore the possibility of shorting the run time, we analyze in detail the 
lipid elution. As shown in Figure 20, the chromatogram obtained running the standard solution in 
our chromatographic conditions, reveals that in the first 10 min., the most-polar lipids, like LPC 
and LPE elute, followed by MG. Then a highly crowded range between 10 and 20 min contain PL 
(PI, PS, PG, PA, PE, PC), and plasmenyl-PL, most of the SP such as SM and CER. In addition, DG 
are also observed in this range. Finally, in the retention time window from 20 to 27 min, CE and 
TG elute, the least-polar species. Thus, the method we developed applied a total run time of 27 min 
and it is a compromise between running time and chromatographic resolution so as to obtain an 
efficient lipid class separation allowing their identification. 
  
Figure 20 Lipid classes separation 
Representative chromatogram obtained from the lipid standard solution showing lipid classes separation. 
CE: cholesteryl ester; CER: ceramide; DG: diacylglycerol; LPC: lysophosphatidylcholine; LPE: 
lysophosphatidylethanolamine; PA: phosphatidic acid; PC: phosphatidylcholine; PC-P: plasmenyl-phosphatidylcholine; 
PE: phosphatidylethanolamine; PE-P: plasmenyl-phosphatidylethanolamine; PG: phosphatidylglycerol; PI: 
phosphatidylinositol; PS: phosphatidylserine; MG: Monoacylglycerol; SM: sphingomyelin; TG: triacylglycerol. 
PC-P
PE-P
TG
CE
MG
SM
PS 
PGPI
PA
PC
CER
PE
DG
LPC/LPE
5. Results 
 
- 76 - 
 
5.3.1.3 Reproducibility 
The reproducibility of our method was tested injecting the same sample for 5 times in 5 consecutive 
days. As represented below, this method has good reproducibility in terms of both RT and peaks 
area. Figure 21 shows chromatograms obtained from different injections of the same sample: their 
overlap demonstrates the high RT reproducibility. Moreover, a high peaks area reproducibility is 
revealed in Figure 22 showing integration of a representative extracted compound for different 
injections of the same sample. The area of the two peaks related to PC (34:1) show a coefficient of 
variation (CV) below 10% (Table 7).  
 
  
Figure 21 Retention times reproducibility 
Chromatograms obtained from 5 different injections of the same sample in 5 consecutive days. 
Figure 22 Peak area reproducibility 
Integration of the two peaks related to phosphatidylcholine (34:1) for 5 different injections of the same sample in 5 
consecutive days.  
Peak 1
RT 15.3 min
Peak 2
RT 16.3 min
Area mean 18804283 120887420
SD 1014173 3849438
CV% 5.4 3.2
Table 7 Peak Area
Peak 1 
RT 15.3 min 
Peak 2 
RT 16.3 min 
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5.3.1.4 Cell amount 
In order to establish the minimum cell number required for adequate lipid coverage, experiments 
were performed on monocyte samples obtained from 2 different subject. Specifically, samples 
containing 62500, 125000, 250000 and 500000 monocytes were collected. 
An increased number of extracted compounds are observed according to the increased number of 
cells (Figure 23). Analysis of samples containing 500000 monocytes, allows good lipid coverage 
and enough intensity signal. Thus at least 500000 monocytes aliquots were collected for the 
untargeted lipidomic analysis. 
 
  
Figure 23 Sample concentration 
Number of extracted compounds in samples containing 62500, 125000, 250000 and 50000 monocytes obtained from 2 
different subject in A) positive and B) negative ionization mode. 
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5.3.2 Untargeted lipidomic analysis of monocytes 
The untargeted method developed was applied to define the lipidomic profile of monocytes obtained 
from HV and CAD patients and to investigate difference in lipid metabolism. 
5.3.2.1 Performance evaluation  
The reproducibility of sample preparation and analysis was evaluated by QC samples approach. 
The total ion current (TIC) of QCs versus the order of injections (Figure 24) showed the good 
reproducibility of the system response during the whole LC-MS analysis both for positive (panel 
A) and negative (panel B) ion mode (CV 8.56% and 2.81% respectively). In addition, the TICs of 
sample replicates showed a very little intra-run variability and no drift was observed. 
  
Figure 24 Performance evaluation 
Total ion current (TIC) values over all observations (100 injections) in A) positive and B) negative ionization mode. 
Quality controls (QC) are represented by red triangles and samples by blue dots. The green line represents QCs’ TIC mean 
value, the black lines ± standard deviation. 
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5.3.2.2 Data processing 
Raw LC-MS chromatograms obtained from 89 monocyte samples, were processed to extract peak 
profiles of positive and negative ionization mode independently (Figure 25) and converted into two 
different data matrices.  
 
Specifically, the processing of the MS data results in a peak table in which every feature is 
characterized by m/z, RT, and intensity represented by the area under the peak. A total of 259 and 
531 features were detected in positive and negative ionization mode, respectively, and among them, 
137 and 323 features were annotated lipids. Identification was attributed by LipidMaps m/z and RT 
matching and by manual MS/MS spectrum confirmation with specific fragment pattern for different 
lipid classes as reported in Appendix A. 
Only reliable lipids were considered for data analysis and statistics. Eleven lipids were removed 
from the dataset for the negative mode due to the high CV% across samples and to the missing 
values count >20%. In addition, a sample obtained from a STEMI patient was removed from the 
analysis in both ionization modes due to reduced lipid detection in this sample. The two define 
datasets included 137 and 312 lipids for positive and negative ionization mode respectively obtained 
from HV, n=27, SA, n=20, NSTEMI, n=21 and STEMI, n=20 monocytes samples.  
Figure 25 Extracted compounds chromatograms 
Representative extracted compounds chromatograms obtained from a monocyte sample in A) positive and B) negative 
ionization mode. Abundance, expressed as counts, is reported on the Y-axis and time, expressed as minutes, on X-axis. 
A) 
B) 
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5.3.2.3 Monocyte lipidomic profile 
The complete lists of lipids identified are reported in Appendix B for positive (Table B1) and 
negative (Table B2) ionization mode respectively. Collectively, the following lipid classes were 
detected: PL as PC (including PC-P and PC-O), PE (including PE-P and PE-O), PG, PS, and PI; 
LPL (including LPC, LPE, and LPI); SP as SM and CER (including HexCer and LacCer), and TAG. 
Specifically, PL were detected in both ionization mode due to their amphoteric properties, TAG 
were only observed in positive ionization mode while CER better ionized in negative mode. In 
addition, Sph and Cho were also detected (Figure 26). 
 
  
Figure 26 Lipid classes detected 
Pie chart of the lipid classes detected in A) positive and B) negative ionization mode.  
CER: ceramide; Cho: cholesterol; HexCer: hexosylceramide; LacCer: lactosylceramide; LPC: lysophosphatidylcholine; 
LPE: lysophosphatidylethanolamine; LPI: lysophosphatidylinositol; PC: phosphatidylcholine; PC-O: plasmanyl-
phosphatidylcholine; PC-P: plasmenyl-phosphatidylcholine; PE: phosphatidylethanolamine; PE-O: plasmanyl-
phosphatidylethanolamine; PE-P: plasmenyl-phosphatidylethanolamine; PG: phosphatidylglycerol; PI: 
phosphatidylinositol; PS: phosphatidylserine; SM: sphingomyelin; Sph: sphingosine; TAG: triacylglycerol.  
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The two datasets were first subjected to PCA analysis (Figure 27) in order to give a comprehensive 
view of the clustering trend of the analyzed samples obtained from the four study groups. The first 
two PCA components explained 22.48% and 12.08% of the total variance for positive ion mode, 
17.83% and 13.97% for negative ion mode. The PCA score plots revealed a clustering distribution 
of samples obtained by HS (grey dots) against CAD samples and it appear to be more prominent in 
positive detection mode (panel A). In contrast, not a clear separation is observed among SA, 
NSTEMI and STEMI samples for both ionization modes.  
  
• HS • SA • NSTEMI • STEMI 
Figure 27 Principal component analysis score plots 
Score plots of principal component analysis (PCA) models in A) positive and B) negative ionization modes showing the 
clustering trend of the analysed samples obtained from healthy subjects (HS, n=27), and coronary artery disease (CAD, n= 
61) patients including patients with stable angina (SA, n=20), non-ST elevation myocardial infarction (NSTEMI, n=21) 
and ST elevation myocardial infarction (STEMI, n=20) patients. 
A) 
B) 
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Heatmaps as graphical representation of the differential expression of each lipid averaged for the 
study population were then generated (Figure 28). For the positive dataset (panel A), the up-
regulation of TAG in HS against all the CAD groups is the most prominent result. In addition, LPC 
and partly LPE, appear strongly up-regulated in STEMI, compared to HS. On the contrary, PC and 
to a lesser extent PE are down-regulated in STEMI against HS. For these lipid species, SA and 
NSTEMI seem to show an intermediate expression between the two extreme conditions HS and 
STEMI. Regarding the negative ionization mode (panel B), CER show a clear down-regulation in 
STEMI compared to HS while SA and NSTEMI appear to be transitional state between the two 
groups. Moreover, PI and PS are strongly up regulated in STEMI patients. 
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Figure 28 Heatmap analysis 
Heatmaps showing a graphic representation of the differences in relative lipids expression among healthy subjects (HS), 
patients with stable angina (SA), non-ST elevation myocardial infarction (NSTEMI) and ST elevation myocardial 
infarction (STEMI) patients in A) positive and B) negative ionization mode. The colour is correlated with the intensity of 
the lipid expression, with red indicating up-regulation and blue indicating down-regulation.  
CER: ceramide; Cho: cholesterol; HexCer: hexosylceramide; LacCer: lactosylceramide; LPC: lysophosphatidylcholine; 
LPE: lysophosphatidylethanolamine; LPI: lysophosphatidylinositol; PC: phosphatidylcholine; PC-O: plasmanyl-
phosphatidylcholine; PC-P: plasmenyl-phosphatidylcholine; PE: phosphatidylethanolamine; PE-O: plasmanyl-
phosphatidylethanolamine; PE-P: plasmenyl-phosphatidylethanolamine; PG: phosphatidylglycerol; PI: 
phosphatidylinositol; PS: phosphatidylserine; SM: sphingomyelin; Sph: sphingosine; TAG: triacylglycerol.  
A) B) 
Cho
CER
LPC
LPE
PC-O
PC-P
PC
PE
PI
PS
SM
TAG
HS           SA     NSTEMI   STEMI
Sph
LPI
LacCer
HS         SA     NSTEMI  STEMI
SM
PS
PI
PG
PE
PE-O
PC
PC-P
PC-O
LPE
LPC
HexCer
CER
5. Results 
 
- 84 - 
 
5.3.2.4 Statistical analysis 
For statistical analysis, ANOVA test performed using one-way, followed by the Benjamini-
Hochberg multiple testing correction, showed 60 (positive ion mode) and 74 (negative ion mode) 
lipids significantly dysregulated among the four study groups (Figure 29) 
  
  
Figure 29 One-way analysis of variance 
Graphical representation of the results obtained after one-way analysis of variance (ANOVA) test for the dataset in A) 
positive and B) negative ion mode. On the y-axis -log10(p) is reported. The dots represent the lipids and the red colour 
highlights the lipids significantly regulated (p < 0.05; -log10(p)>1.3). Black lines represent -log10(p)=1.3 cut off. 
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For the analysis in positive mode (Table 5), mainly TAG, followed by PC, are significantly 
dysregulated among HS and CAD patients. Others PL that significantly differ are PE and PS. In 
addition, among LPL, LPE and LPC are observed. SM is another lipid class that is modified. 
Lipid adj p * 
Pairwise 
test # 
Lipid adj p * 
Pairwise 
test # 
CER 0.0044 αβγ SM (d34:1) [M+H]+ <0.0001 αβγ 
CER (d42:1) [M+H]+ 0.0032 αγ SM (d34:1) [M+Na]+ 0.0066 βγ 
LPC 16:0 [M+H]+ 0.0382 - SM (d42:2) [M+H]+ 0.0063 βγ 
LPC 16:0 [M+H]+ 0.0282 α TAG 44:0 [M+Na]+ 0.0150 βγ 
LPC 18:1 [M+H]+ 0.0349 - TAG 44:0 [M+NH4]
+ 0.0271 αγ 
LPC 18:1 [M+H]+ 0.0326 α TAG 46:0 [M+Na]+ 0.0161 βγ 
LPE 22:4 [M+H]+ 0.0326 α TAG 46:0 [M+NH4]
+ 0.0170 αβγ 
LPE 22:5 [M+H]+ 0.0405 α TAG 47:0 [M+Na]+ 0.0386 γ 
PC (O-32:O) (O-16:0/16:0) [M+H]+ 0.0153 αβγ TAG 48:0 [M+Na]+ 0.0088 αβγ 
PC (P-34:0) (P-18:0/16:0) [M+H]+ 0.0036 αβγ TAG 48:0 [M+NH4]
+ 0.0012 αβγ 
PC 32:0 (16:0/16:0)  [M+Na]+ 0.0073 βγ TAG 50:0 (16:0/16:0/18:0) [M+Na]+ 0.0048 αβγ 
PC 33:1 [M+H]+ 0.0314 γ TAG 50:0 (16:0/16:0/18:0) [M+NH4]
+ 0.0018 αβγ 
PC 36:1 (18:0/18:1) [M+H]+ 0.0048 α TAG 50:1 (16:0/16:0/18:1) [M+Na]+ 0.0003 αβγ 
PC 36:2 (18:1/18:1) [M+H]+ 0.0195 γ TAG 50:1 (16:0/16:0/18:1) [M+NH4]
+ <0.0001 αβγ 
PC 36:4 (16:0/20:4) [M+H]+ 0.0161 αγ 
TAG 52:0 (16:0/18:0/18:0) 
(16:0/16:0/20:0) [M+NH4]+ 
0.0067 αβγ 
PC 36:4 (18:2/18:2) [M+H]+ 0.0447 α 
TAG 52:0 (16:0/18:0/18:0) 
(16:0/18:0/20:0) [M+Na]+ 
0.0048 αβγ 
PC 38:3 (18:0/20:3) [M+H]+ 0.0004 αβγ TAG 52:1 (16:0/18:0/18:1) [M+Na]+ 0.0001 αβγ 
PC 38:4 (18:0/20:4) [M+H]+ 0.0001 α TAG 52:1 (16:0/18:0/18:1) [M+NH4]
+ 0.0003 αβγ 
PC 38:4 (18:0/20:4) [M+Na]+ 0.0087 αγ TAG 52:2 (16:0/18:1/18:1) [M+Na]+ 0.0013 αβγ 
PC 38:5 (16:0/22:5)(18:1/20:4) [M+Na]+ 0.0368 αγ TAG 52:2 (16:0/18:1/18:1) [M+NH4]
+ 0.0007 αβγ 
PC 38:6 (18:2/20:4) [M+H]+ <0.0001 αβγ TAG 52:3 (16:0/18:1/18:2) [M+Na]+ 0.0007 αβγ 
PC 40:5 (18:1/22:4) [M+H]+ 0.0372 β TAG 52:3 (16:0/18:1/18:2) [M+NH4]
+ 0.0003 αβγ 
PC 40:6 (18:0/22:6) [M+H]+ 0.0271 αγ TAG 54:0 (18:0/18:0/18:0) [M+Na]+ 0.0170 αβγ 
PC 40:6 (18:1/22:5) ) [M+H]+ 0.0405 - TAG 54:0 (18:0/18:0/18:0) [M+NH4]
+ 0.0109 αβγ 
PE 34:1 (16:0/18:1) [M+H]+    0.0022 αγ 
TAG 54:1 (18:0/18:0/18:1) 
(16:0/18:1/20:0) [M+NH4]
+ 
<0.0001 αβγ 
PE 36:1 (18:0/18:1) [M+H]+ 0.0207 βγ TAG 54:1 (18:0/18:0/18:1) [M+Na]+ 0.0004 αβγ 
PE 36:2 (18:1/18:1) [M+H]+   0.0036 γ 
TAG 54:2 (18:0/18:1/18:1) 
(16:0/18:1/20:1) [M+NH4]+ 
0.0153 β 
PS 36:2 (18:0/18:2) (18:1/18:1) [M+H]+ 0.0161 α TAG 54:2 (18:0/18:1/18:1) [M+Na]+ 0.0195 αβ 
PS 40:5 (18:0/22:5) [M+H]+ 0.0299 α TAG 54:3 (18:1/18:1/18:1) [M+Na]+ 0.0051 αβ 
SM (d34:0) [M+H]+ <0.0001 αβγ TAG 54:3 (18:1/18:1/18:1) [M+NH4]
+ 0.0077 αβ 
Table 5 One-way analysis of variance for positive dataset 
List of lipids significantly regulated among healthy subjects (HS), patients with stable angina (SA), non-ST elevation 
myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI) patients. 
*: adjusted p-value obtained from one-way analysis (ANOVA) and Benjamini-Hochberg multiple testing correction 
#: pairwise comparison after post hoc Tukey Honest significant difference  
    α: STEMI vs HS 
    β: NSTEMI vs HS 
    γ: SA vs HS 
 
CER: ceramide; LPC: lysophosphatidylcholine; LPE: lysophosphatidylethanolamine; PC: phosphatidylcholine; PC-O: 
plasmanyl-phosphatidylcholine; PC-P: plasmenyl-phosphatidylcholine; PE: phosphatidylethanolamine; PS: 
phosphatidylserine; SM: sphingomyelin; TAG: triacylglycerol.  
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Concerning the negative dataset (Table 6), CER is the class that appears mainly dysregulated and 
specifically LacCer but not HexCer has a significantly different expression in the study groups. 
Moreover, PC and PE and the corresponding lyso forms LPC and LPE show a significant variation. 
Other lipid classes that result after the ANOVA test are PI, PS and SM. 
Lipid adj p * 
Pairwise 
test # 
Lipid adj p* 
Pairwise 
test # 
CER (d39:1) [M+HCOO]- 0.0013 αβγ CER (t42:0) [M+Cl]- 0.0172 α 
CER (d39:1) [M+HCOONH4]
- 0.0127 αβγ CER (t42:0) [M+HCOO]- 0.0017 αβγ 
CER (d40:0) [M+Cl]- 0.0146 α LacCer (d34:1) (d18:1/16:0) [M+Cl]- 0.0008 αβγ 
CER (d40:0) [M+HCOO]- 0.0088 αβγ LacCer (d34:1) (d18:1/16:0) [M+HCOO]- 0.0098 αβγ 
CER (d40:0) [M+HCOO]- 0.0073 αβγ LacCer (d34:1) (d18:1/16:0) [M+HCOONH4]
- 0.0452 αβγ 
CER (d40:0) [M+HCOONH4]
- 0.0172 αβ LPC 16:0 [M+HCOO]- 0.0031 α 
CER (d40:1) [ADDUCT]- 0.0287 αγ LPC 18:1 [M+HCOO]- 0.0201 α 
CER (d40:1) [M+Cl]- 0.0007 αβγ LPC 20:4 [M+HCOO]- 0.0079 αγ 
CER (d40:1) [M+HCOO]- 0.0040 αβγ LPE 22:4 [M-H]- 0.0172 α 
CER (d40:1) [M+HCOONH4]
- 0.0024 αβγ LPE 22:5 [M-H]- 0.0211 βγ 
CER (d40:2) [M+Cl]- <0.0001 αβγ LPE 22:6 [M-H]- 0.0473 α 
CER (d40:2) [M+HCOO]- 0.0179 αβγ PC (P-34:O) (P-18:0/16:0) [M+HCOO]- 0.0044 αβγ 
CER (d40:2) [M+HCOONH4]
- 0.0011 αβγ PC 36:3 (16:0/20:3) [ADDUCT]- 0.0230 γ 
CER (d41:0) [M+Cl]- 0.0017 αβγ PC 36:4 (16:0/20:4)(18:2/18:2) [M+HCOO]- 0.0402 γ 
CER (d41:0) [M+HCOO]- 0.0041 αβγ PC 38:4 (18:0/20:4) [ADDUCT]- 0.0201 αγ 
CER (d41:0) [M+HCOONH4]
- 0.0003 αβγ PC 38:4 (18:0/20:4) [M+HCOO]- 0.0006 αβγ 
CER (d41:1) [ADDUCT]- 0.0287 αβ PC 40:6 (18:1/22:5) / (18:0/22:6) [M+HCOO]- 0.0052 αγ 
CER (d41:1) [M+Cl]- 0.0105 αβ PC 40:7 (18:1/22:6) [M+HCOO]- 0.0333 γ 
CER (d41:1) [M+HCOO]- <0.0001 αβγ PE (O-38:5) (O-16:0/22:5) [M-H]- 0.0302 βγ 
CER (d41:1) [M+HCOONH4]
- <0.0001 αβγ PE 32:0 (16:0/16:0) [M-H]- 0.0003 αβγ 
CER (d41:2) [M+HCOONH4]
- 0.0024 αβγ PE 34:1 (16:0/18:1) [ADDUCT]- 0.0010 αβγ 
CER (d42:0) [ADDUCT]- 0.0460 α PE 34:1 (16:0/18:1) [M-H]- 0.0024 αβγ 
CER (d42:0) [M+HCOO]- 0.0006 αβγ PE 36:1 (18:0/18:1) [M-H]- 0.0024 αβγ 
CER (d42:0) [M+HCOONH4]
- 0.0011 αβγ PE 36:2 (18:1/18:1) [M-H]- 0.0013 αβγ 
CER (d42:1) [M+Cl]- 0.0054 αβγ PE 36:2 [ADDUCT]- 0.0402 α 
CER (d42:1) [M+HCOO]- 0.0037 αβγ PE 38:2 (18:1/20:1) [M-H]- 0.0007 αβγ 
CER (d42:2) [ADDUCT]- 0.0287 - PE 40:7 (18:1/22:6) [M-H]- 0.0037 αβγ 
CER (d42:2) [M+Cl]- 0.0460 γ PI 36:1 (18:0/18:1) [M-H]- 0.0303 α 
CER (d42:2) [M+HCOO]- 0.0260 βγ PI 36:2 (18:1/18:1) [M-H]- 0.0007 αβγ 
CER (d43:0) [M+HCOO]- 0.0211 β PI 36:2 (18:1/18:1) [M-H]- 0.0280 α 
CER (d43:1) [M+HCOO]- 0.0007 αβγ PS 36:1 (18:0/18:1) [M-H]- 0.0302 α 
CER (d43:1) [M+HCOONH4]
- 0.0007 αβγ PS 40:6 (18:0/22:6) [M-H]- 0.0201 α 
CER (d44:1) [M+HCOO]- 0.0036 αβγ SM (d34:0) [M+HCOO]- 0.0001 αβγ 
CER (d44:1) [M+HCOONH4]
- 0.0179 βγ SM (d34:1) [ADDUCT]- 0.0146 βγ 
CER (t34:1) [M+HCOONH4]
- 0.0326 γ SM (d34:1) [M+HCOO]- 0.0022 αβγ 
CER (t40:0) [M+HCOO]- 0.0037 αβ SM (d34:2) [M+HCOO]- 0.0302 γ 
CER (t40:0) [M+HCOONH4]
- 0.0077 α SM (d42:2) [M+HCOO]- 0.0287 βγ 
Table 6 One-way analysis of variance for negative dataset 
List of lipids significantly regulated among healthy subjects (HS), patients with stable angina (SA), non-ST elevation 
myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI) patients. 
*: adjusted p-value obtained from one-way analysis (ANOVA) and Benjamini-Hochberg multiple testing correction 
#: pairwise comparison after post hoc Tukey Honest significant difference  
    α: STEMI vs HS 
    β: NSTEMI vs HS 
    γ: SA vs HS 
 
CER: ceramide; LacCer: lactosylceramide; LPC: lysophosphatidylcholine; LPE: lysophosphatidylethanolamine; PC: 
phosphatidylcholine; PC-P: plasmenyl-phosphatidylcholine; PE: phosphatidylethanolamine; PE-O: plasmanyl-
phosphatidylethanolamine; PI: phosphatidylinositol; PS: phosphatidylserine; SM: sphingomyelin. 
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Specifically, the performed post hoc Tukey HSD highlights the STEMI vs HS, NSTEMI vs HS and 
SA vs HS as significant pairwise comparisons in both ionization modes. On the contrary, no lipids 
appear to be a potential discriminating factor among the patient groups. 
In Figure 30, the Venn diagrams highlighting the number of lipids that characterize significant 
pairwise comparisons are depicted. Most of the lipids are common to the three pairwise 
comparisons: 26 lipids belonging to the CER (and among them LacCer) and PE classes for positive 
and 39, mainly TAGs for negative ion mode. Considering the single comparison, STEMI vs HS is 
characterized by the highest number of lipids (9 and 13 for the positive and negative modes, 
respectively). These lipids belong mainly to the LPL (LPC and LPE) and PS lipid classes. 
Moreover, this result is observed in both datasets. In addition, some PC (for the positive mode) and 
some CER (for the negative mode) are evidenced. A lower number of lipids characterizes the 
NSTEMI vs HS and SA vs HS comparisons. 
 
Overall, the results obtained by the ANOVA test suggest that the lipid composition of monocytes 
is substantially different between patients and healthy subjects, but it is not possible to highlight 
particular differences among the three pathological conditions. Moreover, these statistical results 
are consistent with the results obtained by the PCA analysis.  
Figure 30 Venn diagrams 
Venn diagrams of the differentially expressed lipids resulting from the pairwise comparison of STEMI vs HS, NSTEMI 
vs HS and SA vs HS in A) positive and B) negative ion mode.  
HS: healthy subjects; NSTEMI: non-ST elevation myocardial infarction patients; SA: stable angina patients;  
STEMI: ST elevation myocardial infarction patients. 
A) B) 
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In order to highlight the major differences in terms of lipid composition of monocytes obtained 
from healthy subjects and pathological subjects, SA, NSTEMI and STEMI patients were combined 
into a single group (CAD) and volcano plot analysis was performed (Figure 31). 
 
 
After Moderate t-test followed by Benjamini-Hochberg multiple testing correction and by applying 
a FC cut off of 1.5, 8 and 40 lipids for positive and negative ionization mode respectively, are 
significantly dysregulated between CAD and HS groups. Specifically, among the 8 lipids for the 
positive mode, 3 LPE are up-regulated in patients (FC >1.5) while the others including 2 TAG, PE, 
PC and CER show increased expression in HS (Table 7).  
  
Figure 31 Volcano plot analysis 
Graphical representation of the results obtained after volcano plot analysis for the dataset in A) positive and B) negative 
ion mode. On the y-axis, -log10(p) is reported. On the x-axis, log2(Fold change) is reported. The dots represent the lipids. 
The red colour highlights the lipids significantly up-regulated in patients (p < 0.05; -log10(p)>1.3 and fold change > 1.5; 
log2(Fold change) > 0.58). The grey colour highlights the lipids significantly up-regulated in healthy subjects (p < 0.05; -
log10(p)>1.3 and fold change < 1.5; log2(Fold change) < 0.58). Green lines represent -log10(p)=1.3 and log2(Fold change) 
= 0.58 cut offs. 
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Lipid adj p * FC# Lipid adj p * FC# 
CER 0.0003 -1.95 PC 38:6 (18:2/20:4) [M+H]
+ <0.0001 -1.54 
LPE 22:4 [M+H]+ 0.0164 1.52 PE 36:1 (18:0/18:1) [M+H]+ 0.0035 -1.52 
LPE 22:4 [M+H]+ 0.0246 1.76 TAG 50:1 (16:0/16:0/18:1) [M+Na]+ <0.0001 -1.51 
LPE 22:5 [M+H]+ 0.0052 1.66 TAG 52:3 (16:0/18:1/18:2) [M+NH4]
+ <0.0001 -1.50 
Table 7 Volcano plot analysis for positive dataset 
List of lipids significantly regulated between healthy subjects (HS) and coronary artery disease (CAD) patients. 
*: adjusted p-value obtained from moderate t-test and Benjamini-Hochberg multiple testing correction 
#: fold change (FC) calculated comparing CAD vs HS 
 
CER: ceramide; LPE: lysophosphatidylethanolamine; PC: phosphatidylcholine; PE: phosphatidylethanolamine; 
TAG: triacylglycerol 
 
On the other hand, 21 lipids are up-regulated in CAD while 19 are up-regulated in HS for the 
negative ionization mode. All CER, except for CER (d40:0) [M+HCOO]- and CER (t42:0) 
[M+HCOONH4]
- appear to be increased in HS. On the contrary all the 3 adducts of LacCer (d34:1) 
are significantly higher in CAD. In addition, PC, PE and their lyso form LPC and LPE characterize 
CAD patients. In addition, PI 36:2 (18:1/18:1) [M-H]-, PS 40:4 (18:0/20:4) [M-H]-, and SM (d34:2) 
[M+HCOO]- show a FC >1.5 (Table 8). 
 
Lipid adj p * FC# Lipid adj p * FC# 
CER (d39:1) [M+Cl]- 0.0092 -1.69 LacCer (d34:1) (d18:1/16:0) [M+Cl]
- <0.0001 1.96 
CER (d39:1) [M+HCOO]- <0.0001 -1.63 LacCer (d34:1) (d18:1/16:0) [M+HCOO]- 0.0006 1.61 
CER (d40:0) [M+Cl]- 0.0024 -1.75 LacCer (d34:1) (d18:1/16:0) [M+HCOONH4]
- 0.0045 1.50 
CER (d40:0) [M+HCOO]- 0.0006 -1.66 LPC 16:0 [M+HCOO]- 0.0018 2.51 
CER (d40:0) [M+HCOO]- 0.0006 1.80 LPC 18:1 [M+HCOO]- 0.0270 2.12 
CER (d40:0) [M+HCOONH4]
- 0.0014 -1.61 LPC 20:4 [M+HCOO]- 0.0008 1.98 
CER (d41:0) [M+Cl]- <0.0001 -1.82 LPE 22:4 [M-H]- 0.0048 3.19 
CER (d41:0) [M+HCOO]- 0.0002 -1.91 LPE 22:5 [M-H]- 0.0014 2.16 
CER (d41:0) [M+HCOONH4]
- <0.0001 -1.66 LPE 22:6 [M-H]- 0.0436 1.96 
CER (d41:1) [ADDUCT]- 0.0195 -1.57 PC (P-34:0) (P-18:0/16:0) [M+HCOO]- 0.0002 1.62 
CER (d42:0) [ADDUCT]- 0.0048 -2.01 PC 36:3 (16:0/20:3) [ADDUCT]- 0.0026 1.91 
CER (d42:0) [M+HCOO]- <0.0001 -1.99 PE 32:0 (16:0/16:0) [M-H]- <0.0001 2.79 
CER (d42:0) [M+HCOONH4]
- <0.0001 -1.84 PE 34:1 (16:0/18:1) [ADDUCT]- <0.0001 1.58 
CER (d43:0) [M+HCOO]- 0.0048 -1.74 PE 36:2 (18:1/18:1) [M-H]- 0.0001 1.52 
CER (d44:1) [M+HCOO]- 0.0237 -1.94 PE 38:2 (18:1/20:1) [M-H]- <0.0001 2.47 
CER (d44:1) [M+HCOONH4]
- 0.0092 -1.51 PE 40:4 (18:0/22:4) [ADDUCT]- 0.0061 1.54 
CER (t40:0) [M+HCOO]- 0.0006 -1.52 PE-NMe2 (16:0/20:4) [ADDUCT]- 0.0213 -2.64 
CER (t42:0) [M+Cl]- 0.0106 -1.67 PI 36:2 (18:1/18:1) [M-H]- <0.0001 1.84 
CER (t42:0) [M+HCOONH4]
- 0.0195 2.44 PS 40:4 (18:0/20:4) [M-H]- 0.0405 1.79 
CER (t44:1) [M+Cl]- 0.0299 -1.65 SM (d34:2) [M+HCOO]- 0.0029 1.56 
Table 8 Volcano plot analysis for negative dataset 
List of lipids significantly regulated between healthy subjects (HS) and coronary artery disease (CAD) patients. 
*: adjusted p-value obtained from moderate t-test and Benjamini-Hochberg multiple testing correction 
#: fold change (FC) calculated comparing CAD vs HS 
 
CER: ceramide; LacCer: lactosylceramide; LPC: lysophosphatidylcholine; LPE: lysophosphatidylethanolamine; 
PC: phosphatidylcholine; PC-P: plasmenyl-phosphatidylcholine; PE: phosphatidylethanolamine;  
PI: phosphatidylinositol; PS: phosphatidylserine; SM: sphingomyelin 
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5.3.2.5 Lactosylceramide (d34:1) (d18:1/16:0) 
LacCer (d34:1) (d18:1/16:0) has been identified among the lipids capable of discriminating between 
CAD and HS because all the 3 adducts of this molecule show a high degree of significance 
associated with high FC. 
The identification of LacCer was confirmed through the analysis of the fragmentation spectrum 
obtained by LC-MS/MS. Figure 32 shows the structure and fragmentation spectrum of LacCer 
(d34:1) (d18:1/16:0) [M+HCOO]-. In particular, the [M-H]- ion m/z 860 is observed which is 
generated by the loss of a molecule of formate (46 Da). The neutral loss of sugar residues, typical 
of LacCer, forms the fragments m/z 698 and 536 while the fragment 179 is the residual sugar itself. 
Finally, fragment 263 identifies a rearrangement of the Sph (d18:1) that constitutes the backbone 
of LacCer. 
 
  
Figure 32 Lactosylceramide (d34:1) (d18:1/16:0) fragmentation pattern 
Fragmentation pattern of Lactosylceramide (d34:1) (d18:1/16:0) [M+HCOO]-. Blue arrows reported neutral losses. The 
main fragments and their structures are also reported. 
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The relative intensity of the 3 molecule adducts ([M+Cl]-, [M+HCOO]- and [M+HCOONH4]
-) and 
of their sum are reported in boxplots (Figure 33). 
 
 
 
 
  
Figure 33 Lactosylceramide (d34:1) (d18:1/16:0) boxplots 
Normalized intensity values reported by boxplots of Lactosylceramide (d34:1) (d18:1/16:0) A) [M+Cl]- adduct, B) 
[M+HCOO]- adduct, C) [M+HCOONH4]- adduct and D) sum of the three adducts in coronary artery disease (CAD) 
patients and healthy subjects (HS). 
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5.4 Role of lactosylceramide in monocyte migration 
 
5.4.1 Lactosylceramide synthase levels in monocytes 
The level of β-1,4 GalT-V, the lactosylceramide synthase, was evaluated by ELISA analysis.  
A significant increase of this enzyme was evidenced in monocytes obtained from CAD patients 
compared to HS. 
 
 
  
Figure 34 Lactosylceramide synthase level  
Level of β-1,4 GalT-V, the lactosylceramide synthase enzyme in monocytes obtained from healthy subjects (HS, n=10) 
and coronary artery disease patients (CAD, n=25); *p<0.05. 
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5.4.2 Effect of lactosylceramide synthase inhibitor on monocyte migration 
To evaluate the involvement of LacCer in monocyte migration, monocytes were treated with D-
PDMP, an inhibitor of glucosylceramide synthase and lactosylceramide synthase. TNF-α was used 
as positive control since TNF-α is known to promote the lactosylceramide synthase activity, leading 
to a marked production of LacCer186  
The treatment of monocytes with D-PDMP, markedly reduced the monocyte migration induced by 
TNF-α (Figure 35, panel A). Moreover, D-PDMP significantly reduced the migration of monocyte 
obtained from CAD patients induced by FBS used as chemotactic stimulus, suggesting that the 
increased migration showed by patient’s monocytes may be partially dependent by the increased 
levels of LacCer detected (Figure 35, panel B). 
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Figure 35 Effect of lactosylceramide synthase inhibitor on monocyte migration 
Migration of monocytes obtained from coronary disease patients is performed in the presence of A) tumor necrosis factor 
α (TNF-α, 10 ng/ml) or B) fetal bovine serum (FBS, 10%) as chemotactic stimulus. Monocytes were treated with D-PDMP, 
the lactosylceramide synthase inhibitor, (20 µM, for 1 hour) were indicated.  A) n=3, *p<0.05; B) n=7, **p<0.01 
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5.4.3 Effect of exogenous lactosylceramide on monocyte migration 
Monocytes obtained from HS were treated for 30 min with standard LacCer (d34:1) (d18:1/16:0) at 
different concentrations: 0.1, 0.5 and 2 µM. The treatment of monocytes with LacCer 2 µM allows 
to obtain 2-fold increase in the LacCer content (Figure 36, panel A) similar to the increased 
observed in CAD patients monocytes. Moreover, a significantly increase in HS monocytes 
migration was highlighted after the monocyte treatment with standard LacCer (2 µM) (Figure 36, 
panel B). 
 
  
Figure 36 Effect of exogenous lactosylceramide on monocyte migration 
Monocytes obtained from healthy subjects were treated for 30 min with Lactosylceramide (d34:1) (d18:1/16:0) (LacCer). 
A) Monocyte incorporation of LacCer evaluated by mass spectrometry. Data are expressed as the ratio between the LacCer 
pick area detected before and after the monocyte treatment with LacCer. (n=3); *p<0.05. 
B) Monocyte migration performed after the exogenous addition of LacCer (d34:1) (2 µM); (n=7), *p<0.05. 
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5.4.4 Correlation between endogenous lactosylceramide levels and monocyte subsets  
The LacCer endogenous levels showed a positive correlation with the CD14++CD16+ monocyte 
(intermediate monocytes) count. In contrast, a negative correlation between CD14+CD16++ non-
classical monocyte count and the lipid levels was shown.  
 
 
5.4.5 Correlation between endogenous lactosylceramide levels and monocyte migration  
A significant positive correlation between endogenous LacCer levels and the monocyte migration 
towards autologous serum is demonstrated. In contrast, not a significant correlation is observed 
considering monocyte migration towards FBS. 
 
 
Figure 37 Correlation between lactosylceramide level and monocyte subsets 
Correlation analysis between lactosylceramide (d34:1)(d18:1/16:0) levels and A) CD14++CD16+ intermediate monocytes, 
B) CD14+CD16++ non-classical monocytes. Monocytes are obtained from healthy subjects (HS, n=27) and coronary 
artery disease patients (CAD, n=62).  
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Figure 38 Correlation between lactosylceramide level and monocyte migration 
Correlation analysis between lactosylceramide (d34:1)(d18:1/16:0) levels and monocyte migration towards autologous 
serum as chemotactic agent. Monocytes are obtained from healthy subjects (HS, n=27) and coronary artery disease patients 
(CAD, n=62).  
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Atherosclerosis is a chronic inflammatory disease in which the immune response and several 
metabolic risk factors contribute to the formation and progression of arterial vessel lesions229. It is 
the foremost cause of CAD and specifically the heterogeneity of atherosclerotic plaques leads to 
different clinical manifestation including SA, NSTEMI and STEMI with an associated increasing 
degree of severity. SA patients are characterized by an obstructive stable plaque while NSTEMI 
and STEMI are acute conditions in which the plaque rupture leads to a thrombus formation that will 
result in heart attack50.  
Immune cells, and among them monocytes, play a key role in plaque progression from the early 
lesion to the final plaque rupture229. In this study we delinate the lipidomic profile and the functional 
characterization of circulating monocytes in CAD patients compared to HS. 
Circulating monocytes represent about 10% of total peripheral leukocytes. Several studies have 
described an increase in the count of circulating monocytes in subjects with atherosclerotic 
disease230, 231 and a reduction in the number of monocytes was reported to suppress the progression 
of atherosclerosis in animal models232, 233. Thus, total blood monocyte count appear to be an 
independent predictor of cardiovascular events234, 235 and a risk factor for CAD disease in humans234. 
In this study population, the total monocyte count is higher in CAD group compared to HS and, in 
particular, a progressive increase that goes in parallel with the severity degree of the disease is 
observed. STEMI and NSTEMI patients show an elevated monocyte count compared to SA and 
HS, as symptom of their acute condition. This result is in agreement with a larger cohort study 
involving ACS patients including UA, NSTEMI and STEMI patients236. Moreover, the distribution 
of the three monocyte subsets, classical CD14++CD16-, intermediate CD14++CD16+ and non-
classical CD14+CD16++, was also evaluated. In healthy condition, the three population represents 
about 85%, 10% and 5% of the whole monocyte population respectively. Several studies have 
evaluated the changes in the different subsets of circulating monocytes in relation to cardiovascular 
diseases, and an increase of the intermediate subgroup is considered a predictor of poor 
cardiovascular outcome116. In addition, it was observed that intermediate monocytes increase in 
subjects with coronary plaque compared to those without, markedly in patients with severe 
stenosis237 and in SA patients with a proatherogenic plasma lipoprotein profile238. Accordingly, in 
our study, the intermediate monocyte count is higher in CAD patients, and this increase goes in 
parallel with the severity of the disease supporting the role of this subgroup in the atherosclerosis 
onset and progression. 
On the contrary, the role of classical and non-classical monocytes is still not completely understood. 
Recently, Leers et al showed an increase of all three subsets in ACS patients compared to control 
subjects, at the time of the hospital admission236. However, when the time elapsed between the acute 
event and blood collection is extended, there is no difference in non-classical monocyte count 
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suggesting that the increase occurs only in the acute phases of ACS239. Moreover, a diminish count 
levels of this subset was observed in CAD patients with cumulative high-risk scores or with 
established risk factors such as smoking or CAD familiarity compared to low-risk subjects240. 
Overall, patients enrolled in our study show lower non-classical monocytes than HS. Since this 
subset exhibit patrolling and regenerative potential in ischemic tissue, this result suggests that in 
CAD patients, a reduced extravasion of non-classical monocytes might be occurred. 
Considering classical monocytes, these represent the largest portion of the cell population. 
However, no differences in the count of classical monocytes was evidenced among CAD patients 
and HS. 
Overall, these results suggest that among the three subsets, the imbalance of the intermediates is 
associated to CAD disease since the proportion of these cells is increased both in clinical condition 
with acute or chronic inflammation114, 241. 
Monocyte migration is a crucial step in atherogenesis and plaque progression. The continuous 
recruitment of monocytes into the subendothelium, contributes to vascular inflammation and 
promotes plaque progression and the onset of adverse cardiovascular events242, 243; while the 
suppression of monocyte recruitment towards plaques leads to a regression of the disease244. 
Moreover, the trafficking of monocytes towards the aortic wall is proportional to the severity of the 
disease245 and an increased migration promotes plaque instability and triggers plaque rupture246. 
In our study, monocyte migration was evaluated using FBS as chemotactic stimulus and monocytes 
isolated from CAD patients show a greater propensity to migrate than those obtained from HS. In 
particular, an increase of the migration index from SA to NSTEMI and STEMI patients was 
observed. This result suggest that the trafficking attitude can be due to intrinsic characteristics of 
monocytes that are different for CAD and HS. Moreover, similar results are also obtained when 
migration is evaluated in the presence of autologous serum as a trafficking trigger. These results are 
in accordance with Zalai et al. who observed increase circulating monocyte activation in patients 
with unstable coronary syndromes246. Nevertheless, the exposure of CAD monocytes to a pool of 
sera collected from HS reduced the cells trafficking attitude. In parallel, the migration of HS 
monocytes is increased when a pool of sera obtained from CAD patients is used as a chemotactic 
agent thus highlighting an additional role of serum and its composition in the modulation of 
monocyte migration. Overall, these results suggest that CAD monocytes are functionally altered, 
and that serum is one of the factors that can contribute to their activation.  
The up-regulation of cytokines and chemokines that may be present in serum is indeed critical for 
the recruitment of monocytes to the endothelium and their subsequent migration247 and it represents 
a key mechanism for vascular inflammation and atherogenesis248. Indeed, high circulating levels of 
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CCL19 and CCL21 have been observed to be increased in SA patients and even more in UA 
patients249. Moreover, the high expression of these chemokines and their CCR7 receptor in 
atherosclerotic coronary tissue has been associated with a progression of the atherosclerotic lesion 
due to a promotion of monocyte adhesion and migration248. In contrast, the blocking CCR5, CCR2 
or CX3CR1 reduced the migration of murine monocytes 250 with a decrease of the size of the 
atherosclerotic lesion251. Recently Weber et al. have shown the expression of CCR2 to be peculiar 
of classical and intermediate monocytes in spite of non-classical monocytes252 while the presence 
of CX3CR1 on monocyte surface seems to be upregulated in the intermediate and non-classical 
subsets236. Consistent with the increased adhesion and migration of intermediate monocytes, we 
have observed a positive correlation between the count of intermediate monocytes and the migration 
of monocytes supporting the pro-inflammatory role of this subsets and their involvement in the 
atherosclerotic plaque development.  
During circulation in the blood stream, monocytes are exposed not only to cytokines and 
chemokines but also to other agents and among them lipid mediators, systemic signals that can 
induce functional reprogramming and alter their functions253, 254. In particular, altered blood lipid 
levels may induce an inflammatory phenotype in monocytes255. In in vitro experiments have shown 
that even a short exposure of human monocytes to a low concentration of oxLDL, is able to induce 
a cellular modification resulting in a differentiation of monocyte into a proatherogenic macrophage 
phenotype256. In addition, atherogenic levels of LDL induce changes in monocyte phenotype 
associated to an increase of the expression of adhesion molecules and to a reduction of apoptosis 
detected in early phases of monocyte differentiation into macrophages257. Alterations in the lipid 
metabolism of monocytes may lead to the formation of foamy monocytes characterized by the 
presence of intracellular lipid droplets. For example, it has been observed that a single meal with a 
high fat content is enough to induce an accumulation of lipids in circulating monocytes258. 
Moreover, monocytes obtained from hypercholesterolemic patients have an enhanced capacity to 
infiltrate into arterial wall compared to those from healthy subjects259. In addition, 
hypertriglyceridemia promotes the adhesion of monocytes, especially the intermediate subsets, to 
endothelial cells through VCAM-1 in patients with myocardial infarction260, 261. An opposite effect 
is exerted by reconstituted HDL which administration reduces the expression of CCR2 and 
CX3CR1 on the surface of monocytes262. Overall, lipids play an important role in modulating 
monocyte phenotype and functions likely because off the plasma membrane lipid bilayer 
composition is fundamental for cell proliferation, differentiation, migration, cell-cell contacts and 
signal transduction processes263. As regard to lipid effect on monocyte migration, it has been 
observed that several isoforms of oxidized linoleic acid and LPC were found to be able to stimulate 
the migration of monocytes through the upregulation of the expression of CCR9 and CX3CR1264. 
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In addition, omega-3 FA appear to reduce monocytosis, favorably alter monocyte subsets and 
reduce monocyte recruitment into atherosclerotic lesions in atherosclerotic mice models265. 
Furthermore, the supplementation of PUFA in physiological concentrations induces profound 
alterations in the lipid profile of raft and non-raft plasma membranes microdomains by modifying 
the amount of PUFA substrates available for the synthesis of lipid mediators263.  
On the basis of these observations, in this study, the lipidomic profile of monocytes isolated from 
CAD patients and subjects without a clinical and family history of cardiovascular disease was 
defined and it was related to the migratory capacity of these cells. To this end, an untargeted mass 
spectrometry method was developed that simultaneously detect a broad range of lipid by the use of 
UHPLC system coupled to a QTOF mass spectrometry detector. This equipment compared to 
traditional instruments allows a more efficient ionization of molecules, greater sensitivity and 
linear detector response necessary for this kind of analysis. Moreover, the QTOF instrument 
consents high-resolution performances, which allow to obtain the accurate mass of the detected 
unknown compounds. By this analytical platform, it is possible to perform an untargeted 
lipidomic analysis consisting in the simultaneous detection of different lipid classes so as to 
obtain a wide lipid profile in biological samples. Given the complexity and structural variability 
of lipid molecules, the development process of the method assumes a fundamental role in order 
to define the broadest spectrum of molecules that can be detected simultaneously. For the 
development of this method, different methodological aspects (instrumental parameters. sample 
preparation. chromatographic separation and instrumental reproducibility) have been evaluated 
in order to optimize the conditions for data acquisition so as to obtain reliable results.  
Through this method we were able to detect several lipid classes including LPL such as LPC 
and LPE, PL (PI, PS, PG, PA, PE, PC), and SP such as SM and CER. In addition, among the neutral 
lipids, DG and TG and CE can be detected.  
Overall, in monocytes, 137 and 323 lipids were identified in positive and negative ionization mode 
respectively. Among these, PL (specifically PE and PC and their lyso-forms), SP (particularly CER 
and SM) and TG were found to be the most represented lipid classes. 
However, in our monocyte samples, DG and CE were not identified probably due to low 
concentrations that do not exceed the limit of detection of our method. DG, indeed, is a short-life 
second messenger as it is rapidly metabolized by DG kinase and DG lipase266 to give products 
involved in a variety of cell responses such as cell proliferation, survival and migration267. 
Furthermore, DG is an intermediate of the synthesis of PL and precursors of TG266, which, on the 
contrary, are detected with high amount in our samples. As regard to CE, a recent study highlights 
the ability of monocytes and macrophages, obtained from hypercholesterolemic mice, to 
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accumulate CE when exposed to high concentrations of cholesterol. In addition, a lower activity of 
cholesterol acyltransferase and CE hydrolase in monocytes was observed compared to 
macrophages268. Thus, in monocytes, free cholesterol is likely incorporate in cell membranes while 
it is converted to a reduced extent in CE. These observations may explain the low CE concentration 
in our monocyte samples that do not exceed the limit of detection of our method since  
Considering all other detected lipid classes, we compared the lipid profile of monocytes obtained 
from HS with that obtained from CAD patients. Through the PCA analysis and heatmaps, we 
observed that the lipid profile is similar for monocytes obtained from patients with different CAD 
severity degree: SA, NSTEMI and STEMI, while the differences between HS and CAD are 
considerable. Specifically, we observed elevated levels of LPC against low levels of PC in STEMI 
monocytes while in HS monocytes an opposite behavior is observed. PC are source of arachidonic 
acid that acts as precursor for the synthesis of lipid mediators such as eicosanoids269, 270. The 
upregulation of LPC against PC may therefore mean that in monocytes obtained by patients, PC are 
converted to LPC probably releasing arachidonic acid, mediator needed for the inflammatory 
response271. This result is confirmed by a recent study by Lee et al who defined the lipid profile of 
macrophages raw264.7 and observed down-regulated PC and up-regulated LPC after stimulation 
with a pro-inflammatory stimulus272. LPC in fact are known to be related to atherosclerotic disease 
because patients with atherosclerosis show high plasma levels273, 274 and LPC are also the major 
components of OxLDL275. Moreover, there is a great number of evidence showing the pro-
inflammatory and atherogenic effects of LPCs, which are chemotactic factors for monocytes274, and 
are able to induce the expression of VCAM-1 and ICAM-1276 or MCP-1276, 277. 
In addition, the most striking result showed by the heatmaps graphical representation is the low 
level of CER and TG observed in CAD patients’ monocytes.  
The high TG levels in HS might suggest an increased ability of HS monocytes to remove TG from 
the bloodstream. Indeed, high plasma levels of TG-rich lipoproteins are related to CAD and an 
inefficient clearance induces atherogenesis278 promoting the adhesion of monocytes to 
endothelium279 and the recruitment of monocytes to atherosclerotic plaques280. In accordance with 
these observations, ACS patients enrolled in our study show higher plasma levels of TG than HS, 
lower TG intracellular levels that are associated with increased monocyte migration.  
In addition, the augmented TG intracellular levels observed in HS could be linked to the role of TG 
that act as storage molecules of metabolic energy and FA. A reduced activity of the enzyme that 
catalyzes the final step of TG synthesis in the whole body seems to ameliorate atherosclerotic lesion 
development281, however an increased synthesis of TG, specifically in macrophages, is sufficient to 
protect against inflammation which result from diet-induced obesity and counteract the activation 
of M1 macrophages induced by in vitro treatment with cytokines or FA282. Indeed, increased 
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esterification of FA, as palmitate, in TG pool reduces the FA availability for the synthesis of 
inflammation-related signaling metabolites such as CER, DAG, LPA and eicosanoids283. However, 
we have also observed high levels of CER in HS monocytes, meaning that although the de-novo 
synthesis, starting from palmitate, may be reduced; CER may also derive from SM through 
sphingomyelinase activity or from Sph by ceramidases284.  
Several papers support CER and their high plasma levels to be related to the development of 
atherosclerosis285, 286. Specifically, CER signaling was also observed to be involved in inflammatory 
responses during the development of atheromasic plaques287 and to mediate plaque instability by its 
pro-apoptotic effect on macrophages and SMCs288. However, considering the role of CER as 
membrane components, high levels of CER cause a change in viscosity170, 289, 290, and an increase 
in membrane rigidity resulting in an impaired cell migration as observed in circulating angiogenic 
cells whose release from bone marrow and extravasation towards retinal vascular injury are reduced 
following intracellular CER increase291. The increase in CER production indeed, induces the 
formation of CER-enriched microdomains that strongly influence the organization and dynamic 
properties of the membrane292. In addition, CER can be further metabolized into S1P, a mediator 
that shows proliferation, migration and pro-survival effects293.  
All in all, the high levels of CER observed in HS monocytes may confer membrane rigidity resulting 
in lower monocyte migration. In contrast, in CAD monocytes, CER could be converted into second 
messengers such as S1P that stimulate their migration via autocrine mechanism.  
The conversion of CER into more complex SP such as GlcCer or LacCer is another potential 
mechanism for CER levels reduction. Indeed, what we observe is that among the lipids that 
discriminate CAD patients from HS, LacCer (d34:1) (d18:1/16:0), specifically all three adducts that 
form [M+HCOO]-, [M+Cl]- and [M+HCOONH4]
-, appears to be significantly increased in CAD 
patients compared to HS.  
LacCer is a bioactive SP expressed in vascular cells, macrophages, neutrophils, platelets and 
monocytes189. In our study, monocytes obtained from CAD patients show increased levels of 
LacCer which are also associated with a higher expression of the enzyme β-1,4GalT-V, the 
lactosylceramide synthase, compared to HS monocytes. This enzyme is the target for activation by 
TNF-α187, 188 and OxLDL199, which leads to increased production of LacCer which in turn stimulates 
endothelial cells expression of ICAM-1 thus highlighting the role of this enzyme in proliferative 
disease including atherosclerosis189. The activity of lactosylceramide synthase has been reported to 
be elevated in human atherosclerotic plaques and calcified plaques189, 202 . Several studies have 
demonstrated the role of LacCer in atherosclerosis by showing its high levels in human 
atherosclerotic plaques compared to healthy vascular tissue202 that positively correlate with plaque 
content of pro-inflammatory cytokines as IL-6 and MCP-1 and with lipid and macrophage 
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content294. In addition, LacCer modulates different functions in cells involved in the development 
of atheromasic plaque. In SMCs, LacCer directly stimulates cell proliferation190 and this lipid is 
also involved in the OxLDL-mediated increase in SMCs proliferation since OxLDL induce the 
activation of lactosylceramide synthase and the consequent production of LacCer200. In neutrophils, 
LacCer stimulates their adhesion to endothelial cells through the activation of PLA2, which 
catabolizes PC to arachidonate that in turn causes the increase of expression on the cell surface of 
Mac-1203. Moreover, in monocytes, LacCer activates PKC and PLA2 and stimulates the expression 
of PECAM-1 and the subsequent adhesion to endothelial cells193. The FA moiety of LacCer seems 
also important for the modulation of the effect induced by this lipid since LacCer, isolated from 
patients with polycystic kidney disease295 or from human atherosclerotic plaques202, rich in C16:0, 
C22:1 and C24:0, induce higher cell proliferation than synthetic stearoyl LacCer296. However, 
studies on neutrophils revealed that C24:0 and C24:1 but not C16:0 LacCer are preferentially 
involved in LacCer-mediated neutrophil superoxide generation and migration297.  
Based on these observations, in this study we evidenced that increased levels of C16:0 LacCer, in 
monocytes may contribute to increase cell migration since a positive correlation between the LacCer 
levels and the monocyte migration towards autologous serum was observed. Moreover, by treating 
monocytes with TNF-α we observed a stimulation of migration. TNF-α indeed is known to promote 
the activity of lactosylceramide synthase leading to an overproduction of LacCer that in turn active 
nuclear transcription factor NF-κB increasing the expression of ICAM-1 and the adhesion of 
monocytes to endothelial cells187. This signal transduction pathway induced by TNF- α, is abrogated 
by D-PDMP187, a non-selective inhibitor of lactosylceramide synthase191. In our experimental 
conditions, D-PDMP is able to inhibit not only the migration of monocytes induced by TNF-α but 
also the migration obtained toward FBS as chemotactic agent, suggesting the involvement of 
endogenous LacCer in this process. However, D-PDMP, as a non-selective inhibitor is also able to 
inhibit GlcCer synthesis191. Thus, the reduction in migration observed after treatment of monocytes 
with D-PDMP, could be the result of the inhibited synthesis of GlcCer, precursor of LacCer191 , 
rather than to a direct inhibition of lactosylceramide synthase. However, several papers that have 
studied the mechanism of action by which LacCer induces cellular proliferation and migration, have 
shown that LacCer signaling pathway is mitigated by the addition of D-PDMP and bypassed by 
exogenous LacCer but not by a variety of GSL including GlcCer 187, 188, 298 further endorsing the 
role of LacCer as a mediator of cellular migration. To further confirm the role of LacCer in 
monocyte migration, we treated monocytes obtained from HS with exogenous LacCer. The addition 
of LacCer 2 µM resulted in a 2-fold increase in LacCer levels comparable to that observed for CAD 
monocytes. Under these conditions, LacCer-loading monocytes showed a significant increase in 
migration, still supporting the role of LacCer in monocyte migration.   
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In this study, through an untargeted lipidomic approach, a different lipid profile in CAD patient 
monocytes compared to HS was found. Specifically, a marked increase in lactosylceramide in CAD 
patient’s monocytes was observed which positively correlated with the monocyte migration. In 
addition, monocytes obtained from CAD patients showed, a significant increase in cell migration, 
induced by both FBS and autologous serum, compared to HS. 
The results obtained in this study suggest that the monocyte lipidomic profile can evidence a 
specific lipid composition that may lead to changes in cellular function.  
In particular, by highlighting the key role of lactosylceramide in monocyte migration and thus in 
the inflammatory process underlying the progression of atherosclerotic plaque, this study may help 
to define a potential target for new pharmacological strategies. 
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9.1 Appendix A 
  
Figure A1 Phosphatidylcholine fragmentation 
Representative MS/MS spectra for phosphatidylcholine PC (34:1) (16:0/18:1) in A) positive [M+H]+ and B) negative 
[M+HCOO]- ionization mode. 
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A) 
B) 
Figure A2 Phosphatidylinositol fragmentation 
Representative MS/MS spectra for phosphatidylinositol PI (34:1) (16:0/18:1) in A) positive [M+H]+ and B) negative 
[M+H]- ionization mode. 
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A) 
B) 
Figure A3 Phosphatidylethanolamine fragmentation 
Representative MS/MS spectra for phosphatidylethanolamine PE (34:1) (16:0/18:1) in A) positive [M+H]+ and B) 
negative [M+H]- ionization mode. 
 
(CH2)16CH3
(CH2)14CH3
[M-H]
-
[FA 18:1]
-
[F
A
 1
6
:0
]-
C3H5O-O2
[M+H]+
718.5381
141 Da 
9. Appendixes 
 
- 123 - 
 
  
A) 
B) 
Figure A4 Phosphatidylglycerol fragmentation 
Representative MS/MS spectra for phosphatidylglycerol PG (34:1) (16:0/18:1) in A) positive [M+H]+ and B) 
negative [M+H]- ionization mode. 
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A) 
B) 
Figure A5 Phosphatidylserine fragmentation 
Representative MS/MS spectra for phosphatidylserine PS (34:1) (16:0/18:1) in A) positive [M+H]+ and B) negative 
[M+H]- ionization mode. 
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A) 
B) 
Figure A6 Phosphatidic acid fragmentation 
Representative MS/MS spectra for phosphatidic acid PA (34:1) (16:0/18:1) in A) positive [M+H]+ and B) negative 
[M+H]- ionization mode. 
(CH2)16CH3
(CH2)14CH3
[M+H]+
675.4959
98 Da 
[M-H]
-
[F
A
 1
8
:1
]-
[FA 16:0]
-
FA 18:1 
9. Appendixes 
 
- 126 - 
 
  
[M+NH4]
+
579.53403
[M+NH4]
+
[M+H-H2O]
+
A) 
B) 
C) 
Figure A7 Glycerolipids fragmentation 
Representative MS/MS spectra for A) monoacylglycerol MG (16:0) [M+Na]+, B) diacylglycerol DG (34:1) 
(18:1/16:0) [M+NH4]+, and C) triacylglycerol TG (52:1) (18:0/18:1/16:0) [M+NH4]+ in positive ionization mode. 
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A) 
B) 
Figure A8 Sphingomyelin fragmentation 
Representative MS/MS spectra for sphingomyelin SM (d34:1) (d18:1/16:0) in A) positive [M+H]+ and B) negative 
[M+HCOO]- ionization mode. 
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A) 
B) 
Figure A9 Ceramide fragmentation 
Representative MS/MS spectra for ceramide CER (d34:1) (d18:1/16:0) in A) positive [M+H]+ and B) negative 
[M+HCOO]- ionization mode. 
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A) 
B) 
Figure A10 Hexosylceramide fragmentation 
Representative MS/MS spectra for hexosylceramide HexCer (d34:1) (d18:1/16:0) in A) positive [M+H]+ and B) 
negative [M+HCOO]- ionization mode. 
 
CH3(CH2)14
[M+H]+
[M
+
H
-H
2
O
]+
682.5580
282.2780
162 Da 
[M
+
H
C
O
O
]-
744.57452
[M-H]
-
46 Da 
162 Da 
9. Appendixes 
 
- 130 - 
 
  
A) 
B) 
Figure A11 Lactosylceramide fragmentation 
Representative MS/MS spectra for lactosylceramide LacCer (d42:1) (d18:1/24:0) in A) positive [M+H]+ and B) 
negative [M+HCOO]- ionization mode. 
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9.2 Appendix B 
Table B1: List of lipids detected in positive ionization mode 
Calculated 
m/zα 
Measured 
m/zβ 
Mass error 
(Da)γ 
RT 
(min)δ 
Lipid 
Classε 
IDζ 
538.39683 538.39843 0.0016 17.17 CER CER 
576.56955 576.57196 0.0024 20.80 CER CER 
650.64269 650.64460 0.0019 20.40 CER CER (d42:1) [M+H]+ 
648.62729 648.62890 0.0016 19.62 CER CER (d42:2) [M+H]+ 
369.35110 369.35213 0.0010 15.31 Cho CHOLESTEROL 
496.33866 496.33980 0.0011 5.40 LPC LPC 16:0 [M+H]+ 
496.33869 496.33980 0.0011 4.98 LPC LPC 16:0 [M+H]+ 
522.35396 522.35540 0.0015 5.38 LPC LPC 18:1 [M+H]+ 
522.35424 522.35540 0.0012 5.76 LPC LPC 18:1 [M+H]+ 
520.33396 520.33980 0.0058 4.38 LPC LPC 18:2 [M+H]+ 
520.33518 520.33980 0.0046 4.08 LPC LPC 18:2 [M+H]+ 
544.33832 544.33980 0.0014 4.11 LPC LPC 20:4 [M+H]+ 
544.33842 544.33980 0.0013 3.93 LPC LPC 20:4 [M+H]+ 
568.33743 568.33980 0.0023 3.71 LPC LPC 22:6 [M+H]+ 
568.33793 568.33980 0.0018 3.86 LPC LPC 22:6 [M+H]+ 
502.29169 502.29280 0.0011 4.34 LPE LPE 20:4 [M+H]+ 
502.29189 502.29280 0.0009 4.11 LPE LPE 20:4 [M+H]+ 
524.27420 524.27480 0.0006 4.12 LPE LPE 20:4 [M+Na]+ 
524.27676 524.27480 0.0020 4.35 LPE LPE 20:4 [M+Na]+ 
530.32289 530.32410 0.0012 5.52 LPE LPE 22:4 [M+H]+ 
530.32304 530.32410 0.0011 5.80 LPE LPE 22:4 [M+H]+ 
528.30691 528.30850 0.0015 4.60 LPE LPE 22:5 [M+H]+ 
528.30695 528.30850 0.0015 4.37 LPE LPE 22:5 [M+H]+ 
528.30698 528.30850 0.0015 4.94 LPE LPE 22:5 [M+H]+ 
526.29098 526.29280 0.0018 4.05 LPE LPE 22:6 [M+H]+ 
526.29141 526.29280 0.0014 3.87 LPE LPE 22:6 [M+H]+ 
720.58840 720.59020 0.0018 17.70 PC PC (O-32:O) (O-16:0/16:0) [M+H]+ 
744.58748 744.59020 0.0027 16.76 PC PC (O-34:2) (O-16:0/18:2)/(P-34:1) (P-16:0/18:1) [M+H]+ 
772.61932 772.62150 0.0021 17.89 PC PC (O-36:2) (O:18:0/18:2)/(P-36:1) (P-18:1/18:O) [M+H]+ 
768.58897 768.59020 0.0012 16.52 PC PC (O-36:4) (O-18:0/20:4) [M+H]+ 
796.61704 796.62150 0.0044 17.50 PC PC (O-38:4) (O-16:0/22:4) [M+H]+ 
796.61939 796.62150 0.0021 17.78 PC PC (O-38:4) (O-18:0/20:4) [M+H]+ 
792.58834 792.59020 0.0018 16.23 PC PC (O-38:6) (O-16:0/22:6) [M+H]+ 
746.60402 746.60580 0.0018 17.73 PC PC (P-34:0) (P-18:0/16:0) [M+H]+ 
768.58679 768.58780 0.0010 17.71 PC PC (P-34:0) (P-18:0/16:0) [M+Na]+ 
794.60417 794.60580 0.0016 16.57 PC PC (P-38:4) (P-18:0/20:4) [M+H]+ 
816.58572 816.58780 0.0020 16.58 PC PC (P-38:4) (P-20:0/20:4) [M+Na]+ 
818.60367 818.60580 0.0021 16.27 PC PC (P-40:6) [M+H]+ 
734.56817 734.56940 0.0013 16.61 PC PC 32:0 (16:0/16:0) [M+H]+ 
756.55003 756.55140 0.0013 16.62 PC PC 32:0 (16:0/16:0) [M+Na]+ 
732.55058 732.55380 0.0032 15.59 PC PC 32:1 (16:0/16:1) [M+H]+ 
746.56474 746.56940 0.0047 16.17 PC PC 33:1 [M+H]+ 
762.59843 762.60070 0.0023 17.89 PC PC 34:0 (16:0/18:0) [M+H]+ 
760.58385 760.58510 0.0012 16.71 PC PC 34:1 (16:0/18:1) [M+H]+ 
782.56637 782.56700 0.0007 16.74 PC PC 34:1 (16:0/18:1) [M+Na]+ 
758.56804 758.56940 0.0014 15.79 PC PC 34:2 (16:0/18:2) [M+H]+ 
780.54958 780.55140 0.0018 15.79 PC PC 34:2 (16:0/18:2) [M+Na]+ 
774.59949 774.60070 0.0012 17.39 PC PC 35:1 (17:0/18:1) [M+H]+ 
788.61497 788.61640 0.0014 17.98 PC PC 36:1 (18:0/18:1) [M+H]+ 
810.59667 810.59830 0.0017 17.97 PC PC 36:1 (18:0/18:1) [M+Na]+ 
786.59939 786.60070 0.0013 16.98 PC PC 36:2 (18:1/18:1) [M+H]+ 
808.58161 808.58270 0.0011 16.87 PC PC 36:2 (18:1/18:1) [M+Na]+ 
784.58315 784.58510 0.0019 15.95 PC PC 36:3 (16:0/20:3) [M+H]+ 
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Calculated 
m/zα 
Measured 
m/zβ 
Mass error 
(Da)γ 
RT 
(min)δ 
Lipid 
Classε 
IDζ 
806.56563 806.56700 0.0014 15.94 PC PC 36:3 (16:0/20:3) [M+Na]+ 
782.56803 782.56940 0.0014 15.56 PC PC 36:4 (16:0/20:4) [M+H]+ 
804.54982 804.55140 0.0015 15.57 PC PC 36:4 (16:0/20:4) [M+Na]+ 
782.56714 782.56940 0.0023 14.99 PC PC 36:4 (18:2/18:2)[M+H]+ 
814.63028 814.63200 0.0017 18.06 PC PC 38:2 (18:1/20:1) [M+H]+ 
812.61338 812.61640 0.0030 17.37 PC PC 38:3 (18:0/20:3) [M+H]+ 
810.59769 810.60070 0.0030 16.44 PC PC 38:4 (16:0/22:4) [M+H]+ 
810.59895 810.60070 0.0018 16.81 PC PC 38:4 (18:0/20:4) [M+H]+ 
832.58129 832.58270 0.0014 16.80 PC PC 38:4 (18:0/20:4) [M+Na]+ 
830.56550 830.56700 0.0015 15.68 PC PC 38:5 (16:0/22:5) (18:1/20:4) [M+Na]+ 
808.58347 808.58510 0.0016 15.68 PC PC 38:5 (18:1/20:4) (16:0/22:5) [M+H]+ 
806.56759 806.56940 0.0018 15.28 PC PC 38:6 (16:0/22:6) [M+H]+ 
806.56791 806.56940 0.0015 14.72 PC PC 38:6 (18:2/20:4) [M+H]+ 
838.63013 838.63200 0.0019 17.71 PC PC 40:4 (18:0/22:4) [M+H]+ 
836.61460 836.61640 0.0018 16.87 PC PC 40:5 (18:0/22:5) [M+H]+ 
836.61315 836.61640 0.0032 16.55 PC PC 40:5 (18:1/22:4) [M+H]+ 
834.59964 834.60070 0.0011 16.50 PC PC 40:6 (18:0/22:6) [M+H]+ 
834.60089 834.60070 0.0002 15.86 PC PC 40:6 (18:1/22:5) [M+H]+ 
832.58328 832.58510 0.0018 15.34 PC PC 40:7 (18:1/22:6) [M+H]+ 
718.53760 718.53810 0.0005 16.65 PE PE 34:1 (16:0/18:1) [M+H]+ 
746.57841 746.56940 0.0090 17.70 PE PE 36:1 (18:0/18:1) [M+H]+ 
744.55311 744.55380 0.0007 16.92 PE PE 36:2 (18:0/18:2) [M+H]+ 
744.55294 744.55380 0.0008 16.77 PE PE 36:2 (18:1/18:1) [M+H]+ 
742.53650 742.53810 0.0016 15.92 PE PE 36:3 (18:1/18:2) [M+H]+ 
740.52105 740.52250 0.0014 15.62 PE PE 36:4 (16:0/20:4) [M+H]+ 
768.55289 768.55380 0.0009 16.77 PE PE 38:4 (18:0/20:4) [M+H]+ 
790.53690 790.53570 0.0012 16.77 PE PE 38:4 [M+Na]+ 
764.52128 764.52250 0.0012 15.31 PE PE 38:6 (16:0/22:6) [M+H]+ 
796.58688 796.58510 0.0018 17.51 PE PE 40:4 (18:0/22:4) [M+H]+ 
794.56848 794.56940 0.0010 16.81 PE PE 40:5 (18:0/22:5) [M-H]+ 
792.55470 792.55380 0.0009 16.49 PE PE 40:6 [M+H]+ 
790.53875 790.53810 0.0006 15.41 PE PE 40:7 (18:1/22:6) [M+H]+ 
887.56316 887.56440 0.0012 15.07 PI PI 38:4 (18:0/20:4) [M+H]+ 
909.54448 909.54630 0.0019 15.07 PI PI 38:4 (18:0/20:4) [M+Na]+ 
904.58949 904.59100 0.0015 15.07 PI PI 38:4 (18:0/20:4) [M+NH4]
+ 
790.56736 790.55930 0.0081 16.45 PS PS 36:1 (18:0/18:1) [M+H]+ 
788.54059 788.54360 0.0030 15.33 PS PS 36:2 (18:0/18:2) (18:1/18:1) [M+H]+ 
812.54327 812.54360 0.0003 15.34 PS PS 38:4 (18:0/20:4) [M+H]+ 
834.52388 834.52560 0.0017 15.35 PS PS 38:4 (18:0/20:4) [M+Na]+ 
838.55775 838.55930 0.0015 15.38 PS PS 40:5 (18:0/22:5) [M+H]+ 
675.54181 675.54350 0.0017 13.74 SM SM (d32:1) (M+H]+ 
689.54849 689.55920 0.0107 14.49 SM SM (d33:1) (M+H]+ 
705.58803 705.59050 0.0025 15.70 SM SM (d34:0) [M+H]+ 
703.57327 703.57480 0.0016 15.22 SM SM (d34:1) [M+H]+ 
725.55518 725.55680 0.0016 15.20 SM SM (d34:1) [M+Na]+ 
701.55758 701.55920 0.0016 13.99 SM SM (d34:2) [M+H]+ 
731.60446 731.60610 0.0017 16.50 SM SM (d36:1) [M+H]+ 
759.63580 759.63740 0.0016 17.74 SM SM (d38:1) [M+H]+ 
787.66714 787.66870 0.0016 18.82 SM SM (d40:1) [M+H]+ 
785.65147 785.65310 0.0016 17.84 SM SM (d40:2) [M+H]+ 
815.69844 815.70000 0.0016 19.91 SM SM (d42:1) [M+H]+ 
813.68309 813.68440 0.0013 18.74 SM SM (d42:2) [M+H]+ 
835.66477 835.66630 0.0016 18.76 SM SM (d42:2) [M+Na]+ 
811.66716 811.66870 0.0016 17.87 SM SM (d42:3) [M+H]+ 
300.28898 300.28970 0.0007 4.02 Sph Sph d18:1 
773.66133 773.66300 0.0016 22.27 TAG TAG 44:0 [M+Na]+ 
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Calculated 
m/zα 
Measured 
m/zβ 
Mass error 
(Da)γ 
RT 
(min)δ 
Lipid 
Classε 
IDζ 
768.70598 768.70760 0.0016 22.27 TAG TAG 44:0 [M+NH4]
+ 
782.72165 782.72320 0.0016 22.56 TAG TAG 45:0 [M+NH4]
+ 
801.69252 801.69430 0.0017 22.88 TAG TAG 46:0 [M+Na]+ 
796.73727 796.73890 0.0016 22.88 TAG TAG 46:0 [M+NH4]
+ 
815.70745 815.70990 0.0025 23.18 TAG TAG 47:0 [M+Na]+ 
810.75308 810.75450 0.0014 23.18 TAG TAG 47:0 [M+NH4]
+ 
829.72395 829.72560 0.0016 23.51 TAG TAG 48:0 [M+Na]+ 
824.76881 824.77020 0.0013 23.51 TAG TAG 48:0 [M+NH4]
+ 
857.75537 857.75690 0.0015 24.16 TAG TAG 50:0 (16:0/16:0/18:0) [M+Na]+ 
852.79983 852.80150 0.0016 24.16 TAG TAG 50:0 (16:0/16:0/18:0) [M+NH4]
+ 
855.73987 855.74120 0.0013 23.53 TAG TAG 50:1 (16:0/16:0/18:1) [M+Na]+ 
850.78427 850.78580 0.0015 23.53 TAG TAG 50:1 (16:0/16:0/18:1) [M+NH4]
+ 
880.83082 880.83280 0.0019 24.82 TAG TAG 52:0 (16:0/18:0/18:0) (16:0/16:0/20:0) [M+NH4]
+ 
885.78627 885.78820 0.0019 24.82 TAG TAG 52:0 (16:0/18:0/18:0) (16:0/18:0/20:0) [M+Na]+ 
883.77080 883.77250 0.0017 24.18 TAG TAG 52:1 (16:0/18:0/18:1) [M+Na]+ 
878.81462 878.81710 0.0025 24.17 TAG TAG 52:1 (16:0/18:0/18:1) [M+NH4]
+ 
881.75530 881.75690 0.0016 23.56 TAG TAG 52:2 (16:0/18:1/18:1) [M+Na]+ 
876.79982 876.80150 0.0016 23.56 TAG TAG 52:2 (16:0/18:1/18:1) [M+NH4]
+ 
879.73995 879.74120 0.0013 23.02 TAG TAG 52:3 (16:0/18:1/18:2) [M+Na]+ 
874.78445 874.78580 0.0014 23.03 TAG TAG 52:3 (16:0/18:1/18:2) [M+NH4]
+ 
913.81735 913.81950 0.0021 25.49 TAG TAG 54:0 (18:0/18:0/18:0) [M+Na]+ 
908.86224 908.86410 0.0018 25.49 TAG TAG 54:0 (18:0/18:0/18:0) [M+NH4]
+ 
906.83977 906.84840 0.0086 24.84 TAG TAG 54:1 (18:0/18:0/18:1) (16:0/18:1/20:0) [M+NH4]
+ 
911.79810 911.80380 0.0057 24.84 TAG TAG 54:1 (18:0/18:0/18:1) [M+Na]+ 
904.83021 904.83280 0.0025 24.19 TAG TAG 54:2 (18:0/18:1/18:1) (16:0/18:1/20:1) [M+NH4]
+ 
909.78631 909.78820 0.0018 24.20 TAG TAG 54:2 (18:0/18:1/18:1) [M+Na]+ 
907.77072 907.77250 0.0018 23.59 TAG TAG 54:3 (18:1/18:1/18:1) [M+Na]+ 
902.81532 902.81710 0.0018 23.59 TAG TAG 54:3 (18:1/18:1/18:1) [M+NH4]
+ 
Table 9 List of lipids detected in positive ionization mode 
α: theoretical m/z values matched in Lipid Maps database; 
β: experimental m/z values as calculated by MZmine 2.3 software; 
γ: mass error calculated as difference between theoretical m/z and observed m/z 
δ: retention time values as calculated by MZmine 2.3 software; 
ε: lipid class assign according to Lipid Maps Lipid Classification 
ζ: putative ID assign through m/z matched to databases, retention time and MS/MS spectra interpretation. 
CER: ceramide; Cho: cholesterol; LPC: lysophosphatidylcholine; LPE: lysophosphatidylethanolamine; PC: 
phosphatidylcholine; PC-O: plasmanyl-phosphatidylcholine; PC-P: plasmenyl-phosphatidylcholine; PE: 
phosphatidylethanolamine; PI: phosphatidylinositol; PS: phosphatidylserine; SM: sphingomyelin; Sph: sphingosine; TAG: 
triacylglycerol.  
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Table B2: List of lipids detected in negative ionization mode 
Calculated 
m/zα 
Measured 
m/zβ 
Mass error 
(Da)γ 
RT 
(min)δ 
Lipid 
Classε 
IDζ 
622.46586 622.46590 0.0001 15.45 CER CER (d32:1) [ADDUCT]- 
544.44968 544.45020 0.0005 15.45 CER CER (d32:1) [M+Cl]- 
554.47828 554.47900 0.0007 15.45 CER CER (d32:1) [M+HCOO]- 
571.46881 571.50500 0.0362 15.45 CER CER (d32:1) [M+HCOONH4]
- 
558.46532 558.46590 0.0005 16.09 CER CER (d33:1) [M+Cl]- 
568.49206 568.49470 0.0026 16.09 CER CER (d33:1) [M+HCOO]- 
585.48455 585.52060 0.0361 16.09 CER CER (d33:1) [M+HCOONH4]
- 
652.51309 652.51282 0.0003 17.12 CER CER (d34:0) [ADDUCT]- 
574.49670 574.49720 0.0005 17.14 CER CER (d34:0) [M+Cl]- 
574.49698 574.49720 0.0002 17.37 CER CER (d34:0) [M+Cl]- 
584.52525 584.52600 0.0007 17.12 CER CER (d34:0) [M+HCOO]- 
584.52553 584.52600 0.0004 17.38 CER CER (d34:0) [M+HCOO]- 
601.51595 601.55195 0.0360 17.12 CER CER (d34:0) [M+HCOONH4]
- 
601.51603 601.55195 0.0359 17.38 CER CER (d34:0) [M+HCOONH4]
- 
582.51026 582.51030 0.0000 16.69 CER CER (d34:1) (d18:1/16:0) [M+HCOO]- 
650.49759 650.49717 0.0004 16.69 CER CER (d34:1) [ADDUCT]- 
572.48142 572.48150 0.0001 16.69 CER CER (d34:1) [M+Cl]- 
599.50056 599.53630 0.0357 16.69 CER CER (d34:1) [M+HCOONH4]
- 
536.50406 536.50480 0.0008 16.69 CER CER (d34:1) [M-H]- 
648.48156 648.48152 0.0000 15.66 CER CER (d34:2) [ADDUCT]- 
570.46597 570.46590 0.0001 15.66 CER CER (d34:2) [M+Cl]- 
580.49418 580.49470 0.0005 15.66 CER CER (d34:2) [M+HCOO]- 
597.48445 597.52065 0.0362 15.66 CER CER (d34:2) [M+HCOONH4]
- 
596.52493 596.52600 0.0010 17.26 CER CER (d35:1) [M+HCOO]- 
602.52808 602.52850 0.0004 18.19 CER CER (d36:0) [M+Cl]- 
612.55486 612.55730 0.0024 18.17 CER CER (d36:0) [M+HCOO]- 
629.54804 629.58325 0.0352 18.17 CER CER (d36:0) [M+HCOONH4]
- 
678.52860 678.52847 0.0001 17.79 CER CER (d36:1) [ADDUCT]- 
600.51403 600.51280 0.0012 17.79 CER CER (d36:1) [M+Cl]- 
610.54136 610.54160 0.0002 17.79 CER CER (d36:1) [M+HCOO]- 
627.53180 627.56760 0.0358 17.79 CER CER (d36:1) [M+HCOONH4]
- 
598.50004 598.49720 0.0029 16.88 CER CER (d36:2) [M+Cl]- 
608.52549 608.52600 0.0005 16.88 CER CER (d36:2) [M+HCOO]- 
625.51588 625.55195 0.0361 16.88 CER CER (d36:2) [M+HCOONH4]
- 
624.55472 624.55730 0.0025 18.31 CER CER (d37:1) [M+HCOO]- 
641.54711 641.58325 0.0361 18.30 CER CER (d37:1) [M+HCOONH4]
- 
630.55924 630.55980 0.0005 19.10 CER CER (d38:0) [M+Cl]- 
640.58302 640.58860 0.0055 19.05 CER CER (d38:0) [M+HCOO]- 
657.57904 657.61455 0.0355 19.09 CER CER (d38:0) [M+HCOONH4]
- 
706.55982 706.55977 0.0000 18.76 CER CER (d38:1) [ADDUCT]- 
628.54675 628.54410 0.0027 18.76 CER CER (d38:1) [M+Cl]- 
638.57266 638.57290 0.0002 18.76 CER CER (d38:1) [M+HCOO]- 
655.56313 655.59890 0.0358 18.76 CER CER (d38:1) [M+HCOONH4]
- 
636.55672 636.55730 0.0005 17.97 CER CER (d38:2) [M+HCOO]- 
653.54733 653.58325 0.0359 17.97 CER CER (d38:2) [M+HCOONH4]
- 
642.55962 642.55980 0.0001 19.22 CER CER (d39:1) [M+Cl]- 
652.58770 652.58860 0.0009 19.22 CER CER (d39:1) [M+HCOO]- 
669.57851 669.61455 0.0360 19.21 CER CER (d39:1) [M+HCOONH4]
- 
736.60839 736.60672 0.0017 19.90 CER CER (d40:0) [ADDUCT]- 
658.59059 658.59110 0.0005 19.90 CER CER (d40:0) [M+Cl]- 
668.61188 668.61990 0.0080 20.30 CER CER (d40:0) [M+HCOO]- 
668.61948 668.61990 0.0004 19.90 CER CER (d40:0) [M+HCOO]- 
685.60974 685.64585 0.0361 19.90 CER CER (d40:0) [M+HCOONH4]
- 
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Calculated 
m/zα 
Measured 
m/zβ 
Mass error 
(Da)γ 
RT 
(min)δ 
Lipid 
Classε 
IDζ 
734.59136 734.59107 0.0003 19.61 CER CER (d40:1) [ADDUCT]- 
656.57640 656.57540 0.0010 19.61 CER CER (d40:1) [M+Cl]- 
656.57639 656.57540 0.0010 19.13 CER CER (d40:1) [M+Cl]- 
666.60396 666.60420 0.0002 19.61 CER CER (d40:1) [M+HCOO]- 
666.60275 666.60420 0.0015 19.09 CER CER (d40:1) [M+HCOO]- 
683.59460 683.63020 0.0356 19.60 CER CER (d40:1) [M+HCOONH4]
- 
683.59340 683.63020 0.0368 19.10 CER CER (d40:1) [M+HCOONH4]
- 
732.57642 732.57540 0.0010 18.77 CER CER (d40:2) [ADDUCT]- 
732.57596 732.57540 0.0006 18.88 CER CER (d40:2) [ADDUCT]- 
654.56116 654.55980 0.0014 18.78 CER CER (d40:2) [M+Cl]- 
654.56183 654.55980 0.0021 18.90 CER CER (d40:2) [M+Cl]- 
664.58827 664.58860 0.0003 18.77 CER CER (d40:2) [M+HCOO]- 
664.58822 664.58860 0.0003 18.91 CER CER (d40:2) [M+HCOO]- 
681.57888 681.61455 0.0357 18.77 CER CER (d40:2) [M+HCOONH4]
- 
681.57870 681.61455 0.0358 18.90 CER CER (d40:2) [M+HCOONH4]
- 
652.54499 652.54410 0.0009 18.01 CER CER (d40:3) [M+Cl]- 
662.57221 662.57290 0.0007 18.00 CER CER (d40:3) [M+HCOO]- 
679.56265 679.59890 0.0363 18.00 CER CER (d40:3) [M+HCOONH4]
- 
672.60575 672.60670 0.0009 20.26 CER CER (d41:0) [M+Cl]- 
682.63296 682.63550 0.0025 20.28 CER CER (d41:0) [M+HCOO]- 
699.62543 699.66150 0.0361 20.28 CER CER (d41:0) [M+HCOONH4]
- 
748.60926 748.60672 0.0025 20.00 CER CER (d41:1) [ADDUCT]- 
670.59093 670.59110 0.0001 20.01 CER CER (d41:1) [M+Cl]- 
680.61963 680.61990 0.0002 20.00 CER CER (d41:1) [M+HCOO]- 
697.61012 697.64585 0.0357 20.00 CER CER (d41:1) [M+HCOONH4]
- 
668.57547 668.57540 0.0001 19.19 CER CER (d41:2) [M+Cl]- 
678.60369 678.60420 0.0005 19.19 CER CER (d41:2) [M+HCOO]- 
678.60357 678.60420 0.0006 19.34 CER CER (d41:2) [M+HCOO]- 
695.59427 695.63020 0.0359 19.19 CER CER (d41:2) [M+HCOONH4]
- 
695.59418 695.63020 0.0360 19.33 CER CER (d41:2) [M+HCOONH4]
- 
764.63849 764.63802 0.0005 20.62 CER CER (d42:0) [ADDUCT]- 
696.65100 696.65120 0.0002 20.62 CER CER (d42:0) [M+HCOO]- 
713.64096 713.67715 0.0362 20.63 CER CER (d42:0) [M+HCOONH4]
- 
762.62298 762.62237 0.0006 20.36 CER CER (d42:1) [ADDUCT]- 
762.62355 762.62237 0.0012 19.88 CER CER (d42:1) [ADDUCT]- 
684.60686 684.60670 0.0002 20.36 CER CER (d42:1) [M+Cl]- 
684.60482 684.60670 0.0019 19.87 CER CER (d42:1) [M+Cl]- 
694.63560 694.63550 0.0001 20.36 CER CER (d42:1) [M+HCOO]- 
694.63465 694.63550 0.0009 19.88 CER CER (d42:1) [M+HCOO]- 
711.62606 711.66150 0.0354 20.36 CER CER (d42:1) [M+HCOONH4]
- 
711.62532 711.66150 0.0362 19.87 CER CER (d42:1) [M+HCOONH4]
- 
760.60765 760.60672 0.0009 19.57 CER CER (d42:2) [ADDUCT]- 
682.59117 682.59110 0.0001 19.57 CER CER (d42:2) [M+Cl]- 
682.59301 682.59110 0.0020 19.22 CER CER (d42:2) [M+Cl]- 
692.61989 692.61990 0.0000 19.57 CER CER (d42:2) [M+HCOO]- 
692.61945 692.61990 0.0004 19.74 CER CER (d42:2) [M+HCOO]- 
692.61874 692.61990 0.0011 19.21 CER CER (d42:2) [M+HCOO]- 
709.60904 709.64585 0.0368 19.21 CER CER (d42:2) [M+HCOONH4]
- 
709.61025 709.64585 0.0356 19.57 CER CER (d42:2) [M+HCOONH4]
- 
758.59206 758.59110 0.0010 18.88 CER CER (d42:3) [ADDUCT]- 
680.57535 680.57540 0.0000 18.88 CER CER (d42:3) [M+Cl]- 
690.60390 690.60420 0.0003 18.88 CER CER (d42:3) [M+HCOO]- 
707.59432 707.63020 0.0359 18.88 CER CER (d42:3) [M+HCOONH4]
- 
710.66520 710.66680 0.0016 20.95 CER CER (d43:0) [M+HCOO]- 
727.65664 727.69280 0.0362 20.95 CER CER (d43:0) [M+HCOONH4]
- 
708.65095 708.65120 0.0002 20.71 CER CER (d43:1) [M+HCOO]- 
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725.64126 725.67715 0.0359 20.71 CER CER (d43:1) [M+HCOONH4]
- 
706.63476 706.63550 0.0007 19.95 CER CER (d43:2) [M+HCOO]- 
723.62546 723.66150 0.0360 19.95 CER CER (d43:2) [M+HCOONH4]
- 
724.68193 724.68250 0.0005 21.25 CER CER (d44:0) [M+HCOO]- 
741.67265 741.70845 0.0358 21.26 CER CER (d44:0) [M+HCOONH4]
- 
722.66655 722.66680 0.0003 21.03 CER CER (d44:1) [M+HCOO]- 
722.66536 722.66680 0.0014 20.55 CER CER (d44:1) [M+HCOO]- 
739.65713 739.69280 0.0357 21.03 CER CER (d44:1) [M+HCOONH4]
- 
739.66151 739.69280 0.0313 20.63 CER CER (d44:1) [M+HCOONH4]
- 
720.65044 720.65120 0.0007 20.31 CER CER (d44:2) [M+HCOO]- 
737.64125 737.67715 0.0359 20.31 CER CER (d44:2) [M+HCOONH4]
- 
752.71442 752.71380 0.0007 21.79 CER CER (d46:0) [M+HCOO]- 
769.70487 769.73975 0.0349 21.82 CER CER (d46:0) [M+HCOONH4]
- 
588.47602 588.47640 0.0004 16.11 CER CER (t34:1) [M+Cl]- 
598.50558 598.50520 0.0004 16.11 CER CER (t34:1) [M+HCOO]- 
615.48716 615.53121 0.0441 16.27 CER CER (t34:1) [M+HCOONH4]
- 
684.61025 684.61480 0.0045 19.18 CER CER (t40:0) [M+HCOO]- 
701.60452 701.64076 0.0362 19.17 CER CER (t40:0) [M+HCOONH4]
- 
698.62697 698.63040 0.0034 19.62 CER CER (t41:0) [M+HCOO]- 
715.62009 715.65651 0.0364 19.61 CER CER (t41:0) [M+HCOONH4]
- 
702.61345 702.61730 0.0038 19.98 CER CER (t42:0) [M+Cl]- 
712.64038 712.64610 0.0057 19.92 CER CER (t42:0) [M+HCOO]- 
729.57734 729.67206 0.0947 19.98 CER CER (t42:0) [M+HCOONH4]
- 
700.60079 700.60160 0.0008 19.16 CER CER (t42:1) [M+Cl]- 
710.62804 710.63040 0.0024 19.16 CER CER (t42:1) [M+HCOO]- 
727.62058 727.65641 0.0358 19.16 CER CER (t42:1) [M+HCOONH4]
- 
726.65937 726.66170 0.0023 20.35 CER CER (t43:0) [M+HCOO]- 
743.65162 743.68771 0.0361 20.34 CER CER (t43:0) [M+HCOONH4]
- 
740.67649 740.67740 0.0009 20.67 CER CER (t44:0) [M+HCOO]- 
757.66754 757.70336 0.0358 20.67 CER CER (t44:0) [M+HCOONH4]
- 
728.63055 728.63290 0.0024 19.95 CER CER (t44:1) [M+Cl]- 
738.66120 738.66170 0.0005 19.95 CER CER (t44:1) [M+HCOO]- 
738.66102 738.66170 0.0007 20.64 CER CER (t44:1) [M+HCOO]- 
755.65215 755.68771 0.0356 19.94 CER CER (t44:1) [M+HCOONH4]
- 
755.65196 755.68771 0.0358 20.65 CER CER (t44:1) [M+HCOONH4]
- 
754.69208 754.69300 0.0009 20.97 CER CER (t45:0) [M+HCOO]- 
771.68365 771.71901 0.0354 20.97 CER CER (t45:0) [M+HCOONH4]
- 
758.67717 758.67990 0.0027 21.28 CER CER (t46:0) [M+Cl]- 
768.70883 768.70870 0.0002 21.27 CER CER (t46:0) [M+HCOO]- 
785.69926 785.73466 0.0354 21.27 CER CER (t46:0) [M+HCOONH4]
- 
766.69343 766.69300 0.0004 20.62 CER CER (t46:1) [M+HCOO]- 
783.68413 783.71901 0.0349 20.63 CER CER (t46:1) [M+HCOONH4]
- 
782.72634 782.72430 0.0020 21.54 CER CER (t47:0) [M+HCOO]- 
796.74210 796.74000 0.0021 21.83 CER CER (t48:0) [M+HCOO]- 
761.55339 761.58912 0.0357 15.45 CER HexCer (d34:1) [M+HCOONH4]
- 
734.53419 734.53430 0.0001 15.44 CER HexCer (d34:1) [M+Cl]- 
744.56319 744.56310 0.0001 15.44 CER HexCer (d34:1) [M+HCOO]- 
828.65741 828.65700 0.0004 18.59 CER HexCer (d40:1) [M+HCOO]- 
924.68203 924.67520 0.0068 19.40 CER HexCer (d42:1) [ADDUCT]- 
846.66390 846.65950 0.0044 19.40 CER HexCer (d42:1) [M+Cl]- 
856.68920 856.68830 0.0009 19.39 CER HexCer (d42:1) [M+HCOO]- 
873.67992 873.71430 0.0344 19.40 CER HexCer (d42:1) [M+HCOONH4]
- 
922.66462 922.65955 0.0051 18.55 CER HexCer (d42:2) [ADDUCT]- 
844.64500 844.64390 0.0011 18.55 CER HexCer (d42:2) [M+Cl]- 
854.67328 854.67270 0.0006 18.55 CER HexCer (d42:2) [M+HCOO]- 
871.66388 871.69867 0.0348 18.55 CER HexCer (d42:2) [M+HCOONH4]
- 
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760.55677 760.55800 0.0013 15.05 CER HexCer (t34:1) [M+HCOO]- 
896.58722 896.58720 0.0001 14.81 CER LacCer (d34:1) (d18:1/16:0) [M+Cl]- 
906.61654 906.61600 0.0006 14.80 CER LacCer (d34:1) (d18:1/16:0) [M+HCOO]- 
923.60696 923.64195 0.0350 14.80 CER LacCer (d34:1) (d18:1/16:0) [M+HCOONH4]
- 
540.33003 540.33070 0.0007 5.26 LPC LPC 16:0 [M+HCOO]- 
540.33018 540.33070 0.0005 4.87 LPC LPC 16:0 [M+HCOO]- 
566.34522 566.34640 0.0011 5.25 LPC LPC 18:1 [M+HCOO]- 
566.34549 566.34640 0.0009 5.62 LPC LPC 18:1 [M+HCOO]- 
564.33025 564.33070 0.0004 3.97 LPC LPC 18:2 [M+HCOO]- 
564.33004 564.33070 0.0007 4.14 LPC LPC 18:2 [M+HCOO]- 
588.33010 588.33070 0.0006 3.84 LPC LPC 20:4 [M+HCOO]- 
588.33006 588.33070 0.0006 3.96 LPC LPC 20:4 [M+HCOO]- 
452.27527 452.27830 0.0030 5.09 LPE LPE 16:0 [M-H]- 
452.27730 452.27830 0.0010 5.46 LPE LPE 16:0 [M-H]- 
480.30908 480.30960 0.0005 7.66 LPE LPE 18:0 [M-H]- 
478.29328 478.29390 0.0006 5.49 LPE LPE 18:1 [M-H]- 
478.29313 478.29390 0.0008 5.83 LPE LPE 18:1 [M-H]- 
476.27762 476.27830 0.0007 4.16 LPE LPE 18:2 [M-H]- 
476.27786 476.27830 0.0004 4.44 LPE LPE 18:2 [M-H]- 
502.29318 502.29390 0.0007 4.73 LPE LPE 20:3 [M-H]- 
704.23984 704.23999 0.0001 4.04 LPE LPE 20:4 [ADDUCT]- 
568.26526 568.26514 0.0001 4.04 LPE LPE 20:4 [ADDUCT]- 
568.26535 568.26514 0.0002 4.24 LPE LPE 20:4 [ADDUCT]- 
500.27804 500.27830 0.0002 4.03 LPE LPE 20:4 [M-H]- 
500.27782 500.27830 0.0005 4.26 LPE LPE 20:4 [M-H]- 
498.26153 498.26260 0.0011 3.13 LPE LPE 20:5 [M-H]- 
498.26023 498.26260 0.0024 3.30 LPE LPE 20:5 [M-H]- 
596.29664 596.29644 0.0002 5.41 LPE LPE 22:4 [ADDUCT]- 
596.29677 596.29644 0.0003 5.61 LPE LPE 22:4 [ADDUCT]- 
528.30938 528.30960 0.0002 5.42 LPE LPE 22:4 [M-H]- 
528.30937 528.30960 0.0002 5.71 LPE LPE 22:4 [M-H]- 
594.28126 594.28079 0.0005 4.28 LPE LPE 22:5 [ADDUCT]- 
526.29374 526.29390 0.0002 4.28 LPE LPE 22:5 [M-H]- 
526.29322 526.29390 0.0007 4.53 LPE LPE 22:5 [M-H]- 
526.29318 526.29390 0.0007 4.84 LPE LPE 22:5 [M-H]- 
526.28626 526.29390 0.0077 5.09 LPE LPE 22:5 [M-H]- 
592.26547 592.26514 0.0003 3.79 LPE LPE 22:6 [ADDUCT]- 
524.27790 524.27830 0.0004 3.79 LPE LPE 22:6 [M-H]- 
524.27779 524.27830 0.0005 3.95 LPE LPE 22:6 [M-H]- 
619.28853 619.28890 0.0004 2.99 LPI LPI 20:4 [M-H]- 
619.28851 619.28890 0.0004 3.16 LPI LPI 20:4 [M-H]- 
764.58084 764.58110 0.0003 17.52 PC PC (O-32:0) (O-16:0/16:0) [M+HCOO]- 
812.58101 812.58110 0.0001 16.36 PC PC (O-36:4) (O-18:0/20:4) [M+HCOO]- 
840.61228 840.61240 0.0001 17.66 PC PC (O-38:4) (O-16:0/22:4) (O-18:0/20:4) [M+HCOO]- 
790.59669 790.59680 0.0001 17.57 PC PC (P-34:0) (P-18:0/16:0) [M+HCOO]- 
838.59650 838.59680 0.0003 16.41 PC PC (P-38:4) (P-20:0/20:4) [M+HCOO]- 
846.54792 846.54723 0.0007 16.47 PC PC 32:0 (16:0/16:0) [ADDUCT]- 
914.53538 914.53466 0.0007 16.47 PC PC 32:0 (16:0/16:0) [ADDUCT]- 
778.56054 778.56040 0.0002 16.46 PC PC 32:0 (16:0/16:0) [M+HCOO]- 
776.54426 776.54470 0.0005 15.43 PC PC 32:1 (16:0/16:1) [M+HCOO]- 
806.59146 806.59170 0.0002 17.74 PC PC 34:0 (16:0/18:0) [M+HCOO]- 
872.56343 872.56288 0.0006 16.56 PC PC 34:1 (16:0/18:1) [ADDUCT]- 
940.55031 940.55031 0.0000 16.57 PC PC 34:1 (16:0/18:1) [ADDUCT]- 
804.57627 804.57600 0.0003 16.56 PC PC 34:1 (16:0/18:1) [M+HCOO]- 
870.54774 870.54723 0.0005 15.65 PC PC 34:2 (16:0/18:2) [ADDUCT]- 
802.56043 802.56040 0.0001 15.65 PC PC 34:2 (16:0/18:2) [M+HCOO]- 
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900.59450 900.59418 0.0003 17.84 PC PC 36:1 (18:0/18:1) [ADDUCT]- 
832.60727 832.60730 0.0000 17.81 PC PC 36:1 (18:0/18:1) [M+HCOO]- 
898.57891 898.57853 0.0004 16.86 PC PC 36:2 (18:1/18:1) [ADDUCT]- 
830.59184 830.59170 0.0002 16.82 PC PC 36:2 (18:1/18:1) [M+HCOO]- 
896.56307 896.56288 0.0002 15.80 PC PC 36:3 (16:0/20:3) [ADDUCT]- 
828.57573 828.57600 0.0003 15.80 PC PC 36:3 (16:0/20:3) [M+HCOO]- 
894.54755 894.54723 0.0003 15.43 PC PC 36:4 (16:0/20:4) [ADDUCT]- 
826.56045 826.56040 0.0001 15.43 PC PC 36:4 (16:0/20:4) (18:2/18:2) [M+HCOO]- 
840.57440 840.57600 0.0016 16.04 PC PC 37:4 (17:0/20:4) [M+HCOO]- 
856.60676 856.60730 0.0006 17.23 PC PC 38:3 (18:0/20:3) [M+HCOO]- 
854.59135 854.59170 0.0003 16.33 PC PC 38:4 (16:0/22:4) [M+HCOO]- 
922.57897 922.57853 0.0004 16.67 PC PC 38:4 (18:0/20:4) [ADDUCT]- 
854.59178 854.59170 0.0001 16.66 PC PC 38:4 (18:0/20:4) [M+HCOO]- 
852.57603 852.57600 0.0000 16.28 PC PC 38:5 (16:0/22:5) [M+HCOO]- 
852.57610 852.57600 0.0001 15.54 PC PC 38:5 (18:1/20:4) [M+HCOO]- 
850.56039 850.56040 0.0000 15.56 PC PC 38:6 (16:0/22:6) [M+HCOO]- 
850.56009 850.56040 0.0003 15.09 PC PC 38:6 (18:2/20:4) [M+HCOO]- 
880.60647 880.60730 0.0009 16.72 PC PC 40:5 (18:0/22:5) / (18:1/22:4) [M+HCOO]- 
878.59156 878.59170 0.0001 16.36 PC PC 40:6 (18:1/22:5) / (18:0/22:6) [M+HCOO]- 
876.57587 876.57600 0.0001 15.20 PC PC 40:7 (18:1/22:6) [M+HCOO]- 
724.52829 724.52870 0.0004 16.38 PE PE (O-36:4) (O-16:0/20:4) [M-H]- 
752.55956 752.56000 0.0004 17.46 PE PE (O-38:4) (O-18:0/20:4) [M-H]- 
750.54439 750.54430 0.0001 16.44 PE PE (O-38:5) (O-16:0/22:5) [M-H]- 
748.52938 748.52870 0.0007 16.26 PE PE (O-38:6) (O-16:0:/22:6) / (P-38:5) (P-18:1/20:4) [M-H]- 
778.57100 778.57560 0.0046 18.26 PE PE (O-40:5) / (P-40:4) [M-H]- 
778.56999 778.57560 0.0056 17.97 PE PE (O-40:5) / (P-40:4) [M-H]- 
776.56032 776.56000 0.0003 17.25 PE PE (O-40:6) (O-18:0/22:6) [M-H]- 
722.51315 722.51300 0.0001 16.19 PE PE (P-36:4) (P-16:0/20:4) [M-H]- 
750.54556 750.54430 0.0012 16.93 PE PE (P-38:4) (P-16:0/22:4) [M-H]- 
750.54407 750.54430 0.0002 17.30 PE PE (P-38:4) (P-18:0/20:4) [M-H]- 
746.51374 746.51300 0.0007 15.83 PE PE (P-38:6) (P-16:0/22:6) [M-H]- 
774.54717 774.54430 0.0029 17.04 PE PE (P-40:6) (P-18:0/22:6) [M-H]- 
690.50765 690.50790 0.0003 16.45 PE PE 32:0 (16:0/16:0) [M-H]- 
784.51084 784.51045 0.0004 16.58 PE PE 34:1 (16:0/18:1) [ADDUCT]- 
716.52360 716.52360 0.0000 16.58 PE PE 34:1 (16:0/18:1) [M-H]- 
714.50764 714.50790 0.0003 15.71 PE PE 34:2 (16:0/18:2) [M-H]- 
744.55503 744.55490 0.0001 17.62 PE PE 36:1 (18:0/18:1) [M-H]- 
812.54249 812.54175 0.0007 17.62 PE PE 36:1 [ADDUCT]- 
880.52978 880.52918 0.0006 17.63 PE PE 36:1 [ADDUCT]- 
810.52676 810.52610 0.0007 16.84 PE PE 36:2 (18:0/18:2) [ADDUCT]- 
742.53923 742.53920 0.0000 16.85 PE PE 36:2 (18:0/18:2) [M-H]- 
742.53921 742.53920 0.0000 16.70 PE PE 36:2 (18:1/18:1) [M-H]- 
810.52694 810.52610 0.0008 16.29 PE PE 36:2 [ADDUCT]- 
740.52334 740.52360 0.0002 15.84 PE PE 36:3 (18:1/18:2) [M-H]- 
806.49543 806.49480 0.0006 15.55 PE PE 36:4 (16:0/20:4) [ADDUCT]- 
738.50805 738.50790 0.0001 15.54 PE PE 36:4 (16:0/20:4) [M-H]- 
770.56991 770.57050 0.0006 17.68 PE PE 38:2 (18:1/20:1) [M-H]- 
768.55486 768.55490 0.0000 17.13 PE PE 38:3 (18:0/20:3) [M-H]- 
766.53912 766.53920 0.0001 16.38 PE PE 38:4 [M-H]- 
834.52679 834.52610 0.0007 16.70 PE PE 38:4 (18:0/20:4) [ADDUCT]- 
902.51393 902.51353 0.0004 16.70 PE PE 38:4 (18:0/20:4) [ADDUCT]- 
896.49706 896.55031 0.0532 16.70 PE PE 38:4 (18:0/20:4) [ADDUCT]- 
766.53966 766.53920 0.0004 16.70 PE PE 38:4 (18:0/20:4) [M-H]- 
764.52682 764.52360 0.0032 15.78 PE PE 38:5 (16:0/22:5) [M-H]- 
764.52402 764.52360 0.0004 15.67 PE PE 38:5 (18:1/20:4) / (18:0/20:5) [M-H]- 
832.51136 832.51045 0.0009 15.67 PE PE 38:5 (18:1/20:4) [ADDUCT]- 
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762.50797 762.50790 0.0000 15.23 PE PE 38:6 (16:0/22:6) [M-H]- 
862.55797 862.55740 0.0006 17.42 PE PE 40:4 (18:0/22:4) [ADDUCT]- 
794.57066 794.57050 0.0001 17.42 PE PE 40:4 (18:0/22:4) [M-H]- 
794.57059 794.57050 0.0001 17.72 PE PE 40:4 [M-H]- 
792.55535 792.55490 0.0005 16.73 PE PE 40:5 (18:0/22:5) [M-H]- 
792.55964 792.55490 0.0048 17.12 PE PE 40:5 [M-H]- 
858.52692 858.52610 0.0008 16.41 PE PE 40:6 (18:0/22:6) [ADDUCT]- 
790.54187 790.53920 0.0026 16.41 PE PE 40:6 (18:0/22:6) [M-H]- 
788.52562 788.52360 0.0020 15.37 PE PE 40:7 (18:1/22:6) [M-H]- 
802.56044 802.52102 0.0394 16.51 PE PE-NMe2 (16:0/18:1) [ADDUCT]- 
824.54473 824.50537 0.0394 15.56 PE PE-NMe2 (16:0/20:4) [ADDUCT]- 
773.53315 773.53380 0.0007 14.60 PG PG 36:2 (18:1/18:1) [M-H]- 
863.56628 863.56550 0.0008 15.99 PI PI 36:1 (18:0/18:1) [M-H]- 
861.54945 861.54990 0.0004 15.00 PI PI 36:2 (18:1/18:1) [M-H]- 
861.54964 861.54990 0.0002 15.16 PI PI 36:2 (18:1/18:1) [M-H]- 
857.51868 857.51860 0.0001 13.78 PI PI 36:4 (16:0/20:4) [M-H]- 
887.56543 887.56550 0.0001 15.47 PI PI 38:3 (18:0/20:3) [M-H]- 
953.53710 953.53673 0.0004 15.03 PI PI 38:4 (18:0/20:4) [ADDUCT]- 
885.55038 885.54990 0.0005 15.03 PI PI 38:4 (18:0/20:4) [M-H]- 
883.53461 883.53420 0.0004 13.93 PI PI 38:5 (18:1/20:4) [M-H]- 
883.53485 883.53420 0.0006 14.09 PI PI 38:5 [M-H]- 
913.58105 913.58120 0.0001 15.81 PI PI 40:4 (18:0/22:4) [M-H]- 
911.56550 911.56550 0.0000 15.08 PI PI 40:5 (18:0/22:5) [M-H]- 
909.54974 909.54990 0.0001 14.74 PI PI 40:6 (18:0/22:6) [M-H]- 
788.54512 788.54470 0.0004 16.29 PS PS 36:1 (18:0/18:1) [M-H]- 
786.52902 786.52910 0.0000 15.44 PS PS 36:2 (18:0/18:2) (18:1/18:1) [M-H]- 
812.54474 812.54470 0.0000 15.76 PS PS 38:3 (18:0/20:3) [M-H]- 
810.52928 810.52910 0.0002 15.32 PS PS 38:4 (18:0/20:4) [M-H]- 
838.56140 838.56040 0.0010 16.10 PS PS 40:4 (18:0/20:4) [M-H]- 
836.54484 836.54470 0.0001 15.36 PS PS 40:5 (18:0/22:5) [M-H]- 
834.52918 834.52910 0.0001 15.00 PS PS 40:6 (18:0/22:6) [M-H]- 
719.53434 719.53450 0.0001 13.63 SM SM (d32:1) (M+HCOO]- 
733.54990 733.55010 0.0002 14.37 SM SM (d33:1) [M+HCOO]- 
749.58075 749.58140 0.0007 15.59 SM SM (d34:0) [M+HCOO]- 
815.55329 815.55265 0.0006 15.05 SM SM (d34:1) [ADDUCT]- 
747.56597 747.56580 0.0002 15.05 SM SM (d34:1) [M+HCOO]- 
745.54989 745.55010 0.0002 13.88 SM SM (d34:2) [M+HCOO]- 
775.59636 775.59710 0.0007 16.39 SM SM (d36:1) [M+HCOO]- 
803.62831 803.62840 0.0001 17.63 SM SM (d38:1) [M+HCOO]- 
899.64925 899.64655 0.0027 18.70 SM SM (d40:1) [ADDUCT]- 
831.66013 831.65970 0.0004 18.68 SM SM (d40:1) [M+HCOO]- 
829.64434 829.64400 0.0003 17.76 SM SM (d40:2) [M+HCOO]- 
859.69285 859.69100 0.0019 19.77 SM SM (d42:1) [M+HCOO]- 
925.66573 925.66220 0.0035 18.62 SM SM (d42:2) [ADDUCT]- 
857.67609 857.67530 0.0008 18.62 SM SM (d42:2) [M+HCOO]- 
855.66032 855.65970 0.0006 17.75 SM SM (d42:3) [M+HCOO]- 
Table 10 List of lipids detected in positive ionization mode 
α: theoretical m/z values matched in Lipid Maps database; 
β: experimental m/z values as calculated by MZmine 2.3 software; 
γ: mass error calculated as difference between theoretical m/z and observed m/z 
δ: retention time values as calculated by MZmine 2.3 software; 
ε: lipid class assign according to Lipid Maps Lipid Classification 
ζ: putative ID assign through m/z matched to databases, retention time and MS/MS spectra interpretation. 
CER: ceramide; HexCer: hexosylceramide; LacCer: lactosylceramide; LPC: lysophosphatidylcholine; LPE: 
lysophosphatidylethanolamine; LPI: lysophosphatidylinositol; PC: phosphatidylcholine; PC-O: plasmanyl-
phosphatidylcholine; PC-P: plasmenyl-phosphatidylcholine; PE: phosphatidylethanolamine; PE-O: plasmanyl-
phosphatidylethanolamine; PE-P: plasmenyl-phosphatidylethanolamine; PG: phosphatidylglycerol; PI: phosphatidylinositol; 
PS: phosphatidylserine; SM: sphingomyelin. 
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